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SUMMARY 
 
Lymphomas are neoplasms derived from B or T lymphocytes. Peripheral T-cell lymphomas 
(PTCL) are a group of malignancies that vary in their biology, genetics, clinical presentation, 
response to therapy, and outcome. While B-cell lymphomas are relatively well studied, only 
limited research has been performed to elucidate the pathobiology and identify novel 
pharmacological approaches in PTCL. With the purpose of delineating the mechanisms 
responsible for PTCL tumorigenesis, a variety of approaches including microRNA, mRNA and 
protein expression analysis was used. The microRNA analysis revealed a series of aberrantly 
expressed microRNAs including downregulation of let-7 family, miR-10, miR-15, miR-16, miR-
101, miR-29, miR-215, miR-150, miR-139, miR-126 and miR-195 regulating stemness, stress 
response, apoptosis, proliferation, angiogenesis, and cell cycle pathways. Furthermore, a 
group of PTCL with a null-phenotype (lacking normal T-cell subpopulations’ markers) has been 
identified, expressing an oncogenic microRNA signature. This group showed an increased 
proliferation with enrichment of Ras and Rho associated pathways.  
 
At present, no curative treatment is available for cutaneous T-cell lymphoma (CTCL) patients 
and many commonly used therapeutic strategies achieve remission in only a subset of cases. 
Although PUVA and IFNα are commonly used therapies in CTCL, a large proportion of patients 
show resistance to treatment, and the factors responsible for this resistance are unknown. In 
order to identify factors responsible for resistance to PUVA and IFN treatment in mycosis 
fungoides (MF) patients, the gene expression profiling of pre-treatment samples from 29 MF 
patients enrolled in a randomized clinical trial was analyzed using cDNA microarrays. Genes 
involved in NF-B, T-cell receptor, cytokine signaling and proliferation were differentially 
expressed between responders and non-responders. Moreover, many of the markers 
identified to be associated with PUVA and IFNα resistance, were expressed not only by 
tumoral cells but also by the tumor microenvironment, highlighting the important role of the 
stroma in conferring therapy resistance in MF. 
 
Vorinostat (SAHA), a pan-histone deacetylase inhibitor, is the FDA approved treatment for 
refractory CTCL. However, despite emerging information on vorinostat effect on many cancer 
types, there is still little knowledge on mechanism and the kinetics of gene expression, 
essential for its effective use in combination therapy. Time course experiments in CTCL derived 
cell lines, showed that vorinostat decreased T-cell receptor (TCR) signaling through inhibition 
of kinase phosphorylation (ZAP70, AKT). Additionally, combined concomitant administration of 
vorinostat and PI3K inhibitors (LY249002 and new ETP-45658) resulted in synergism and could 
be potentially efficacious for the treatment of CTCL. Besides, vorinostat and PIM inhibitors 
showed an additive effect while the use of vorinostat and HSP90 inhibitor (17-AAG) produced 
antagonistic reaction.  
 
In summary, our findings bring new ideas on the molecular heterogeneity of PTCLs and suggest 
combination therapies using HDACi and PI3K inhibitors for the treatment of CTCLs. 
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RESUMEN 
 
Los Linfomas son neoplasias derivadas de linfocitos B o T. Los Linfomas periféricos de célula T 
(LPCT) son un grupo de enfermedades que varían en su biología, genética, presentación clínica, 
respuesta a terapia y resultado. Mientras que los linfomas de célula B están relativamente bien 
estudiados, sólo se ha realizado una investigación limitada para elucidar la patobiología de 
LPCT e identificar nuevas estrategias farmacológicas. Se han usado gran variedad de 
aproximaciones para delinear los mecanismos responsables de la generación de los LPCT 
incluyendo análisis de la expresión de microARN, ARNm y proteínas. El análisis de microARN 
reveló una serie de microARNs que se expresaban de manera aberrante, incluyendo la 
disminución en los niveles de expresión de la familia de let-7, miR-10, miR-15 miR-16, miR-101, 
miR-29, miR-215, miR-150, miR-139, miR-126 y miR-195 que regulan las rutas implicadas en las 
propiedades de células troncales, respuesta a estrés, apoptosis, proliferación, angiogénesis y 
ciclo celular. Además, se ha identificado un grupo de LPCT con un fenotipo nulo (carecen de los 
marcadores de las subpoblaciones normales de células T), que expresan una firma de 
microARNs oncogénicos. Este grupo mostró una mayor proliferación y un enriquecimiento en 
la expresión de genes de las rutas asociadas a Ras y Rho. 
 
Aún no hay disponible ningún tratamiento curativo para los pacientes con linfomas cutáneos 
de célula T (LCCT) y muchas de las terapias comunes consiguen la remisión sólo en un grupo de 
casos. Aunque rutinariamente se usan PUVA e IFNα, una gran proporción de los pacientes son 
resistentes al tratamiento y los factores responsables de esta resistencia son desconocidos. 
Con el objetivo de identificar los factores responsables de esta resistencia en pacientes con 
micosis fungoides (MF), se analizó la expresión génica de muestras antes del tratamiento de 29 
pacientes con MF inscritos en un ensayo clínico aleatorizado usando micromatrices de ADNc. 
Los genes implicados en la vÍa de NF-B, receptor de célula T, señalización por citoquinas y 
proliferación se expresan de manera diferencial entre pacientes sensibles y resistentes al 
tratamiento. Además, muchos de los marcadores identificados como asociados a la resistencia 
a PUVA e IFNα se expresaban en las células tumorales y también en el microambiente, 
subrayando la importancia del estroma en otorgar resistencia a la terapia en MF. 
 
Vorinostat (SAHA), un inhibidor de desacetilasas de histonas (HDACi), es el tratamiento 
aprobado por la FDA contra el LCCT resistente al tratamiento.  Sin embargo, a pesar de la 
emergente información sobre vorinostat en diferentes tipos de cáncer, aún poco se sabe sobre 
su mecanismo de acción y la cinética de expresión génica, esenciales para su uso eficaz en 
combinación con otras terapias. Los experimentos realizados a diferentes tiempos en líneas 
derivadas de LCCT mostraron que el vorinostat disminuye la señalización del receptor de célula 
T mediante la inhibición de la fosforilación de quinasas (ZAP70, AKT). Adicionalmente, la 
administración combinada de vorinostat e inhibidores de PI3K (LY249002 y ETP-45658) resultó 
en un comportamiento sinérgico y podría ser potencialmente eficaz para el tratamiento de 
LCCT. El vorinostat y los inhibidores de PIM mostraron un efecto aditivo mientras que el uso de 
vorinostat y un inhibidor de HSP90 (17-AAG) indujo una reacción antagonista. 
 
En resumen, nuestros descubrimientos aportan nuevas ideas sobre la heterogeneidad 
molecular de los LCCT y sugieren la aplicación de terapias combinadas usando HDACi e 
inhibidores de PI3K para el tratamiento de LCCT. 
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1 Lymphoma 
Lymphoma is a type of cancer that involves the white blood cells of the immune system, called 
lymphocytes. Just as cancer represents many different diseases, lymphoma represents many 
different cancers of lymphocytes. There are many entities of lymphomas, and in turn, 
lymphomas are a part of the broad group of diseases called hematological neoplasms. The first 
description of lymphoma has been published in 1832 by Thomas Hodgkin, specifically the form 
bearing his name, Hodgkin lymphoma (Hellman, 1999). There are two main types of lymphoma 
that include Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). Lymphoma is a 
malignant transformation of B or T lymphocytes and the most common blood cancer. It arises 
from abnormal growth of lymphocytes in many parts of the body, including the lymph nodes, 
spleen, bone marrow, blood or other organs. Although both cell types – B and T lymphocytes 
can develop into lymphomas, B-cell lymphomas are more common and better studied.  
1.1 T cell lymphoma 
The T cell non-Hodgkin´s lymphomas (T-NHL) are a group of malignancies that vary in their 
biology, genetics, clinical presentation, response to therapy, and outcome (Table 1). Of all 
cancers involving the same class of blood cells, 8% of cases are mature T cell lymphomas. 
Among those cases, 2% are precursor T lymphoblastic and 2% are cutaneous T cell lymphomas 
(Turgeon, 2005). 
Table 1. WHO Classification of T-Cell Lymphomas (Cheson, 2007) 
Type Examples 
Precursor T-LBL/T-ALL 
 
 
 
Peripheral 
T-PLL 
Large granular lymphocytic leukemia 
MF/Sézary 
Peripheral T-cell lymphoma, unspecified type 
Angioimmunoblastic lymphoma 
Angiocentric lymphoma 
Intestinal T-cell lymphoma 
Subcutaneous panniculitis-like lymphoma 
Gamma-delta T-cell lymphoma 
Adult T-cell leukemia/lymphoma 
Anaplastic large cell lymphoma 
Abbreviations: MF, mycosis fungoides; T-ALL, T-cell acute lymphoblastic leukemia; T-LBL, T-cell lymphoblastic 
leukemia; T-PLL, T-cell prolymphocytic leukemia; WHO, World Health Organization 
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T-cell lymphoma (TCL) accounts for about 15% of all cases of NHL in the United States, 
although some forms of TCL are more common in Asia and other parts of the world. There are 
many different types of TCL and some are extremely rare, occurring in only a few patients per 
year throughout the world.  
1.1.1 Peripheral T-cell lymphoma 
Malignancies derived from mature (post-thymic) T cells and NK cells, collectively referred to as 
peripheral T-cell lymphomas (PTCLs), encompass a variety of uncommon and rare diseases, 
altogether accounting for about 15% of all NHL on a worldwide basis. T-cell and NK-cell 
lymphomas demonstrate significant variations in incidence in different geographical regions 
and racial populations, showing higher prevalence in Asia and Central/South America than in 
Western countries (Rudiger et al., 2002). Human T-lymphotropic virus-1 (HTLV-1) and Epstein-
Barr virus (EBV) have been observed to be associated with increased risk of PTCLs (Vose, 2008). 
PTCLs show great morphological diversity, and a spectrum of histological appearances can be 
seen within individual disease entities. These neoplasms often present an advanced stage at 
diagnosis, and most commonly have an aggressive clinical course requiring prompt treatment. 
These disorders are among the most aggressive of all lymphoid neoplasms, with only four 
exceptions, the mycosis fungoides (MF), the primary cutaneous anaplastic large cell lymphoma 
(ALCL), primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma 
(CSMTCL) and the large granular lymphocytic (LGL) leukemia, which have usually a more 
indolent course. The rarity of these tumors requires additional studies to better understand 
their biology and search for new therapies which may hopefully improve the dismal outcome 
of most patients. 
Immunophenotypic markers have been less useful in the classification of T-cell lymphomas 
than B-cell lymphomas, as one marker is frequently shared by multiple disease entities. 
Additionally, the molecular pathogenesis for most T-cell lymphomas is yet undiscovered. 
However, the World Health Organisation (WHO) classification of PTCLs takes into account a 
combination of morphologic, immunophenotypic, genetic and clinical features in attempt to 
correlate disease entities with the normal cellular counterpart (Swerdlow, 2008). The list of 
entities according to the updated WHO classification is presented in Table 2.  
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Table 2. WHO 2008 classification of mature T/NK-cell neoplasms (Swerdlow, 2008). 
 
Leukemic or disseminated 
          T-cell prolymphocytic leukemia 
          T-cell large granular lymphocytic leukemia 
          Chronic lymphoproliferative disorders of NK cells* 
          Aggressive NK-cell leukemia 
          Adult T-cell lymphoma/leukemia (HTLV1-positive) 
          Systemic EBV-positive T-cell lymphoproliferative disorders of childhood 
 
Extranodal 
          Extranodal NK/T-cell lymphoma, nasal type 
          Enteropathy-associated T-cell lymphoma 
          Hepatosplenic T-cell lymphoma 
 
Extranodal – cutaneous  
          Mycosis fungoides 
          Sézary syndrome 
          Primary cutaneous CD30+ lymphoproliferative disorders 
                    Primary cutaneous anaplastic large cell lymphoma 
                    Lymphomatoid papulosis 
          Subcutaneous panniculitis-like T-cell lymphoma 
          Primary cutaneous  T-cell lymphoma* 
          Primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma* 
          Primary cutaneous small/medium CD4+ T-cell lymphoma* 
 
Nodal 
          Angioimmunoblastic T-cell lymphoma 
          Anaplastic large cell lymphoma, ALK-positive 
          Anaplastic large cell lymphoma, ALK-negative* 
          Peripheral T-cell lymphoma, not otherwise specified 
 
* designates provisional entities 
The most common subtypes of mature T-cell lymphomas are peripheral T-cell lymphoma, 
unspecified (PTCLU), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell 
lymphoma (ALCL) and cutaneous T-cell lymphoma (CTCL).  
1.1.1.1 Peripheral T-cell lymphoma, unspecified (PTCLU) 
Peripheral T-cell lymphoma, unspecified (PTCLU) represents the largest PTCL subtype 
constituting 40-50% (Savage et al., 2004). Pathologically, there is typically a diffuse atypical 
infiltrate of intermediate and large lymphoid cells that are CD4+, CD2+ and CD3+ but they 
often lack mature T-cell antigens, such as CD7. Approximately a third may be CD30+ or EBV+. 
Usually, PTCLU occurs in the fifth to sixth decade of life, and there is no evidence of sex 
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predilection. PTCLU more often presents in stage III-IV, with nodal, skin, liver, spleen, bone-
marrow or peripheral blood involvement (Evens and Gartenhaus, 2004; Gisselbrecht et al., 
1998; NHL-Group, 1997). PTCL can express CD30 irrespectively of anaplastic morphology as 
well as cytotoxic markers, including TIA1, granzyme B, perforin, CD56 and CD57 (Rudiger et al., 
2002). Activation markers are often expressed, including HLA-DR, CD25 or CD71 and antigen 
expression may change over time (Rodriguez-Abreu et al., 2008). Most cases of PTCLU are 
CD4+ CD8-, prompting speculation that within the CD4+, T-helper (Th) phenotype some of the 
biological heterogeneity may be explained by variable expression of Th1 and/or Th2 surface 
chemokine receptors (Ishida et al., 2004).  
Despite being classified in as a nodal PTCL in the WHO, the majority of patients have 
extranodal site involvement including the gastrointestinal tract, liver, bone marrow and skin 
(Savage, 2007). On clinical grounds, PTCLU are among the most aggressive non-Hodgkin 
lymphomas. The 5 year survival of patients with PTCLU is approximately 30% using standard 
chemotherapy (Gisselbrecht et al., 1998).   
1.1.1.2 Angioimmunoblastic T-cell lymphoma (AITL) 
Angioimmunoblastic T-cell lymphoma (AITL), initially described in 1970s, is an aggressive 
peripheral T-cell lymphoma that comprises 5-20% of peripheral T-cell lymphomas and 1-2% of 
all non-Hodgkin lymphomas (Dogan A, 2008; Rudiger et al., 2002). Approximately, 75% of 
patients are clinical stages III–IV at diagnosis and despite aggressive therapies their median 
survival is less than 3 years (Lachenal et al., 2007). The disease preferentially affects elderly 
males (male-to-female ratio 3:1, median age around 60 years). Patients present with 
symptoms, such as generalized lymphadenopathy (up to 90%), hepatosplenomegaly (50–79%), 
cutaneous rash (50%), hypergammaglobulinemia (50%), B-symptoms (70%), pleural effusion 
(37%) and autoimmune phenomena (20%) (Iannitto et al., 2008; Lachenal et al., 2007). 
Histologically, the majority of cases show regressed follicles, a polymorphous infiltrate of 
medium-sized lymphocytes with mild cytological atypia, Epstein-Barr virus (EBV)-positive large 
B blasts and characteristically expanded follicular dendritic cell meshworks encircling high 
endothelial venules (Dogan A, 2008). AITL usually has the phenotype of a mixture of CD4+ and 
CD8+ T-cells, with a CD4:CD8 ratio greater than unity. The neoplastic T cells in AITL express 
CD10 and sometimes BCL6, suggesting origin of germinal center (known as follicular helper T 
(TFH) cells) (Dunleavy and Wilson, 2007; Kim et al., 2004; Pautier et al., 1999). TFH derivation is 
also supported by demonstration of CXCL13 expression, a chemokine produced in high 
quantities by normal TFH cells following costimulation via the CD28 and T cell receptors (Dupuis 
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et al., 2006a; Kim et al., 2004). Additional markers of normal TFH cells, including CXCR5, CD154, 
programmed death-1 (PD-1), a member of the CD28 costimulatory membrane receptor family, 
and SLAM-associated protein (SAP), a cytoplasmic adaptor protein were demonstrated 
(Krenacs et al., 2006; Roncador et al., 2007). Moreover, polyclonal plasma cells and CD21+ 
follicular dendritic cells were also seen (Jaffe, 2001). Clonality studies demonstrated a 
monoclonal rearrangement of the -chain of the T-cell receptor (TCR) in the majority of cases. 
1.1.1.3 Anaplastic large cell lymphoma (ALCL) 
Anaplastic large cell lymphoma (ALCL) was first recognized by Stein et al in 1985, who reported 
the consistent expression of the Ki-1 antigen (later designated as CD30) in tumors with 
frequent cohesive proliferation of large pleomorphic cells of T- or null-cell lineage (Stein et al., 
1985). CD30 is a transmembrane receptor and a member of tumor necorosis factor 
superfamily that is normally expressed by activated T cells (Al-Shamkhani, 2004). ALCL occurs 
as two distinct clinical entities, as a widespread systemic disease, or as a localized cutaneous 
disease. When ALCL presents in the cutaneous form it is called primary cutaneous anaplastic 
large cell lymphoma. Systemic ALCL comprises 2% to 8% of non-Hodgkin lymphomas in adults 
and 10% to 15% of these lymphomas in children (Kadin et al., 1986). ALCL is heterogenous and 
includes two subtypes: neoplasms that aberrantly express ALK (anaplastic lymphoma kinase) 
and others that are ALK negative. ALK, also known as CD246, is a tyrosine kinase that belongs 
to the insulin receptor superfamily (Pulford et al., 2004). The ALK+ ALCLs represent 
approximately 50% to 80% of all ALCLs and usually affects children and young adults and has 
striking male predominance. The ALK- ALCLs is more commonly found in older patients over 
age 60. It is recognized that patients with ALK+ have a favorable prognosis compared with 
other types of T-cell lymphoma, including ALK- ALCL (Benharroch et al., 1998; Gascoyne et al., 
1999). The majority of ALK+ ALCL cases present as advanced stage (III or IV) systemic disease 
with generalized lymphadenopathy and extranodal involvement (Gascoyne et al., 1999). The 
immunophenotype of ALK- ALCL shares many features with ALK+ ALCL (Falini et al., 1999; 
Saffer et al., 2002). In T-cell ALK- ALCLs, an abberant T-cell immunophenotype is common, and 
these neoplasms are commonly negative for pan-T-cell antigens (e.g. CD3 and T-cell receptors) 
(Bonzheim et al., 2004). These tumors usually have a high proliferation rate and express 
activation markers, similar to ALK+ ALCL. However, in contrast to ALK+ ALCL, many ALK- ALCL 
express BCL-2 (Rassidakis et al., 2001) and can be positive for CD15 and Epstein-Barr virus 
(Herling et al., 2004).  
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1.1.1.4 Cutaneous T-cell lymphoma (CTCL) 
One of the most common forms of T-cell lymphoma is cutaneous T-cell lymphoma (CTCL) 
which actually describes many different disorders with various signs and symptoms, outcomes, 
and treatment considerations. Mycosis fungoides (MF) is the most common type of CTCL and is 
an indolent T-cell lymphoma attributed to the clonal expansion of skin-homing, 
epidermotropic CD4+ helper T-cells (Willemze et al., 1997). The term “mycosis fungoides” 
originally referred to the mushroom-like nodules in the tumor stage of disease. MF accounts 
for approximately 1% of all NHL and 65% of all lymphomas originating in the skin, with a 
median age of presentation of 57 years and a male/female ratio of 2:1 (Edelson, 1980; Kim et 
al., 2003). The incidence is estimated at 0.36-0.90 cases per 100,000 per year and is rising 
(Bradford et al., 2009; Chuang et al., 1990; Weinstock and Gardstein, 1999). However, onset 
may occur at any age, from infancy upwards. MF present with patch type skin lesions (Figure 
1A), plaque type lesions (Figure 1B) and tumor type lesions (Figure 1C). The Sézary syndrome 
(SS), a more aggressive form of cutaneous T-cell lymphoma, also defined as the leukemic 
variant of MF, is characterized by erythroderma and measurable presence of malignant 
pleomorphic T-lymphocytes with convoluted nucleus in the peripheral blood as well as skin 
involvement. 
 
 
Figure 1. Clinical manifestation of MF 
A) Patch stage lesions are oval or ring-shaped (annular) pink dry patches on covered skin; B) MF plaques 
are infiltrated lesions due to epidermal hyperplasia or significant neoplastic lymphoid infiltrate;  
C) Tumor-stage CTCL may arise from patches, from plaques or de novo. Lesions are typically 
erythematoviolaceous, exophytic, mushroom-shaped tumors. 
Since symptoms of early MF bear many resemblances to common inflammatory dermatoses, it 
is often misdiagnosed as chronic contact dermatitis, atopic dermatitis, or psoriasis. The 
malignant T cell of MF expresses surface markers characteristic of a skin-homing memory T 
cell, such as CD2, CD3, CD4, CD5, CD45RO and cutaneous lymphocyte antigen (CLA). The MF/SS 
malignant cells frequently lack CD7, CD26, CD49 and CD60 expression (Kim et al., 2005). In the 
early stages of MF a clonally expanded population of T cells can be detected by analysis of T-
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cell-receptor- rearrangement (Wood et al., 1994). With the progression of the disease the 
number of the normal CD8+ lymphocyte population in skin lesions and in the peripheral blood 
decreases (Heald et al., 1994; Hoppe et al., 1995; Lu et al., 2002). Cytotoxic (CD8+) T 
lymphocytes mount an antitumor response in cutaneous T-cell lymphoma and may induce 
apoptosis by the expression of Fas ligand (FasL) and the engagement of cell-surface Fas (CD95) 
on the malignant cells. This is consistent with the decrease in Fas expression within the CD8+ 
T-cell population in the later stages of MF (van Doorn et al., 2002). Depending on the stage of 
the disease, different cytokine profiles have been identified. In the early patch stage of MF the 
Th1 cytokines dominate whereas in the late stages of the disease as well as in SS a bias 
towards a Th2 profile has been identified (Saed et al., 1994). The malignant T cells of MF/SS 
express such cytokines as IL-4, IL-5 and IL-10, which are representative for Th2 cytokines and 
fail to display IL-12 and IFN- - characteristic of Th1 (Vowels et al., 1994). Both, neoplastic MF 
cells and reactive T cells have been found to express abundant amounts of CCR4, CXCR3, 
CXCR4 and CCR7 in the early patch and plaque stages of MF. Involvement of the chemokine 
receptors – CCR4 and CXCR3 – in skin homing of T cells in early MF and its loss is associated 
with the progression of the disease (Lu et al., 2001).  
Staging of patients with MF and SS is based on the tumor-node-metastasis system (Bunn and 
Lamberg, 1979), though a new WHO – EORTC classification has recently been developed on 
the base of the EORTC classification for cutaneous lymphomas (Willemze et al., 1997) and the 
WHO classification for nodal lymphomas (Jaffe ES). The new consensus WHO – EORTC 
classification reconciles these two systems, and takes into account different clinical behaviors 
of primary cutaneous lymphomas as well as their distinct histological, phenotypical and 
molecular features as compared to nodal counterparts. This staging expands the traditional 
staging system to include a B rating on the basis of molecular evidence of leukemic 
involvement (Sausville et al., 1988; Vonderheid et al., 2002). Staging of CTCL patients is 
summarized in Table 3. The most frequent forms of CTCL, MF proceeds slowly (5-20 years) but 
leads mostly to death, which is often caused in the late phase of CTCL by rapidly growing, 
ulcerating tumors and immune disorders. In addition to generalized erythroderma, patients 
with SS have leukemic T cells in the blood and life expectancy is generally shorter (3 years) 
than it is for patients with MF. 
 
 
Introduction 
 
 
10 
 
Table 3. TNMB staging system for CTCL - ISCL/EORTC revision (Olsen et al., 2007). 
 Clinical signs 
T: Tumor stage (skin) 
T1 Patches/plaques < 10% body surface area 
T2 Patches/plaques  10% body surface area 
T3 Tumors (rounded or dome-shaped lesions  1cm in diameter) 
T4 Erythroderma ( 80% of body surface area affected) 
N: Nodal stage 
N0 No clinically abnormal peripheral lymph nodes, pathological findings not CTCL 
N1 Clinically abnormal (palpable) peripheral lymph nodes, pathological findings not CTCL 
N2 No clinically abnormal peripheral lymph nodes, pathological findings positive for CTCL 
N3 Clinically abnormal (palpable) peripheral lymph nodes, pathological findings positive for CTCL 
M: Visceral organs 
M0 No visceral organ involvement 
M1 Visceral involvement with pathological confirmation 
B: Peripheral blood 
B0 Atypical circulating cells not present ( 5%) 
B1 Atypical circulating cells present (5% or more) 
B2 
High blood tumor burden:  1000/l Sézary cells with positive clone; CD4/CD8 ratio  10, 
aberrant expression of normal T-cell markers, molecular evidence of clonality, or 
chromosomal abnormality in a T-cell clone 
Stage T N M B 
IA 1 0 0 0-1 
IB 2 0 0 0-1 
II 1-2 1-2 0 0-1 
IIB 3 0-2 0 0-1 
III 4 0-2 0 0-1 
IIIA 4 0-2 0 0 
IIIB 4 0-2 0 1 
IVA1 1-4 0-2 0 2 
IVA2 1-4 3 0 0-2 
IVB 1-4 0-3 1 0-2 
 
1.1.2 Biological and Molecular Prognostic Factors in T-cell lymphoma 
Apart from the pathologic characterization according to different cytokine and chemokine 
expression by PTCLs, several other biological and prognostic factors have been identified in 
these types of lymphomas. Interestingly, a proliferation signature has recently been reported 
to correlate with an aggressive clinical course (Cuadros et al., 2007) and EBV has been 
proposed as a negative prognostic factor in PTCL (Cheng et al., 1993; Dupuis et al., 2006b; Kluin 
et al., 2001). The relationship between the overexpression of p53 and Ki-67 has also been 
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suggested as representative of high proliferation and subsequently worse prognosis. 
Consistently, elevated Ki-67 expression, EBV status and CD15 staining were related to worse 
outcome in PTCLU patients (Went et al., 2006). Recently, CD26 and a positive regulatory 
domain 1 (PRDM1) have emerged as unfavorable prognostic factors in PTCL (Carbone et al., 
1994; Carbone et al., 1995). PRDM1 is upregulated in PTCLU, ALCL and in T/NK lymphomas and 
is characteristically lost in AITL. High CYP3A4 expression was found to be significantly 
associated with lower complete remission rate (Rodriguez-Antona et al., 2007). In contrast, 
PTCL patients with tumors expressing a CD57 or CD4+/CD8- profile showed a tendency 
towards a more favorable outcome (Bekkenk et al., 2003; Kojima et al., 2004).  
In addition, the factors reported to herald a poor prognosis in MF include: age  60, elevated 
LDH (Diamandidou et al., 1999), elevated soluble interleukin-2 receptor levels (Wasik et al., 
1996), a low percentage of CD8+ tumor infiltrating lymphocytes (Hoppe et al., 1995), extent of 
skin involvement in patients with T3 disease (Quiros et al., 1996), T-cell clonality within the 
cutaneous infiltrate (Guitart et al., 2003), an identical T-cell clone in the skin and peripheral 
blood (Berth-Jones, 2005), and T-cell clonality in dermatopathic lymph nodes (Bakels et al., 
1993). Moreover, increased expression of cell death regulating genes, such as MCL-1 and 
inactivation of cell death promoting BAD and BAX proteins have been observed in the course 
of MF/SS progression. 
Several predictors related to therapy outcome have been identified. These include predictors 
of chemotherapy efficacy, such as the expression of TOPO2-alpha and other detoxifying agents 
including GST-pi, which are related to resistance to anthracycline and alkylating agents therapy 
in PTCL (Rodriguez et al., 2008). Interestingly, p53+ patients overexpressing p-glycoprotein, 
were found to be resistant to most major drugs effective in the aggressive lymphomas, such as 
anthracyclins, etoposide or vincristine (Dalton et al., 1989; Pescarmona et al., 2001). In the 
case of ALK+ ALCL, the presence of less antiapoptotic active mechanisms (BCL-2, BCL-xL) than 
in other subtypes may explain the better prognosis with standard chemotherapy (Rassidakis et 
al., 2003). 
1.1.3 Gene Expression Profiling of T-cell lymphoma 
The molecular pathogenesis of most PTCLs is poorly understood. One of the disadvantages of 
genomic profiling studies is related to the lack of suitable cell lines in most of the aggressive 
PTCL. Thus most studies have been performed on cutaneous T-cell lymphoma (CTCL). Although 
there is a great overlapping between entities some authors have found differences between 
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some PTCL, such as AITL and ALCL (de Leval et al., 2007; Thompson et al., 2005). PTCL have 
been the subject of a limited number of GEP studies. In particular, our group (Tracey et al., 
2003), Lamant (Lamant et al., 2007)  and Leval (de Leval et al., 2007) focused on MF, ALK-
positive and –negative ALCLs, and AITL, respectively.  
Peripheral T-cell lymphoma, unspecified (PTCLU): There are several studies aiming at 
identification of different molecular subgroups within PTCLU based on gene expression profile. 
They define discrete subgroups based on differences in expression levels of genes related to 
NF-B (Martinez-Delgado et al., 2005) and IFN/JAK/STAT pathways (Ballester et al., 2006). The 
latter study allowed the division of PTCLU into three groups named U1, U2, U3 based on gene 
expression signature and prognosis. Additionally, enrichment of CD8+ T cell signature and a 
repertoire of cytotoxic molecules (perforin, granulysin, granzymes and cathepsins) have been 
lately suggested in PTCLU (Iqbal et al., 2009). 
Angioimmunoblastic T-cell lymphoma (AITL): Recent gene-expression profiling studies 
suggested that TFH (follicular helper T cells) may be the cell of origin of AITL (de Leval et al., 
2007; Piccaluga et al., 2007). TFH cells are CXCR5+/CCR7- T cells, located in germinal centres, 
which provide help to B cells in cellular immune responses, through the acquisition of other 
molecules, such as ICOS (immune costimulatory molecule), CD40L and IL-21 (King et al., 2008). 
Among the genes upregulated in TFH cells are CXCL13, BCL6 and programmed death-1 (PD1) 
(Kim et al., 2004). PD1 and CXCL13 are particularly useful markers in the diagnosis of AITL, 
helping to differentiate this condition from lymphoid hyperplasias and PTCLU (Dorfman et al., 
2006; Dupuis et al., 2006a). In addition, gene expression profiling revealed a strong 
microenvironment imprint with overexpression of B cell and follicular dendritic cell-related 
genes, chemokines, and genes related to extracellular matrix and vascular biology (de Leval et 
al., 2007). Different cytokine and chemokine expression analysis demonstrated a TH1 
phenotype of AITL characterized by expression of TH1 related markers, CXCR3, TNF receptor, 
OX40 and CXCL13 (Ohshima et al., 2004; Tsuchiya et al., 2004). Recently, AITL classifier has 
been described, which included B-cell, a follicular dendritic cell (FDC) and  cytokine signatures 
confirming previously published data (Iqbal et al., 2009). 
Anaplastic large cell lymphoma (ALCL): Recently, differences in molecular signature of ALCL 
with or without ALK expression have been established. Overexpression of four genes CCR7, 
CNTFR, IL22 and IL21 were related to ALCL ALK- while BCL6, PTPN12, CEBPB and SERPINA1 
genes were upregulated in ALCL ALK+ (Thompson et al., 2005). With regards to the expression 
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of cytokines and chemokines, ALCL have been associated to a TH2 phenotype. Neoplastic cells 
of these lymphomas usually show expression of CCR4 and CCR3, but are negative for the TH1-
associated chemokine receptor CXCR3 (Ohshima et al., 2004; Tsuchiya et al., 2004). Expression 
of other genes, such as IL13R, FOS and JUNB also suggests association of ALCL with TH2 
differentiation. The newly reported ALCL classifier by Iqbal and colleagues (Iqbal et al., 2009)  
includes ALK, TNFRSF8 (CD30), MUC1, TH17-cell associated molecules (IL17A, IL17F, ROR) and 
immunoregulatory cytokines/receptors modulating STAT3 (IL26, IL31RA) and JAK3 activation 
(IL9). 
Cutaneous T-cell lymphoma (CTCL): Several studies have indicated the importance of NF-B 
activation in CTCL (both in cell lines as well as patient samples) demonstrating the involvement 
of p50 and RELA/p65 (Izban et al., 2000). Besides, our group showed that a deregulation of 
TNF and PI3K-PTEN-AKT signaling pathways impairs apoptosis of malignant cells  in MF (Tracey 
et al., 2003). In addition, it has been suggested that BCL2 and BAX play a role in pathogenesis 
of MF (Dummer et al., 1995; Nielsen et al., 1999). Other members of BCL2 gene family, such as 
apoptosis-inhibiting members: BCL-xL and MCL1 and apoptosis-promoting: BAD and BAX are 
expressed in CTCL cell lines as well as cutaneous lesions. The increase of MCL1 expression was 
observed in the later-stage skin lesions and associated with the disease progression and could 
be implicated in resistance of CTCL cells to some anti-cancer drugs (Zhang et al., 2003). The 
study of the role of oncogenes in the pathogenesis of MF revealed an increased protein 
expression of K-RAS in tumor cells in the late stages of MF (Tosca et al., 1991).  
1.1.4 MicroRNAs in T-cell lymphoma 
Mature microRNAs (miRNAs) are 19-24 nucleotide non-coding single-stranded RNA molecules 
which regulate the expression of target genes through perfect (in plants) or imperfect (in 
animals) binding to the 3’-UTR (un-translated region) and possibly 5’-UTR (Lytle et al., 2007) of 
mRNA. miRNAs are processed by Drosha and Dicer (Wiemer, 2007) and cause translation 
repression or mRNA degradation of their target genes. There are currently over 600 human 
miRNA sequences annotated in the miRBase database 
(http://microrna.sanger.ac.uk/sequences/), although it is believed that the true figure is closer 
to one thousand (Bentwich et al., 2005; Berezikov et al., 2005). Despite the relatively small 
number of miRNAs, because a single miRNA can target  several hundred genes, and conversely 
a single target gene can cooperatively bind to multiple miRNAs (Lewis et al., 2003), it is 
currently believed that between 10% and 30% of all human genes are a target for miRNA 
regulation (John et al., 2004; Lewis et al., 2005). miRNAs are expressed in a tissue-/cell-specific 
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manner, some expressed ubiquitously whilst others appear to be restricted to single cell types 
(Landgraf et al., 2007).  
There is now compelling evidence that dysfunctional expression of miRNAs is a common 
feature of malignancy (Calin and Croce, 2006). Aberrant expression of specific miRNAs has now 
been associated with all cancer types including solid and haematopoietic tumors. Germline 
and somatic mutations in miRNAs or polymorphisms in the mRNAs targeted by miRNAs may 
also contribute to cancer predisposition and progression (Calin and Croce, 2007). Moreover, it 
has been suggested that miRNA expression profiling can distinguish cancers according to 
diagnosis and developmental stage of the tumor to a greater degree of accuracy than 
traditional gene expression analysis (Lu et al., 2005). miRNAs are proposed to play a direct role 
in oncogenesis as they can function as both oncogenes (e.g., miR-155 and members of miR-17-
92 cluster) and tumor suppressor molecules (e.g., miR-15a and miR-16). There are currently 
understood to be at least three mechanisms whereby miRNAs are de-regulated in cancer; (i) 
chromosomal lesions at regions encoding miRNAs, (ii) defects in the miRNA biosynthetic 
pathway machinery and (iii) epigenetic regulation (Lawrie, 2008).  
Little research has been carried out to study the direct role of miRNAs in T cell lymphomas. 
Recently the T lymphoma causing murine leukemia virus (MLV) was used in a screen to identify 
common proviral integration sites and found a high density of integrations upstream of the 
miR-106a cistron (Lum et al., 2007). The same group has shown that the miR-17-92 cluster was 
also a common integration site (Wang et al., 2006). Additionally, miRNAs have been found to 
be encoded in the avian T-cell lymphoma causing virus, Marek’s disease virus (MDV). EBV-
associated microRNAs were recently profiled in a peripheral T cell lymphoma case, which were 
consistent with a type II latency infection (Jun et al., 2008). So far no miRNA profiling has been 
performed for T-cell lymphoma. 
1.1.5 Clinical Management of T-cell lymphoma 
There is no consensus as to the appropriate standard therapy for PTCL. The optimal therapy 
for most PTCL is an area of controversy for multiple reasons including the rarity of the 
diseases, the difficulty to make a rapidly and definite histopathologic diagnosis, their variable 
clinical course with a number of more unusual presentation and different clinical “syndrome” 
which they can present, and especially for the lack of randomized clinical trials that focus 
specifically on T-cell lymphoma. Indeed, the problem of T-cell lymphoma has been defined 
“the next, and largely unexplored, frontier in lymphoma management” (Armitage et al., 2004) 
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and undoubtedly is one of  the most challenging problems for clinicians. In case of CTCL there 
is no cure, so palliation and symptom control comprise current treatment objectives. Although 
partial and complete remission can be achieved, subsequent relapses are common and 
curative therapy remains elusive (Duvic et al., 2001; Kim et al., 2005; Olsen et al., 2001; Prince 
et al., 2003; Querfeld et al., 2005). Prognosis of PTCL is generally poor when treated with 
conventional chemotherapy regimens used in B-cell aggressive lymphomas. Clearly, better 
therapeutic regimens are needed to improve the long-term outcome of these patients. The 
present treatment modalities include: 
Skin-directed therapies: Skin-directed therapies are the appropriate first-line treatment for 
early stages (I-IIA) CTCL patients who have limited patch/plaque disease and include:  
- Topical corticosteroids 
- Topical mechlorethamine (nitrogen mustard) 
- Topical carmustine (BCNU) 
- Topical retinoids/rexinoids 
- Psoralen plus UVA irradiation (PUVA) 
- Total skin electron beam therapy (TSEB) and  
- Superficial X-irradiation 
Psoralen and ultraviolet A photochemotherapy (PUVA) is one of the treatments analyzed in the 
presented work hence its use will be briefly explained. PUVA combines the oral or topical 
administration of psoralen (to sensitize skin) with exposure to UVA light. Psoralens are tricyclic 
aromatic compounds which have phototherapeutic activities. The mechanism of action is not 
precisely known, however generation of reactive oxygen species, inhibition of DNA synthesis 
and mitochondrial dysfunction caused by opening of the permeability transition pore have 
been proposed as possible mechanism of apoptosis generation (Caffieri et al., 2007; Parrish et 
al., 1974; Potapenko, 1991; Yoo et al., 1996).  
At present, PUVA is used for the treatment of several hyperproliferative skin diseases, such as 
MF (Stern, 2007). The clinical benefit of PUVA is well established and response rates of 79–88% 
in stage IA and 52–59% in stage IB patients have been reported. However, relapse is frequent 
after treatment suspension, resulting in frequent re-treatment leading to high total cumulative 
UVA dose and increased risk of skin cancers.  
 
Introduction 
 
 
16 
 
Systemic therapy: Patients with refractory early-stage MF or more severe disease stages (IIB-
IV) are likely to receive systemic therapies, either alone or in combination with skin-directed 
therapies (Trautinger et al., 2006). These agents comprise the main treatment categories: 
- Chemotherapy 
- Extra-corporeal photopheresis (ECP) 
- Biological response modifiers 
- Immunotherapy 
CHOP-type (cyclophosphamide, doxorubicin, vincristine and prednisone) chemotherapy is 
considered  as the standard therapy for PTCLs, however, with the notable exception of ALK+ 
ALCL, outcomes utilizing anthracycline-based regiments has been uniformly disappointing 
(Fisher et al., 1993). In CTCL CHOP regimen demonstrated only moderate anti-tumor activity 
(Bagot, 2008). 
ECP in the treatment of CTCL isolates the malignant cells in the blood, irradiates them and then 
reintroduces into patients for potential immunization against disease. Response rates of 63% 
were reported in CTCL, however, the high cost and availability limit its use.  
Biological response modifiers such as interferon alpha (IFN), retinoids, rexinoids, and 
denileukin diftitox, alemtuzumab, have shown considerable activity in the treatment of 
advanced CTCL. IFNs are cytokines that exhibit pleiotropic cellular effects, including 
immunomodulatory, anti-proliferative and pro-apoptotic effects (Stark et al., 1998). IFN has a 
stimulatory effect upon natural killer cells and macrophages, inducing them to produce IFNγ 
and IL1 in addition to stimulating their cellular cytotoxicity and inducing cellular proliferation 
of T-lymphocyte effector cells (Jonasch and Haluska, 2001). Direct cytostatic effects, induction 
of apoptosis and inhibition of cell growth are observed in tumor cells in response to IFN, with 
targeting of specific components of the cell cycle control apparatus such as c-MYC, Rb, 
CyclinD3, CDC25A and BCL2 (Kumar and Atlas, 1992; Melamed et al., 1993; Resnitzky et al., 
1992; Tiefenbrun et al., 1996) as well as other cell cycle regulators such as p15, p21, p27 
(Sangfelt et al., 1999) and IFN Regulatory Factor (IRF) transcription factors (Xie et al., 2003).  
IFN monotherapy has been reported to produce clinical response in over 50% of patients 
(Olsen, 2003), while others have reported overall response rates of 45–74% and complete 
response rates in 10–27% of patients (Stadler, 2003). When IFN is used in combination with 
PUVA, both response and response duration are improved (Chiarion-Sileni et al., 2002; Rupoli 
et al., 2005), with recent studies reporting overall response and complete response rates of 
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98% and 84%, respectively. A randomised study of IFN and/or PUVA in early-stage MF 
suggests that the response rates are similar, but the cumulative dose is lower and the duration 
of response is prolonged for the combined regimen (Stadler, 2003). 
Homozygous and hemizygous deletions of the IFN gene (Colamonici et al., 1992), alterations 
in some of the IFN response genes, such as well known members of the JAK/STAT signalling 
pathway (STAT1, STAT2, STAT3, SOCS1 or IFNR)  (Abramovich et al., 1994; Gamero et al., 2004; 
Landolfo et al., 2000; McKendry et al., 1991; Roman-Gomez et al., 2004; Sakamoto et al., 1998; 
Sun et al., 1998; Yang et al., 1998), changes in membrane microdomain gene expression 
(Tracey et al., 2002) and infection by Epstein Barr Virus (Nanbo et al., 2002) have all been 
implicated in IFN resistance. However, these studies are largely confined to in vitro studies 
and have therefore not been able to explain the frequent clinical phenomenon of IFN 
resistance.  
Denileukin diftitox (Ontak) is a fusion molecule of IL-2 to diphtheria toxin and has been shown 
to have efficacy in patients with CTCL. Limited reports have also demonstrated tumor 
responses to denileukin diftitox in relapsed PTCLs. IL-2 receptor (IL-2R) is a marker of T-cell 
differentiation and the CD25 subunit of this receptor is expressed in a subset of patients with 
PTCLU and CD30+ ALCL. Denileukin diftitox targets cells expressing the IL-2R, interrupts protein 
synthesis and precipitates cell death (Smith and Wilson, 2003). The US Food and Drug 
Administration have granted approval for its use in refractory CTCL tumors expressing the IL-
2R (Olsen et al., 2001). 
There are several novel agents – including interferons (Armitage and Coiffier, 2000), denileukin 
diftitox (Di Venuti et al., 2003), campath-1H (Enblad et al., 2004), cyclosporine (Cooper et al., 
1993), pentostatine (Mercieca et al., 1994) and cladribine (Saven et al., 1992), which have 
shown some benefit in relapsing patients and will need to be carefully studied in order to be 
optimally incorporated in front line treatments. At present, some ongoing European trials are 
investigating the role of Campath-1H (and anti-CD52 monoclonal antibody) in combination 
(contemporary or sequentially) with chemotherapy using low dose of the monoclonal 
antibody. Moreover, several histone deacetylase inhibitors are in clinical development and 
suberoylanilide hydroxamine acid (vorinostat) has been approved in US for treatment of 
aggressive and refractory CTCL (Vorinostat will be discussed in section 1.3.1).  
Although infrequent, these types of lymphomas are behind the other lymphomas in both 
molecular biology knowledge and treatment results. Only recently international efforts are 
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putting into motion both biological studies and targeted new treatments for this type of 
lymphomas.  
1.2 Epigenetics and Cancer 
Epigenetics is the study of heritable changes in gene expression that are not due to any 
alteration in the DNA sequence (Feinberg, 2008; Fraga et al., 2005a). Epigenetic modification 
can be viewed as “on” and “off” switches for gene expression, where shutting down tumor-
suppressor genes or activating oncogenes can lead to dysregulated cellular proliferation and 
apoptosis (Mack, 2006). 
Histones are a family of proteins that interact with DNA, resulting in DNA being coiled around a 
histone octameric core within the nucleosome. Histone deacetylase (HDAC) enzymes catalyse 
the deacetylation of lysine residues in the histone N-terminal tails and are also found in large 
multiprotein complexes with transcriptional corepressors. The addition of an acetyl group to 
histones (acetylation) loosens this binding and allows expression of tumor suppressor genes. 
Conversely, deacetylation can result in tumor formation. HDACs are enzymes that regulate 
chromatin structure and function through the removal of acetyl groups from lysine residues of 
core histones, facilitating a closed chromatin state and transcriptional repression. The 
opposing activities of  HDAC and histone acetyltransferases regulate histone acetylation and 
chromatin architecture (Bolden et al., 2006). Human HDACs are classified into four classes 
based on their similarity to yeast factors, with 18 different HDACs identified to date (Table 4) 
(Bhalla, 2005; Gregoretti et al., 2004). Class I HDACs are primarily detected in the nucleus, 
while Class II and IV HDACs shuttle between the cytoplasm and nucleus (Bolden et al., 2006; 
Dokmanovic et al., 2007).  
 
The organization of chromatin into either a relatively open or condensed form impacts on key 
molecular processes such as transcription, DNA repair, recombination and replication, with 
clear evidence that gene expression controlled by epigenetic changes can play an important 
role in cancer onset and progression (Baylin and Ohm, 2006; Lund and van Lohuizen, 2004). 
Increased acetylation of histones H3 and H4 is associated with open and active chromatin and 
increased transcription, while deacetylation of these histone residues is associated with 
condensed chromatin and transcriptional repression (Rice and Allis, 2001). Alteration in the 
balance of activity between HDACs, in association with aberrant gene transcription, has been 
observed in cancer cells in both hematological and solid malignancies (Cress and Seto, 2000; 
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Jones and Saha, 2002; Redner et al., 1999; Timmermann et al., 2001). Moreover, the finding 
that global hypoacetylation of histone H4 is a common hallmark of human cancer adds to the 
rationale that HDACs are important potential therapeutic targets in anticancer therapy (Fraga 
et al., 2005b). There is a growing evidence that epigenetic changes play a crucial role in cancer 
and it has been widely recognized in recent years that HDAC are promising targets for 
therapeutic interventions intended to reverse aberrant epigenetic states associated with 
cancer (Lund and van Lohuizen, 2004; Rasheed et al., 2007).  
 
Table 4. Known classes of histone deacetylases 
 
Class Enzyme 
I HDAC 1, HDAC 2, HDAC 3, HDAC 8 
IIa HDAC 4, HDAC 5, HDAC 7, HDAC 9 
IIb HDAC 6, HDAC 10 
III SIRT 1,2,3,4,5,6,7 
IV HDAC 11 
HDAC: Histone deacetylase; SIRT: Sirtuin 
 
1.3 Biological pathways as targets for new therapies in PTCL 
1.3.1 Histone Deacetylase Inhibitors 
Histone deacetylase inhibitors (HDACi) are a new class of chemotherapeutic drugs shown in 
preclinical studies to have potent anticancer activities (Bolden et al., 2006; Rasheed et al., 
2007). Although it is not yet clear exactly how HDACi achieve therapeutic anticancer 
responses, these agents induce rapid histone hyperacetylation,  chromatin remodeling and can 
activate or repress genes regulating apoptosis, proliferation, differentiation, angiogenesis, and 
immune responses (Figure 2) (Bolden et al., 2006). However, the exact pathways that lead to 
the anticancer effects observed in various tumor types remain to be fully elucidated. Despite 
encouraging in vitro activity, early compounds derived from natural products, such as 
depudecin, trapoxin, and trichostatin, have limited in vivo antineoplastic activity, partly 
because of poor retention, instability, and toxicity. The therapeutic action of HDACi in CTCL 
patients may relate to induction of histone hyperacetylation, altered gene expression, and 
subsequent apoptosis of malignant T cells (Zhang et al., 2005), although other effects such as 
loss of cell proliferation and decreased angiogenesis may also play a role (Duvic et al., 2007). 
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Figure 2. Effects of histone deacetylase inhibition 
 
Vorinostat (suberoylanilide hydroxamine acid, SAHA) is the first HDACi in its class to be 
approved by the FDA for cancer therapy (Mann et al., 2007). Vorinostat is a pan-HDACi, which 
inhibits the enzymatic activity of histone deacetylases (HDACs) resulting in the accumulation of 
acetylated histones and nonhistone proteins. Vorinostat causes caspase-dependent apoptotic 
cell death, caspase-independent autophagic cell death and cell cycle arrest of a wide variety of 
transformed cells (Marks et al., 2001; Marks and Dokmanovic, 2005; Marks and Jiang, 2005; 
Shao et al., 2004). Modulated expression of 2-10% of genes  in malignant cells has been 
described (Butler et al., 2002; Gray et al., 2004; Marks et al., 2004; Mitsiades et al., 2004; 
Richon et al., 2000). CDKN1A (p21, WAF1/CIP1) is a commonly induced gene following 
vorinostat treatment and could be related to the arrest in G1 phase of the cell cycle (Richon et 
al., 2000), while cyclin D1, ERBB2 and thymidylate synthase belong to genes repressed 
following vorinostat treatment (Gui et al., 2004). Other targets of vorinostat include 
transcription factors (MyoD, E2F-1, Smad 7, TF11E and GATA1), tumor suppressors (p53, Rb), 
Introduction 
 
 
21 
 
as well as factors involved in cell motility (-tubulin), apoptosis (Bcl-2 family), angiogenesis 
(HIF-1) and reactive oxygen species (thioredoxin) (Bolden et al., 2006; Drummond et al., 
2005; Johnstone and Licht, 2003; Marks and Dokmanovic, 2005; Marks and Jiang, 2005; Rosato 
et al., 2003; Shao et al., 2004; Ungerstedt et al., 2005). In addition, HDACi cause 
hyperacetylation of nonhistone protein, such as chaperone protein Hsp90, Raf, AKT, ErbB2, 
and Bcr-Abl, thus achieving antitumor effects (Kim et al., 2006b). Such a multiplicity of targets 
could partly explain the efficacy of vorinostat as an anticancer agent. However, the exact 
mechanism, the kinetics of gene expression and players involved in resistance to this drug are 
still unknown. 
 
Clinical trials in patients with refractory CTCL demonstrate an objective overall response of 
30% (Duvic et al., 2007) following vorinostat treatment. Presently, vorinostat is in clinical trials 
both as monotherapy and in combination with various anticancer drugs. Vorinostat has been 
reported to have synergistic or additive effects when used with several anticancer agents, 
including anthracyclines, fludarabine, flavopiridol, imatinib, bortezomib, isotretinoin, 
antiangiogenic agents and TNFS10 (Johnstone and Licht, 2003; Marks et al., 2004). At present, 
there are 137 clinical trials registered for this drug (www.cancer.gov). In 41 trials vorinostat is 
used as a monotherapy, while in as many as 96 clinical trials, vorinostat is used in combination 
with other therapies. The conversion from mono- to combination- therapy clinical trials is 
heralding future applications of specific HDACi. However, in order to achieve the desired effect 
following administration of combinatorial drug therapies, the exact mode of action as well as 
the time at which expression of particular genes is altered needs to be identified. 
1.3.2 Heat Shock Protein Inhibitors 
Heat shock proteins (HSPs) were originally defined according to their increased expression in 
response to a cellular insult, such as elevated temperature, heavy metals and oxidative stress 
(Hartl and Hayer-Hartl, 2002; Young et al., 2004). Most, but not all HSPs are molecular 
chaperones that are organized into families according to their molecular size or function, 
including Hsp100, Hsp90, Hsp70, Hsp60, Hsp40 and small HSPs. Chaperones are required for 
essential housekeeping functions, such as de novo protein folding during nascent polypeptide-
chain synthesis, translocation of proteins across membranes, quality control in the 
endoplasmic reticulum, and normal protein turnover as well as regulation of post-translational 
protein homeostasis (Figure 3) (Wegele et al., 2004; Whitesell and Lindquist, 2005).  
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Figure 3. Participation of molecular chaperones in regulating many aspects of post-
translational protein homeostasis 
 
Hsp90 is an abundant molecular chaperone which constitutes 1-2% of total cellular protein. 
Hsp90 and other family members control intracellular trafficking and folding of diverse cellular 
proteins, particularly those involved in signal transduction, cell cycle regulation, and survival 
decisions (Garrido et al., 2001; Richter and Buchner, 2001). However, increased Hsp90 activity 
may also allow survival of genetically unstable cancer cells allowing escape from the 
apopototic death and overexpression of Hsp90 has been reported in many cancers (Ferrarini et 
al., 1992; Lebeau et al., 1991). Hsp90 client proteins include mutated and/or overexpressed 
signaling proteins implicated in cancer, such as mutated p53 (Blagosklonny et al., 1996), Bcr-
Abl (An et al., 2000; Shiotsu et al., 2000), Raf-1 (Schulte et al., 1996), AKT (Hostein et al., 2001; 
Sato et al., 2000), ErbB2(Miller et al., 1994), hypoxia-inducible factor 1 (HIF-1) (Minet et al., 
1999), cyclin-dependent kinases Cdk4 and Cdk6 (Stepanova et al., 1996) and steroid receptors 
including estrogen and androgen receptors (Bagatell et al., 2001). Additionally, it has been 
reported that Hsp90 and its co-chaperones modulate tumor cell apoptosis through effects on 
AKT (Basso et al., 2002), tumor-necrosis factor (TNF)-receptors (Vanden Berghe et al., 2003) 
and nuclear factor-B (NF-B) function (Chen et al., 2002a). 
 
Hsp90 inhibition has several advantages in cancer therapy. First, Hsp90 inhibition minimizes 
toxicities in normal tissues while it maximizes target-specific damage in tumor tissues. This is 
due to increased Hsp90 expression in tumors and preferential accumulation of Hsp90 
inhibitors in malignant tissues (Kitano, 2003). Second, multiple signaling pathways can be 
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targeted simultaneously with Hsp90 inhibition because many of the signaling proteins are 
HSP90 client proteins. Third, as Hsp90 inhibition targets multiple pathways, the likelihood that 
tumor cells will escape a single-target therapy lessens. This is especially relevant in solid 
tumors because by the time of diagnosis, most solid tumors harbor multiple genetic 
abnormalities that could have conferred the ability to overcome a single-target therapy. 17-
allylamino-geldanamycin (17-AAG), a geldanamycin analog, is the first of its class to enter 
clinical trials. 17-AAG inhibits Hsp90-dependent conformational folding and promotes 
degradation of oncoproteins, such as ErbB2, mutant p53, c-Raf, and Bcr-Abl, and has shown 
antitumor activities in preclinical experiments (Ramanathan et al., 2005). 17-AAG is currently 
being tested in various solid and hematological malignancies, either as a single agent or in 
combination therapies. However, clinical trials with 17-AAG failed to show anti-tumor efficacy 
so far, despite extensive testing. It is felt that second-generation and third-generation 
inhibitors may be needed to adequately determine whether Hsp90 is a valid target for cancer 
therapy.  
 
Disruption of HSP-client protein complex can also be achieved by the nonhistone effects of 
HDAC inhibitors. Several reports demonstrate the enhanced acetylation of Hsp90 by HDACi 
and suggest involvement of HDAC6 in modulation of Hsp90 acetylation. These reports 
document the connection between HDACi-mediated Hsp90 acetylation and the depletion of 
numerous Hsp90 client proteins (Atadja et al., 2004; Yu et al., 2002). 
1.3.3 PI3K inhibitors 
The phosphatidylinositol-3-kinase (PI3K) signaling pathway is crucial to many aspects of cell 
growth and survival. It is targeted by genomic aberrations including mutation, amplification 
and rearrangement more frequently than any other pathway in human cancer (with the 
possible exception of the p53 and retinoblastoma (Rb) pathways). There are three classes of 
PI3K, each with its own substrate specificity and distinct lipid products (Engelman et al., 2006; 
Katso et al., 2001). The Class IA of PI3K is the most widely implicated class in cancer and 
consists of three known isoforms of p110 (p110α/p110β/p110δ) with the first two isoforms 
being widely expressed and the third of which is restricted to lymphocytes (Fruman, 2004). The 
most frequent genetic aberrations in breast cancer are somatic missense mutations in the 
gene encoding p110α (PIK3CA). Amplification or mutation of the PIK3CA gene also commonly 
occur in bowel cancer, ovarian cancer, head and neck and cervical squamous cancers, gastric 
and lung cancers, anaplastic oligodendrogliomas, anaplastic astrocytomas, glioblastoma 
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multiforme and medulloblastomas which emphasizes the importance of the pathway 
(Broderick et al., 2004; Campbell et al., 2004; Ma et al., 2000; Mizoguchi et al., 2004; 
Shayesteh et al., 1999; Woenckhaus et al., 2002). PI3K activation initiates a single transduction 
cascade that promotes cancer cell growth, survival and metabolism. AKT, a serine-threonine 
kinase that is directly activated in response to PI3K, is a major effector of PI3K in cancer. There 
are three different AKT isoforms in mammalian cancers, and emerging data suggest that they 
have overlapping and distinct roles in cancers. AKT in response to PI3K activation 
phosphorylates and regulates the activity of a number of targets including kinases, 
transcription factors and other regulatory molecules. These targets include GSK3, BAD, human 
caspase 9, NF-B transcription factors, mTOR, eNOS (Figure 4), Raf protein kinase, BRCA1 and 
p21Cip1/WAF1 (Altiok et al., 1999; Datta et al., 1999; Montagnani et al., 2001; Zhou et al., 2001; 
Zimmermann and Moelling, 1999). AKT, directly or indirectly, phosphorylates and inhibits 
glycogen synthase kinase-3 (GSK3), phosphodiesterase-3B, protein phosphatase 2A and 
possibly PI3K signaling also controls angiogenesis, growth, proliferation, senescence and other 
processes through mechanisms including vascular endothelial growth factor (VEGF) 
transcriptional activation and induced hypoxia inducible factor-1 (HIF1) expression  
(Hennessy et al., 2005; Kim and Kaelin, 2004; Skinner et al., 2004). AKT signaling leads to 
increased cellular growth and survival (Engelman, 2009). One of the major effectors 
downstream of AKT is mTOR complex 1 (mTORC1), which integrates many inputs, such as 
growth factor signaling, the energy state of the cell (AMP levels) and nutrient and O2 
availability. 
 
Several small molecule inhibitors of PI3K-AKT signaling pathway are in clinical development. 
Two chemical inhibitors have been used to probe the function of PI3K: wortmannin, a fungal 
metabolite that irreversibly inhibits p110 by reacting covalently with the catalytic site, and the 
flavenoid derivative LY294002, a reversible inhibitor which, like wortmannin, inhibits all class I 
PI3Ks. However, both inhibitors have off-target activity. Many inhibitors with greater 
selectivity are under development, including GDC-0941, PX-866, SF-1126, XL-147, XL-765, CAL-
101 and RAD-001. However, as the PI3K pathway is important for many normal cellular 
functions and, in particular, signaling by insulin, the main limiting factor for implementing 
drugs that inhibit the pathway will probably be the identification of targets and drugs with a 
sufficient therapeutic index to warrant clinical implementation. 
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Figure 4. Signaling through the phosphatidylinositol-3-kinase (PI3K)/AKT pathway. 
1.3.4 PIM Inhibitors 
The Pim family of proto-oncogenes encodes serine/threonine specific kinases involved in 
cytokine-mediated signaling pathways in hematopoietic cells. The Pim gene family consists of 
three members, Pim-1, Pim-2 and Pim-3 (Bachmann and Moroy, 2005), which are substantially 
homologous, but differ in tissue distribution (Eichmann et al., 2000). Pim-1 and Pim-2 are 
expressed in most hematopoietic cells whereas the highest Pim-3 expression has been 
reported in brain, kidney, and mammary tissue (Mikkers et al., 2004). The Pim protein kinases 
were first cloned as proviral insertions in murine T-cell lymphomas induced by the c-Myc 
oncogene (Cuypers et al., 1984; Hoover et al., 1991). Unlike other serine/threonine kinases, 
the Pim kinases are not regulated by membrane recruitment or phosphorylation but primarily 
by transcription. Activated cytokine receptors recruit JAKs to induce STAT-dependent 
transcription of the Pim genes. The role of Pim signaling for cell survival in nontransformed 
cells has only recently been identified (Fox et al., 2005). Pim-1 contributes to the regulation of 
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cell apoptosis and antiapoptotic activity (Pircher et al., 2000; Shirogane et al., 1999; Wang et 
al., 2001) through its association with and phosphorylation of Bcl-xL/Bcl-2–associated death 
promoter (Bad), which is a proapoptotic member of the Bcl-2 family and capable of forming 
heterodimers with Bcl-2 or Bcl-xL (Datta et al., 2002). Several recently reported substrates of 
Pim are significant of its involvement in cell proliferation at both G1/S and G2/M transition, 
such as p21Cip1/WAF1 (Wang et al., 2002; Zhang et al., 2007), CDC25A (Mochizuki et al., 1999), 
PTPU2 (Wang et al., 2001), NuMA (Bhattacharya et al., 2002), C-TAK1 (Bachmann et al., 2004), 
and CDC25C (Bachmann et al., 2006). Other Pim targets have been described, these include 
the mentioned proapoptotic protein Bad (Fox et al., 2003; Yan et al., 2003), members of the 
suppressor of cytokine signaling (SOCS) family (Chen et al., 2002b; Peltola et al., 2004), the 
translational repressor eIF-4E binding protein 1 (4E-BP1), GSK3β (Fox et al., 2003) and the 
transcription factor Myb (Winn et al., 2003). Additionally, Pim-1 and Pim-2 have been reported 
to be essential components of an endogenous pathway that regulates T cell growth and 
survival (Figure 5) (Fox et al., 2005). 
 
 
Figure 5. Schematic representation of PIM signaling pathway. 
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In human, Pim-1 overexpression is reported in diffuse B-cell lymphoma, chronic lymphocytic 
leukemia, acute myelogenous leukemia, head and neck cancer, and prostate cancer 
(Amaravadi and Thompson, 2005; Cibull et al., 2006) and increase in Pim levels has been 
correlated with progression to a more aggressive disease (Dhanasekaran et al., 2001). 
Similarly, Pim-2 is found to be overexpressed in multiple myeloma, leukemia, lymphoma, and 
prostate cancer and its expression correlates with clinical outcome (Amson et al., 1989; 
Claudio et al., 2002; Dhanasekaran et al., 2001; Neill and Kelsell, 2001; Yoshida et al., 1999). 
Consistently, enhanced levels of nuclear Pim-2 in the tumor cells have been associated with a 
higher risk of prostate-specific antigen recurrence and with perineural invasion of the prostate 
gland (Dai et al., 2005). 
Besides cancer, Pim kinase activity has been shown to be of importance in the pathogenesis of 
vascular smooth muscle proliferation in vessel injury models (Katakami et al., 2004). However, 
in spite of the interest in Pim-mediated signaling, there are few known inhibitors of these 
enzymes. The only reported inhibitor of Pim function is LY294002, which was originally 
identified as a specific PI3K inhibitor (Jacobs et al., 2005). Development of specific inhibitors of 
Pim is underway and several groups have reported structurally novel Pim kinase inhibitors, 
such as imidazo[1,2-b]pyridazines (inhibit Pim and block the growth of leukemia cells) (Bullock 
et al., 2005; Pogacic et al., 2007), substituted pyridines (Cheney et al., 2007) and specific 
flavinoids (Holder et al., 2007a; Holder et al., 2007b). Evidence already exists to suggest that 
inhibitors of survival kinases can contribute to cancer therapy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
OBJECTIVES 
 
 
 
 
 
  
Objectives 
 
 
31 
 
 
 
Peripheral T-cell lymphoma (PTCL) is a relatively uncommon disease, accounting for 10-15% of 
Non-Hodgkin Lymphomas. The most common subtypes of peripheral T-cell lymphomas in 
Europe are peripheral T-cell lymphoma, unspecified (PTCLU), angioimmunoblastic T-cell 
lymphoma (AITL), anaplastic large cell lymphoma (ALCL) and cutaneous T-cell lymphoma 
(CTCL). Our group has significantly contributed to understanding of the pathogenesis and 
resistance to treatment in the field of cutaneous T-cell lymphoma (Tracey et al., 2003; Tracey 
et al., 2002). However, there is still a need to investigate new treatments as new therapies 
appear. The diagnosis of systemic PTCL is frequently challenging, and up to 50% of the cases 
are categorized as PTCL, unspecified (PTCLU) and the molecular alterations underlying the 
pathogenesis of PTCL are largely unknown. Hence, the objectives of the present thesis were 
the following: 
 
1. Exploring  the ontogeny and molecular heterogeneity of PTCL through a microRNA and 
gene expression profiling analysis of a series of AITLs and PTCLU samples 
 
2. Finding the molecular signature associated with response and resistance to PUVA +/- 
IFNα treatment in twenty-nine CTCL patients enrolled in phase IV randomized open 
clinical trial comparing PUVA vs. PUVA + IFNα 
 
3. Identification of genes and pathways that are differentially regulated by two histone 
deacetylase inhibitors (HDACi): vorinostat (SAHA) and panobinostat (LBH589) in five 
CTCL cell lines 
  
4. Providing rationale for novel drug combination partners and identification of a core set 
of HDACi-regulated genes 
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2. Materials and Methods 
 
2.1 Case selection  
 
The tissue samples used in the present work were obtained from the Tumor Bank Network 
coordinated by the Molecular Pathology Program at Spanish National Cancer Research Centre. 
The complete procedures for obtaining and processing the samples by Tumor Bank Network 
can be found on http://www.cnio.es/ing/programas/progTumor11.asp.  Immediately after 
biopsy the samples were processed according to two different protocols: 
1. Paraffin-embedded tissue: samples were fixed in 10% buffered formalin for a minimum 
of 16 hours and a maximum of 48 hours after which time; they were embedded in 
paraffin following conventional techniques.  
2. Frozen tissue: samples were frozen and duly identified in plastic cryomoulds (Cryomold 
standard, Tissue-Tek 4557, Bayer S.A) embedded in a cryosolidifiable medium (OCT-
Compound, Tissue-Tek 4583, Bayer S.A) through immersion in a highly cryogenic 
medium allowing rapid freeze such as isopentane. 
The diagnostics of all samples was centrally revised according to World Health Organization 
Criteria (WHO) using paraffin embedded sections with the help of immunohistochemistry 
techniques. 
 
For PTCL study of T-cell lymphoma pathogenesis, twenty peripheral T-cell lymphoma (PTCL) 
and seven reactive lymph node (LN) samples were selected from the medical records of 
hospitals included in the Spanish Tumor Bank Network. The PTCL cases comprised a total of 20 
cases, 9 of which represented diagnostic samples of patients with PTCLU and 11 patients with 
AITL. Clinical characteristics of all the patients included in PTCL study is presented in Table 5. 
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Table 5. Clinical characteristics of the peripheral T-cell lymphoma patients included in PTCL 
study 
ID 
Patient 
number 
Sex Age Diagnosis Stage PS 
TCL1 01040202 F 77 AITL IVA 1 
TCL2 01040203 F 42 PTCL IVA 1 
TCL3 01030422 F 73 AITL -- 1 
TCL4 01030195 M 49 PTCL IA 1 
TCL5 20030222 -- -- PTCL -- -- 
TCL6 00000326 M 42 AITL IVB 1-2 
TCL7 05011364 M  AITL -- -- 
TCL8 02010182 M 63 PTCL IV 2 
TCL9 02010235 M 39 PTCL IIA 1 
TCL10 05030174 -- -- AITL -- -- 
TCL11 01030194 M 78 PTCL IIA 1 
TCL12 00030729 M 69 PTCL -- -- 
TCL13 00000110 M -- AITL -- -- 
TCL14 00000183 M 27 AITL -- -- 
TCL15 00000311 F 70 AITL IIIA 0 
TCL16 00010062 F 81 AITL IVA 1 
TCL17 00011340 M 65 PTCL IVB 3 
TCL18 00020012 M 66 AITL IIIB 1 
TCL19 00030177 F -- PTCL -- -- 
TCL20 01030191 M 71 AITL IIIA 1 
Abbreviations: PS, Performance Status; AITL, Angioimmunoblastic T-cell lymphoma; PTCL, Peripheral T-cell 
lymphoma; --, no data available 
 
For PUVA +/- IFN study, twenty nine pre-treatment mycosis fungoides (MF) samples and 18 
inflammatory dermatitis (ID) samples were included. MF patients were enrolled in a 
randomised clinical trial, MF99 (ClinicalTrials.gov, registration number NCT00630903) to test 
the efficacy of PUVA vs. PUVA + IFN and were all stage IA, IB or IIB patients. Previous 
treatments included PUVA, topical corticosteroids, PUVA+IFN, BCNU, TSEB, Methotrexate 
and 8-MOP and are listed in Table 6 for each patient. Thirteen patients were previously 
untreated. Patients received no treatment for at least 1 month prior to beginning of the study 
protocol. All paraffin embedded and frozen samples represented biopsies taken in the 2 weeks 
preceding treatment commencement on MF99. 
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Table 6. Characteristics of the 29 MF patient group included in a randomized clinical trial to 
test the efficacy of PUVA vs PUVA + IFN 
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Both study arms consisted of a 24 week treatment period. In the PUVA monotherapy arm, the 
patients were treated with PUVA at the dose dependent on the skin phototype for 24 weeks. 
In the PUVA + IFN arm, IFN alone was given for the first two weeks of treatment in a dose of 
3-6-9MU for 3 days in the first week and the combination PUVA + IFN (IFN dose – 9MU/3 
days per week) was used during the remaining 23 weeks. Treatments continued until complete 
remission, disease progression, significant toxicity, or withdrawal of consent. Responders (R) 
are defined as patients who achieve complete remission (CR) within 24 weeks of the 
commencement of the treatment while non-responders (NR) are patients that do not achieve 
CR within 24 weeks or show disease progression. Twenty nine MF samples were used for 
expression profiling (7 NR and 22 R) while immunohistochemistry analysis was performed on 
paraffin embedded sections from all patients enrolled in the study (35).  
The ID samples used represented cases of interface and spongiotic dermatitis including 
rosacea, lupus erythematosus, dermatitis herpetiformis, seborrheic dermatitis, lichenoid 
dermatitis, psoriasis and spongiotic dermatitis.  All control cases were previously untreated at 
biopsy.  
Informed consent was obtained from all patients under the supervision of the local Ethics 
Committees and followed the Declaration of Helsinki protocols. All samples were centrally 
reviewed by a panel of pathologists and diagnosed using generally accepted criteria (Kallinich 
et al., 2003), with the aid of Haematoxylin/Eosin, CD3, CD4, and CD8 staining, and TCR gene 
rearrangement analysis by PCR. 
 
For HDACi (vorinostat) study peripheral blood lymphocytes (PBL) before and after treatment 
with vorinostat were obtained from CTCL patients (SS) with high percentage of circulating 
malignant cells. The study was conducted after informed consent has been obtained and in 
accordance with regulation of the Hospital 12 de Octubre (Madrid, Spain). PBL from patients 
was isolated on LymphoprepTM (Axis-Shield, Oslo, Norway). 
 
2.2 Cell culture 
2.2.1 Tumor cell lines 
Human MJ, HuT78 and HH CTCL cell lines, derived from peripheral blood of patients with MF, 
SS and non-MF/SS aggressive CTCL, respectively (Gootenberg et al., 1981; Popovic et al., 1983; 
Starkebaum et al., 1991), were obtained from American Type Culture Collection (Rockville, 
MD). The cell line MyLa (Kaltoft et al., 1992) (MF origin) was obtained from European 
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Collection of Cell Cultures (Wiltshire, UK); and SeAx (Kaltoft et al., 1988) (SS) was a kind gift of 
Dr Reinhard Dummer, University Hospital of Zurich, Switzerland. Characteristics and origin of 
all the cell lines used are presented in Table 7. Cells were periodically tested for Mycoplasma 
infection and found to be negative. 
 
Table 7. Characteristics of the cell lines used. 
Cell line Species Source Culture medium Growth Origin 
HH Human Non-MF/SS aggressive CTCL RPMI + 10% FBS Suspension ATCC 
HuT78 Human Sézary syndrome RPMI + 20% FBS Suspension ATCC 
MJ Human Mycosis fungoides RPMI + 20% FBS Suspension ATCC 
MYLA Human Mycosis fungoides RPMI + 20% FBS Suspension ECCC 
SeAx Human Sézary syndrome RPMI + 10% FBS Suspension Zurich 
 
Additionally, spectral karyotyping (SKY) method performed by Cytogenetics Unit at CNIO was 
used to identify and confirm chromosome aberration in cancer cells. SKY is a molecular 
cytogenetic technique used to simultaneously visualize all the pairs of chromosomes in an 
organism in different colors. Briefly, fluorescently-labeled probes for each chromosome are 
made by labeling chromosome-specific DNA with different fluorophores. Due to a limited 
number of spectrally-distinct fluorophores, a combinatorial labeling method is used to 
generate many different colors. Spectral differences generated by combinatorial labeling are 
captured and analyzed using an interferometer attached to a fluorescence microscope. Image 
processing software assigns a pseudo color to each spectrally different combination allowing 
the visualization of the individually colored chromosomes (Schrock et al., 1996). The SKY 
results for all cell lines used in the present study are shown in Table 8. 
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Table 8. Spectral Karyotyping 
 
Cell line Spectral Karyotype (SKY) 
 
 
HH 
 
Karyotype: 45,XY, der(3)t(2;3)(?;p24), t(3;12)(q12;q23), der(4)t(1;4)(?;q32), 
der(5)t(5;9;10)(p15;q?;?), t(6;14)(q25;q12), +8, -9, del(10)(q21), -15, der(18)t(3;18)(?;q22) 
 
 
 
 
 
HuT78 
 
Karyotype: der(X)t(X;18)(p11.2;q11.2)x2, der(1)t(1;18)(q21;q12), der(2)t(2;13)(q21;?), 
der(3)t(3;10)(q2?;?), der(3)t(3;19)(q2?;?), der(3)t(3;?;21)(q;?;?), der(4)t(4;18)(q12;q12), 
der(4)t(4;14)(p11.2;p11.2), del(5)(q11.2qter), t(5;6)(p11.2;q11.2)x2, der(6)t(4;6)(q13;q121)x2, 
der(7)t(7;10)(p13;?), der(8)t(8;21)(q24;?), der(9)t(9;21)(p21;?), del(10)(q22qter), 
der(10)t(7;10)(q?;q22)x2, del(11)(q13qter), del(12)(p12pter), der(12)t(12;15)(p13;p11.2), 
del(13)(q14qter), der(13)t(2;13)(?;q14), der(13)i(13)t(13;20)(q14;q11.2), del(14)(q21q32), 
der(17)t(5;17)(p?;p11.2), del(18)(q11.2qter), der(18)t(2;18)(?;p11.2), der(18)t(X;18)(?;q21), 
der(19)t(19;20)(q13;?)hsr(19)(q13.1?), der(19)t(19;20)(q13.1;?), del(20)(q11.2qter), 
der(21)t(11;21)(q12;p11.2), der(22)t(6;22)(q/:p11.2), der(22)t(19;22)(?;p11.2) 
 
 
 
 
 
MJ 
 
Karyotype: 47,XY, der(15)t(5;15)(q21;q25-26), der(17)t(2;17)(q?;q25)  
 
 
Karyotype: 46,XY, t(9;15)(p24;q21), del(15), der(17)t(2;17)(q?;q25)  
 
 
MYLA 
 
Karyotype: 47,XY, del(1)(q31), t(1;15)(p36;q23), t(2;14)(q33;q12), t(4;5)(q21;q31), del(6)(q21), 
del(9)(p21), der(10)t(10;13)(p15;q?), -13, t(16;22)(p10;p10), +r(17), der(21)t(13;21)(?;q22), +Y  
 
 
SeAx 
 
Karyotype: 47,XY, del(1)(q31), t(1;15)(p36;q23), t(2;14)(q33;q12), t(4;5)(q21;q31), del(6)(q21), 
del(9)(p21), der(10)t(10;13)(p15;q?), -13, der(13)t(13;14)(q34;q12), del(14), t(16;22)(p10;p10), 
+r(17), der(21)t(13;21)(?;q22), +Y  
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2.2.2 Culture and conservation of cell lines 
Cells were grown in RPMI 1640 medium (Sigma Chemical, St Louis, MO) supplemented with 
10-20% heat-inactivated fetal bovine serum – FBS (10% FBS from Euroclone, Ltd, UK and 10% 
FBS from Lonza, Qalkersville, MD), 2mM L-glutamine (Life Technologies, Inc., Grand Island, NY), 
100mg/ml penicillin/streptomycin (Life Technologies, Inc.), and 2.5g/ml fungizone 
(amphotericin B) (Life Technologies, Inc) and grown in a humidified atmosphere at 37OC with 
5% CO2. All the cell lines were cultured in suspension in cell culture flasks (Corning, NY) and 
passaged every 3-4 days. All cell manipulation was performed in the Telstar Biological Safety 
Cabinets (Bio IIA) with the laminar air flow systems. 
For long term storage the cells were cryopreserved. The basic principle of successful 
cryopreservation is a slow freeze and quick thaw. The cells were stored in their habitual 
medium supplemented with 10% of cryoprotectant such as dimethyl sulphoxide (DMSO) to 
help protect the cells from rupture by the formation of ice crystals. Although the precise 
requirement may vary with different cell lines, as a general guide cells should be cooled at a 
rate of –1OC to –3OC per minute and thawed quickly by incubation in a 37OC water bath for 3-5 
minutes.  
2.2.3 Compounds 
Vorinostat (SAHA) was provided by Merck (Boston, Massachusetts). LY294002 was purchased 
from Calbiochem (La Jolla, CA), 17-AAG was obtained from Sigma (St Louis, MO) and 
Panobinostat (LBH589) from Novartis Pharmaceuticals (Basel, Switzerland). ETP-45628 (3-(1-
methyl-4-morpholin-4-yl-pyrazolo[5,4-d]pyrimidin-6-yl)phenol) and ETP-39010 (4-[6-[(4-
fluorophenyl)methylamino]imidazo[2,3-f]pyridazin-3-yl]phenol) were developed by 
Experimental Therapeutics Program at CNIO (Madrid, Spain). All the drugs were dissolved in 
DMSO to stock concentration of 50mM or 10mM and stored at –20OC. Serial dilutions were 
freshly made in RPMI 1640.  
2.2.4 Cell transfection – Microporation 
To transfect HuT78, MYLA and SeAx cells with a plasmid DNA containing ZAP70 target gene 
microporation technology was used. pcDNA3-ZAP70 vector was a kind gift of professor Dimitar 
Efremov, ICGEB, Italy. The MicroPorator (MP-100 MicroPorator) and its accompanying devices 
and materials are manufactured by Digital Bio (Seoul, Korea) (http://www.microporator.com). 
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First, careful calibrations for microporation of each cell line, leading to improved transfection 
yields and cell survival rates were performed. 
Tumor cell preparation for microporation: one day prior to microporation the cells were 
cultured in a fresh growth medium without antibiotics in order to reach 60 to 80% confluency.  
On the day of microporation: The microporations were done in 10l or 100l gold-tips, which 
were inserted into the microporation tube. The size of the tip, whether 10l (3.0x105 cells) or 
100l (2.0x106 cells), depended on the amount of cells undergoing microporation, were used 
according to the manufacturer’s instructions. 
First, to prepare the apparatus, 3ml of Buffer E were added into the microporation tube. Then 
the pulse conditions of the pipette station were set up, as follows: 
for HuT78 cells: pulse voltage, 1150; pulse width, 20; pulse number, 2. 
for MYLA cells: pulse voltage, 1300; pulse width, 20; pulse number, 2. 
for SeAx cells: pulse voltage, 1300; pulse width, 20; pulse number, 2. 
The appropriate amount of cells resusupended in Buffer R was mixed with plasmid DNA and 
the cell-DNA mixture was aspirated using the MicroPorator pipette carrying the gold-tip. 
Afterwards, the MicroPorator pipette was inserted into the Pipette Station and the Start 
button was pressed on the LCD panel. After the pulse, the cell sample was immediately 
transferred into the culture flask containing medium and supplements (including antibiotics).  
 
2.3 Cell – based assays 
2.3.1 Cell proliferation/Viability 
Cell proliferation/viability was measured by the CellTiter-Glo® Luminescent Cell Viability Assay 
(Promega, Madison, WI). The CellTiter-Glo® Luminescent Cell Viability Assay is a homogeneous 
method of determining the number of viable cells in culture based on quantitation of the ATP 
present, which signals the presence of metabolically active cells. The assay relies on the 
properties of a proprietary thermostable luciferase (Ultra-Glo™ Recombinant Luciferase), 
which generates a stable “glow-type” luminescent signal and improves performance across a 
wide range of assay conditions. Briefly, aliquots of 1x104 cells per well were distributed in 96-
well flat bottom tissue culture plates (BD Falcon; New Jersey) in 100L of medium and 
incubated at 37OC in the presence or absence of the drug for 72h (unless stated otherwise). 
Following incubation for the indicated time period, 100µl of a single CellTiter-Glo reagent 
(prepared before adding from the CellTiter-Glo buffer and substrate) was added directly to 
cells cultured in serum-supplemented medium. This addition resulted in cell lysis and 
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generation of a luminescent signal proportional to the amount of ATP present. The plates were 
then mixed for 2min on an orbital shaker and incubated for 10min at room temperature to 
stabilize. Following, the luminescent signal was recorded using Wallac 1420 multilabel counter 
(PerkinElmer Life and Analytical Sciences, Turku, Finland). Wells containing medium alone 
were used as a control for background luminescence. 
2.3.2 Apoptosis measurement 
Evaluation of the early apoptotic populations (Annexin V+/PI-) and late apoptotic or secondary 
necrotic population (Annexin V+/PI+) was performed by Annexin V-APC/PI surface staining. 
Briefly, cells were collected, washed twice with cold PBS, and centrifuged at 1200rpm for 5min. 
Cells were resuspended in 1X binding buffer (Sigma-Aldrich, St Louis, MO) at a concentration of 
1x106 cells/ml, 100l of the solution were transferred to a 5l culture tube, and 5l of annexin 
V-APC (BD Biosciences, Pharmingen, San Jose, CA), and 5l of PI (Sigma-Aldrich) were added. 
Cells were incubated for 15min at room temperature in the dark. Finally, 400L of 1X binding 
buffer was added to each tube and samples were analyzed with FACSCalibur flow cytometer 
(Becton Dickinson, Franklin Lakes, NJ). For each sample, 20,000 gated events were acquired 
and the data were analysed using CellQuest Pro software (Becton Dickinson). 
2.3.3 Cell cycle analysis 
HH, Hut79, MJ, Myla and SeAx cells (1x106 cells) were incubated with DMSO or vorinostat 
(SAHA) at indicated concentrations for 24 and 48h. Cells were collected, washed with cold 
phosphate buffered saline (PBS) and fixed in ice cold 70% ethanol. This suspension was stored 
at -20OC for at least 30min. Next, the cells were washed with 5ml of PBS, centrifuged at 
2000rpm during 5min and resuspended in 500µl of PBS. The cell suspension was treated with 
DNase-free Rnase (Quiagen, Inc., Valencia, CA), and stained with 50g/mL propidium iodide 
(PI). Distribution of the cell-cycle phase by different DNA content was determined with a 
FACSCalibur flow cytometer (Becton Dickinson). For each sample, 10,000-gated events were 
acquired. Analyses of cell-cycle distribution (including apoptosis: sub-G0) were performed 
using CellQuest Pro software (Becton Dickinson). 
2.3.4 Determination of drug synergy 
Cells were seeded in 96-well plates and treated with serial dilutions of each drug individually or 
with both drugs simultaneously at a fixed ratio of doses 0.25, 0.5, 1, 2, 4 times the individual 
Materials and Methods 
 
 
44 
 
IC50 (ED50) values (Table 9). After 72h of exposure, the luminescence was measured using 
CellTiter-Glo Assay. 
 
Table 9. Scheme of drug combinations.  
 
DRUG 1 
D
R
U
G
 2
 
 0 
0.25 x 
(ED50)1 
0.5 x 
(ED50)1 
1 x 
(ED50)1 
2 x 
(ED50)1 
4 x 
(ED50)1 
0 
Control 
(fa)0 
(fa)1 (fa)1 (fa)1 (fa)1 (fa)1 
0.25 x 
(ED50)2 
(fa)2 (fa)1,2     
0.5 x 
(ED50)2 
(fa)2  (fa)1,2    
1  x 
(ED50)2 
(fa)2   (fa)1,2   
2  x 
(ED50)2 
(fa)2    (fa)1,2  
4  x 
(ED50)2 
(fa)2     (fa)1,2 
 
fa – the fraction affected by the dose 
 
To determine synergism the isobologram analyses based on the Chou and Talalay method 
implemented in Calcusyn software (Biosoft, Ferguson, MO) were applied. 
Combination Index (CI) values were calculated using CalcuSyn program. The dose-effect 
relationships analyzed using the median-effect equation was first obtained for each single drug 
by its serial dilution. A CI value for each combination treatment was then calculated based on 
the following formula: 
 
 
 
where Dx1 and Dx2 are the doses of drug 1 and drug 2 alone required to produce x% effect, and 
D1 and D2 are the doses of drug 1 and drug 2 in combination required to produce the same 
effect (Chou and Talalay, 1984). CI was used to express synergism (CI < 1), additive effect (CI = 
1), or antagonism (CI > 1). Detailed definition of synergism and antagonism with respect to CI 
values can be found in Table 10. 
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Table 10. Description of combination index (CI) values. 
Range of CI Symbol Description 
< 0.1 +++++ Very strong synergism 
0.1 – 0.3 ++++ Strong synergism 
0.3 – 0.7 +++ Synergism 
0.7 – 0.85 ++ Moderate synergism 
0.85 – 0.90 + Slight synergism 
0.90 – 1.10  Nearly additive 
1.10 – 1.20 - Slight antagonism 
1.20 – 1.45 -- Moderate antagonism 
1.45 – 3.3 --- Antagonism 
3.3 – 10 ---- Strong antagonism 
> 10 ----- Very strong antagonism 
 
 
2.4 mRNA – based techniques 
2.4.1 RNA isolation 
2.4.1.1 microRNA extraction 
Total RNA isolation for microRNA hybridization was performed using Trizol protocol 
(Invitrogen, Carlsbad, CA, USA) as follows: Sections of the frozen tissue were made using a 
microtome at -20OC and 1ml of Trizol (monophasic solutions of phenol and guanidine 
isothiocyanate) was added to the tube containing the sectioned tissue and kept in dry ice until 
homogenisation. The tissue was homogenised using a polytron or syringe, and 1μl of linear 
acrylamide (Life technologies Inc.) was added. During sample homogenization or lysis, TRIZOL 
Reagent maintains the integrity of the RNA, while disrupting cells and dissolving cell 
components. The sample containing the linear acrylamide was incubated at room temperature 
for 5-10 minutes. 200μl of chloroform was added and the tubes were mixed for 15 seconds. 
The tubes were incubated at room temperature for 10min and centrifuged at 12,000g for 
15min at 4OC. Addition of chloroform followed by centrifugation separates the solution into an 
aqueous phase and an organic phase. RNA remains exclusively in the aqueous phase. The 
aqueous phase was removed to a fresh tube and the RNA was precipitated using isopropyl 
alcohol. The pellet was washed twice using ice-cold 70% ethanol, dried and re-suspended in 
RNase-free water. RNA quality was checked using a total RNA (small fraction chip) with the 
Agilent 2100 Bioanalyzer (Agilent Technologies Inc., Santa Clara, CA, USA). In addition, total 
RNA integrity was evaluated by 1% agarose electrophoresis, following the standard procedure. 
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2.4.1.2 total RNA extraction from frozen tissue 
Total RNA extraction from whole frozen tissue was carried out using the Trizol reagent 
(Invitrogen) as described in section 2.4.1.1. The resulting RNA was further purified using the 
RNeasy kit (Qiagen Inc., Valencia, CA) and digested with RNase-free DNase I following the 
manufacturer’s instructions and procedures described in the following section.  
The integrity of RNA was verified by electrophoresis and/or automatically using the 2100 
Bioanalyzer (Agilent Technologies) and the quantity was measured by NanoDrop ND-100 
(NanoDrop, Wilmington, DE) or by the 2100 Bioanalyzer (Agilent Technologies). 
 
2.4.1.3 total RNA extraction from cell lines 
Total cellular RNA was extracted from cells using QIAshredder spin column (homogenization) 
and purified with RNeasy Mini-Kit (Qiagen Inc., Valencia, CA) following the manufacturer’s RNA 
Clean-up protocol with the optional on-column digestion with RNase free DNase I. Briefly, cells 
were lysed and homogenized in the presence of highly denaturing buffer RLT containing 
guanidine isothiocyanate and 2-mercaptoethanol (10µl of 2-mercaptoethanol for 350µl of RLT 
buffer). Ethanol was then added to the lysate, creating conditions that promote selective 
binding of RNA to RNeasy silica-gel membrane. Following, the sample was applied to the 
RNeasy mini column. Total RNA binds to the membrane, contaminants are efficiently washed 
away, and a high quality RNA is eluted in RNase-free water. All centrifugation steps were 
performed at 20-25OC in a standard microcentrifuge. RNA quality and integrity were verified 
using the RNA 6000 Nano Chips, Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). 
2.4.2 Reverse transcription and RT-PCR 
First-strand cDNA was synthesized from 500ng of total RNA using the High-Capacity cDNA 
Archive Kit (Applied Biosystems, Foster City, CA) according to manufacturer’s protocol. Reverse 
transcription reactions were performed in the total volume of 20µl containing 500ng DNase 
treated total RNA, 1x reaction buffer, dNTP mixture, random primers, Rnase inhibitor and 50U 
MultiScribe reverse transcriptase. Reaction mixtures were incubated at 25OC for 10min 
followed by incubation at 37OC for 2h and 5sec at 85OC. 
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2.4.3 Quantitative Real-Time PCR 
Expression of mRNA for eight differentially expressed genes associated with TCR pathway was 
measured with the use of TaqMan Gene Expression Assays on demand (Applied Biosystems, 
Foster City, CA). The following assays has been used: FYN (Hs00941608_g1), IFNGR1 
(Hs00988302_m1), STAT3 (Hs00374286_g1), ZAP70 (Hs00896347_m1), CD3G 
(Hs00962185_g1), LAT (Hs01065378_g1), IL4R (Hs00965052_m1) and CD3E (Hs99999153_m1). 
Quantitative reverse transcriptase PCR (RT-PCR) reactions were performed in triplicate with 
the ABI Prism 7900 Sequence Detector System (Applied Biosystems). The PCR cycling 
conditions were standard: 95OC for 10min for one cycle, 95OC for 15sec, and 60OC for 1min for 
40 cycles. The relative changes in gene expression were calculated by the Ct method using 
the Sequence Detection System (SDS) 2.1 software (Applied Biosystems). The Ct method 
gives the amount of target normalized to an endogenous reference and relative to a calibrator. 
The expression of each of the genes in all specimens was related to its expression in a 
reference RNA pool (Stratagene) used as a calibrator. The level of each transcript was 
quantified by the cycle at which the PCR amplification was in log phase where there was 
significant fluorescent signal (Ct) with HGUSB as the endogenous control. All standards and 
samples were run in the total volume of 15µl in triplicate. 
2.4.4 Gene expression microarrays 
Gene expression microarrays are powerful techniques, which allow the analysis of the 
expression of thousands of genes simultaneously. The past decade has witnessed a revolution 
in the field of expression profiling in cancer. Microarray technology has changed both the view 
of cancer and how research in molecular oncology can be conducted (Raetz and Moos, 2004). 
The schematic diagram of gene expression microarray labeling, hybridization and analysis is 
presented in Figure 6.  
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Figure 6. Gene expression microarray labeling, hybridization and analysis.  
 
2.4.4.1 Oncochip v. 1.1c 
In PUVA +/- IFNα study, the CNIO OncoChip was used. The OncoChip is a cDNA microarray 
developed at the Genomics Unit of Spanish National Cancer Centre (CNIO) that has been 
especially designed for the study of cancer and contains 6386 genes including a core of 2489 
cancer-relevant genes in addition to genes involved in drug-response, tissue-specific genes and 
control genes. The 6386 genes are represented by a total of 7237 clones represented by 13057 
spots on the array.  
 
2.4.4.1.1 RNA amplification 
T-7 based mRNA amplifications were carried out as described previously (Eberwine, 1996; Van 
Gelder et al., 1990). Briefly, 0.5-5μg of total RNA was converted to double stranded cDNA. For 
first strand cDNA synthesis, an oligo-dT primer containing a T7 RNA polymerase promoter 
(Ambion, Austin, TX) was used. The first strand cDNA synthesis reaction was performed using 
Superscript II Reverse Transcriptase, DTT (Dithiothreitol) and 10mM dNTPs (2'-
Deoxyribonucleoside-5'-triphosphates) (all supplied by Life Technologies, Inc.) and RNase 
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inhibitor (RNAsin) (Promega, Madison, WI), and was incubated for 2 hours at 42OC. Second 
strand cDNA synthesis was performed using DNA polymerase, Escherischia coli DNA ligase, 
RNaseH and dNTPs (Life Technologies, Inc.) at 16OC for 2h. The double stranded cDNA was 
purified using phenol-chloroform-isoamyl alcohol (25:24:1) pH 8.0 (Ambion) and precipitated 
using ethanol, 7.5M ammonium acetate (Sigma Chemical Company) and linear acrylamide 
(Ambion). T7 in vitro transcription was carried out using the Megascript T7 in vitro 
transcription kit (Ambion), following the manufacturer's instructions. T7 in vitro transcription 
was allowed to continue for between 2 and 14 hours at 37OC, depending on the quantity of 
total RNA used. 
 
2.4.4.1.2 Preparation of fluorescent cDNA from aRNA 
Fluorescent first strand cDNA was made with 2.5 or 5μg of amplified RNA (aRNA) in the 
presence of Cy3 or Cy5 (Amersham, Uppsala, Sweden), random hexamer primers (Promega), 
DTT (Life Technologies Inc), RNase inhibitor (RNAsin) (Promega), unlabelled dNTPs (Fermentas 
Life sciences, Lithuania) and Superscript II Reverse Transcriptase (Life Technologies Inc). 10μg 
of Cot1 human DNA (Life Technologies Inc.) was added to the labeled probe. The microarray 
slides were denaturalized by placing in boiling water for 3min. Slides were incubated in a 
buffer filtered using a 45μm filter and containing 4X SSC (Saline Sodium Citrate buffer), 1X BSA 
(Bovine serum albumin)(Sigma Chemical Co.), 2μg/ml denatured salmon sperm DNA (DNAs) 
(Sigma Chemical Co.) and 0.1% SDS (Sodium Dodecyl Sulphate) for 45min at 65OC, followed by 
washing with sterile water. The probe was added to a solution containing 50% formamide, 20X 
SSC (Saline Sodium Citrate buffer) and 10% SDS (Sodium Dodecyl Sulphate) and incubated at 
100OC for 3min followed by 20min at 42OC before applying to the microarray slide. 
 
2.4.4.1.3 Hybridization 
The slides were prepared for hybridization first by submerging in hot water for 3min, followed 
by incubation in prehybridization buffer (SSC 4X, SDS 0.1%, 0.001% BSA) at 65OC for 45-60min 
and washed in water at room temperature. The hybridization mixture was then applied on the 
printed side of the array and carefully the cover slide was placed on the top (Hybri-slips 22 x 
60mm; Sigma). Slides were inserted in the hybridization chamber (Corning) and the 
hybridization was carried out at 42OC overnight (15-20h). After that time, the slides were 
washed three times (3X) with 600ml of SSC 2X, 0.5% SDS and another 3X with 600ml of SSC 
0.5X, 0.5% SDS. All the washing steps were carried out at 42OC for 15min, with shaking. Slides 
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were scanned for Cy3 and Cy5 fluorescence using Scanarray 5000 XL (GSI Lumonics, Kanata, 
Ontario, Canada). 
 
2.4.4.1.4 Data analysis 
Using GenePix Pro 4.0 software (Axon instruments Inc., Union City, CA), the fluorescence 
intensity ratios (Cy3/Cy5 o Cy5/Cy3) were quantified for each point. Fluorescence intensity 
measurements were subjected to automatic background subtraction and the Cy5/Cy3 ratio 
values were normalized to the median ratio value of all spots in the array. For patient samples, 
the sum of the median background for each channel was calculated and spots with total 
intensity values below the calculated sum of median backgrounds were discarded. 
Additionally, all spots with total intensity values lower than 250 were discarded. Furthermore, 
bad spots or areas of the array with obvious defects were manually flagged and discarded from 
analysis. All ratio values were log-transformed (base 2). Inconsistent duplicates were discarded 
and all consistent duplicate spots and genes were averaged (Herrero et al., 2003). The genes 
with less than 70-80% of valid data were excluded from the analysis. The preprocessing was 
performed using bioinformatics tools developed at the Bioinformatics Unit at CNIO (Gene 
Expression Pattern Analysis Suite (GEPAS), available at http://gepas.bioinfo.cnio.es). 
 
2.4.4.2 Agilent Spike-In v. 44K and v. 4X 44K 
2.4.4.2.1 cDNA synthesis from total RNA 
2µg of total RNA was mixed with 2µl of a 5,000-fold dilution of Agilent's Two-Color Spike-in 
RNA control and amplified using Agilent Low RNA Input Fluorescent Amplification Kit (Agilent 
Technologies, Inc., Santa Clara, CA). The mixture in a final volume of 6.5µl (total concentration 
at least 5ng/µl) was mixed with 5µl of T7 promoter primer. The primer and the template were 
denatured by incubating the reaction at 65OC for 10min and placing on ice for 5min. Following, 
8.5µl of cDNA Master Mix was added and the samples were incubated first at 40OC in a 
circulating water bath for 2h and then at 65OC in a heating block for 15min to inactivate 
MMLV-RT. Following that time, the samples were incubated on ice for 5min. 
 
cDNA Master Mix composition: 4µl of 5X First strand buffer, 0.1M DTT 2µl, 10mM dNTP mix 
1µl, 1µl of MMLV-RT  and 0.5µl of RNaseOUT. 
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2.4.4.2.2 Fluorescent cRNA synthesis: in vitro trasnscription and incorporation of 
fluorochromes 
To each sample tube, either 2.4µl of 10mM cyanine 3-CTP (sample) or 2.4µl of 10mM cyanine 
5-CTP (Stratagene Universal Human Reference RNA) was added and mixed. Following, to each 
sample, 57.6µl of Transcription Master Mix was added an incubated in a circulated water bath 
at 40OC for 2h. Following amplification and labeling, each sample was assessed on the 
Nanodrop ND-1000 to measure yield and specific activity. 
 
Transcription Master Mix composition: 15.3µl of Nuclease-free water, 20µl of 4X Transcription 
buffer, 0.1M DTT 6µl, 8µl of NTP mix, 50% PEG 6.4µl, 0.5µl of RNase OUT, 0.6µl of Inorganic 
pyrophosphatase and 0.8µl T7 RNA Polymerase. 
 
2.4.4.2.3 Hybridization 
cRNA target was prepared as follows: 0.75µg cyanine 3-labeled, linearly amplified sample 
cRNA was mixed with 0.75µg cyanine 5-labeled, linearly amplified reference pool cRNA, 50µl of 
10X control targets and Nuclease-free water to final volume of 240µl. The hybridization 
solution was prepared by adding 240µl of 2X target solution to 10µl of 25X fragmentation 
buffer. The mixture was incubated at 60OC in the heating block for 30min. Following, 250µl of 
2X hybridization buffer (from In situ Hybridization kit) to the final volume of 500µl, mixed, 
spinned and 490µl of the hybridization solution was applied to 60-mer Agilent 44K (or 4X 44K) 
Human Whole Genome oligonucleotide microarrays and assembled in microarray hybridization 
chamber (G2534A). Once fully assembled, the chambers were loaded into the hybridization 
rotator rack and set to rotate at 4rpm. The hybridization was performed in a rotating oven at 
60OC for 17h. 
All the washing steps were performed at room temperature. First the sandwiched slides were 
submerged in Wash Solution 1 to remove oligo microarray slide. The slides were washed for 
1min in the Wash Solution 1 with the magnetic stir. The slides were then transferred to the 
staining dish containing Wash Solution 2 and washed for 1min. Following, the slides were 
transferred to the staining dish containing the Wash Solution 3 and washed for 30sec. All steps 
were performed in the dark. The dried slides were scanned with a G2565BA Microarray 
Scanner System (Agilent Technologies, Palo Alto, CA). 
 
Wash solution 1 composition: 6X SSPE, 0.005% N-Lauroylsarcosine, deionized nuclease free 
water.  
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Wash solution 2 composition: 0.06X SSPE, 0.005% N-Lauroylsarcosine, deionized nuclease free 
water. 
The buffers 1 and 2 are passed through a 0.2µm sterile filtration unit before use. 
Wash solution 3 composition: The Agilent Stabilization and Drying Solution contain an ozone 
scavenging compound dissolved in acetonitrile. 
2.4.4.2.4 Data analysis 
The data were processed and normalized with the use of Feature Extraction (v.9.0) software. In 
HDACi (vorinostat) study each time point was additionally normalized to time 0 and genes with 
more than 30% of missing values were discarded. The preprocessing was performed using 
bioinformatics tools developed at the Bioinformatics Unit at CNIO (Gene Expression Pattern 
Analysis Suite (GEPAS), available at http://gepas.bioinfo.cnio.es). 
2.4.5 MicroRNA expression microarrays 
2.4.5.1 Agilent v. 1.0 
2.4.5.1.1 Labeling 
100ng of total RNA were hybridized onto an Agilent 8x15K Human microRNA Microarray Kit for 
the detection of 470 human and 64 viral microRNAs, following the manufacturer’s instructions 
(Agilent Technologies). Briefly, this procedure consisted of a RNA dephosphorylation step 
where the mixture of 100g RNA, 10X CIP Buffer and CIP (16U/l) was incubated at 37OC for 
30min. Following, a denaturation step was performed through addition of DMSO to samples 
carried out at 100OC for 5min. Samples were then treated with T4 ligase (15U/l) and labeled 
with Cy3 at 16OC for 2h.  The reaction was performed in a total volume of 20l. Subsequently, 
RNA was purified with Bio-spin 6 columns (BioRad, Hercules, CA) and dried in a speed vacuum 
(45OC, 45min).  
Ligation master mix compostition: 10X T4 ligase Buffer 2l, 0.1% BSA 2l, pCp-Cy3 3l and T4 
ligase diluted (15U/l)* 1l. 
 
2.4.5.1.2 Hybridization 
Labeled RNA was resuspended in the appropriate volume of hybridization mix (H2O 18l, 
blocking agent 4.5l and hybridization buffer 22.5l)  to a final volume of 45l and incubated 
at 100OC for 5min, quickly cooled and pipetted into the 8X gasket, closed with the Agilent 
8x15K Human miRNA platform, and locked with the appropriate support. Hybridization was 
carried out at 55OC for 20h at 20rpm. After that time the slides were washed first with WB1 
buffer and then with WB2 buffer. Both washing steps were performed at 37OC for 7min each, 
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with shaking. Finally, the array was submerged in acetonitrile for 1min and dried. The arrays 
were scanned for Cy3 fluorescence with a G2565BA Microarray Scanner System (Agilent 
Technologies, Palo Alto, CA).  
 
2.4.5.1.3 Data analysis 
The data were extracted using Feature Extraction (v.9.0) software. Following, the average 
values of the replicate spots of each miRNA were background subtracted, normalized, and 
subjected to further analysis. microRNA was normalized using Loess within array normalization 
and quantile between-array normalization. microRNAs were retained when present in at least 
30% of samples, (meaning the miRNAs were measured as present in at least the smallest group 
in the dataset) and when at least 30% of the miRNA had fold change of more than 1.5 from the 
gene median. Following the data was analyzed using the bioinformatics tools described in 
section 2.4.6. 
2.4.6 Bioinformatics tools 
2.4.6.1 Significance Analysis of Microarrays (SAM) 
Significance Analysis of Microarrays (SAM) (Tusher et al., 2001), was performed for analysis of 
miRNA/genes significantly different between two classes (e.g. normal vs. cancer) in which case 
the t-test statistics was used (PTCL study).  SAM calculated a score for each miRNA/gene on 
the basis of the change in expression relative to the standard deviation of all measurements. In 
PUVA +/- IFN study stastistics based on the Cox model was used to identify genes correlated 
with overall response. SAM calculated the score for each gene by measuring the strength of its 
correlation with response. The aforementioned score is the maximum-likelihood score statistic 
from Cox-s proportional hazards model (Cox score). 
A threshold of q-value ≤ 0.01 (PTCL study) and ≤ 0.25 (PUVA +/- IFN study) was used and 
1000 permutations were applied. The genes with >20% missing values were excluded. The 
biological functions of the significant genes, were assigned using the Gene Ontology 
(www.geneontology.org), EntrezGene, EntrezOMIM (http://www.ncbi.nlm.nih.gov/entrez/), 
Genecards (Rebhan et al., 1997; Rebhan et al., 1998) databases and using Ingenuity Pathways 
Analysis v.6.3 (Ingenuity Systems, Inc., Redwood City, CA, U.S.A.) (www.ingenuity.com).  
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2.4.6.2 Gene Set Enrichment Analysis (GSEA) 
Gene Set Enrichment Analysis (GSEA) (Mootha et al., 2003; Subramanian et al., 2005) was 
performed to test for the sets of related genes that could be correlated with peripheral T-cell 
lymphoma pathogenesis (PTCL study) or PUVA +/- IFNα therapy resistance (PUVA +/- IFN 
study). Briefly, this method identifies predefined database gene sets that are associated with 
phenotypic differences utilizing t-test statistics. Genes with >30% of missing values were 
excluded. We used the modified Biocarta database (www.biocarta.com) enriched in pathways 
derived from the literature and other databases, known to be involved in lymphoma 
pathogenesis. The rank positions of all members of the sets were identified, enrichment score 
was calculated and random class permutations (1000 permutations) were performed. Taking 
into consideration the low number of samples (29 patients) in PUVA +/- IFN study and their 
uneven phenotypic distribution, the GSEA was used for stating and testing the hypothesis 
rather than for statistical analysis in this study.  
 
2.4.6.3 Connectivity Map (cMap) 
Identification of molecules (drugs) that could reverse the gene expression signatures 
associated with poor prognosis and drug resistance (PUVA +/- IFN study) was performed 
using Connectivity Map (Lamb et al., 2006) (also known as cMap). cMap is a collection of 
genome-wide transcriptional expression data from cultured human cells treated with bioactive 
small molecules and simple pattern-matching algorithms that together enable the discovery of 
decisive functional connections between drugs, genes and diseases through the transitory 
feature of common gene expression changes. Enrichment of both the up- and downregulated 
genes from the submitted gene expression profiles for each treatment were estimated using a 
metric based on the Kolmogorov-Smirnov statistic and combined to produce the connectivity 
score (Lamb et al., 2006).  
 
2.4.6.4 Short Time Series Expression Miner (STEM) 
Assignment of genes to temporal expression profiles and detection of statistically enriched 
gene families within each profile was conducted using Short Time Series Expression Miner 
(STEM)(Ernst et al., 2005). Briefly, STEM implements a novel clustering method that depends 
on a set of distinct and representative short temporal expression profiles and each probe in 
the dataset is assigned to a profile with the closest match. The expected number of probes 
assigned to each profile is estimated by permutation and the statistically significantly over-
expressed profiles are then identified. Genes were deemed to be upregulated or 
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downregulated if the expression change was at least 2-fold and the correlation between the 
duplicate arrays for each gene was at least 0.8. The p-values derived from STEM analysis were 
corrected for multiple hypotheses testing using a FDR of < 0.05. The significant genes were 
annotated and classified using FatiGO+ (Al-Shahrour et al., 2004) and Ingenuity Pathway 
Analysis software v.6.3 (Ingenuity Systems, Inc., Redwood City, CA, U.S.A.) 
 
The significant genes were clustered by average linkage clustering using Cluster (Eisen et al., 
1998) and visualized by TreeView v.1.6 (EisenSoftware, Berkley, CA). Interaction networks in 
PTCL study were depicted using Cytoscape bioinformatics software (Shannon et al., 2003) 
(www.cytoscape.org). 
 
2.5 Fundamental molecular biology techniques 
2.5.1 Bacterial Strains 
Plasmids were produced in the TOP10 E. coli strain (Invitrogen) having the following genotype: 
F- mcrA ∆(mrr-hsdRMS-mcrBC) 80lacZ∆M15 ∆lacX74 deoR recA1 araD139 ∆(ara-leu)7697 
galU galK rpsL endA1 nupG and grown in low-salt Luria Bertani (LB) medium.  
 
2.5.1.1 Production of chemicompetent cells 
The TOP10 E. coli cells were pre-cultured in 10ml of LB medium (10g/l de triptone, 5g/l of yeast 
extract, 10g/l de NaCl, pH 7.0) at 37OC, overnight with shaking. This culture was inoculated in 
300ml of LB (1ml of miniculture for 100ml of LB medium) and incubated at 37OC until the 
optical density at 600nm reached approximately 0.6. The culture was cooled on ice during 
30min with ice-cold Cl2Mg (100mM, 150ml). Following the mixture was centrifuged at 3,000 x g 
during 15min at 4OC and cell pellet resuspended in 75ml of ice-cold CaCl2 100mM. Next, 30ml 
of 50% glycerol was added and the aliquots of 200-300l were frozen immediately in liquid 
nitrogen and stored at -80OC until use.  
 
2.5.1.2 Transformation of chemicompetent cells 
The necessary aliquots of chemicompetent cells were thawed on ice and the adequate 
quantity of plasmid DNA was added (1ng of plasmid for each kilobase in the gene of interest). 
Typically, 1l of plasmid DNA is mixed with 100l of bacteria. The mixture was incubated for 
30min on ice and then placed in heat block previously set at 42OC for 30sec. After that time, 
250l of SOC medium (20g/l de triptone, 5g/l of yeast extract, NaCl10mM, KCl 2.5mM, MgCl2 
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10mM, MgSO4 10mM, glucose 20mM) was added and the mixture was incubated at 37
OC for 
1h with shaking (350rpm) to allow expression of antibiotic resistance gene. Part of the culture 
(50-100l) was spread over LB-agar plates containing appropriate antibiotics (ampicillin at a 
concentration of 100g/ml). The plates were incubated at 37OC for 14-16h. The obtained 
colonies were analyzed through restriction digestion of plasmid DNA and conserved at -80OC in 
liquid culture LB medium with 20% glycerol.  
2.5.2 Purification of DNA from agarose gel 
The extraction of the DNA from agarose electrophoresis gel band was performed using 
QIAQuick Gel Extraction Kit (Qiagen). This system is based on the selective DNA adsorption to 
silico gel QIAQuick membrane. Briefly, the DNA fragment was excised from agarose gel and 
weighted. Following, three volumes of Buffer QG for 1 volume of gel were added and 
incubated at 50OC for 10min to completely dissolve the gel. Next, the sample was applied on 
the QIAQuick column (to bind DNA) and centrifuged at 10,000 x g for 1min. After washing with 
Buffer PE, the DNA was eluted with H2O. 
2.5.3 DNA digestion with restriction enzymes 
Typically, a mixture (of the total volume 20-50µl) containing 1-5µg of DNA, 2 units of enzyme 
per microgram of DNA, buffer appropriate for the enzyme mixture diluted to a concentration 
1X in distilled water was prepared. The mixture was incubated during 1-3 hours at 37OC and 
analyzed through running on electrophoresis gel.  
2.5.4 Ligation 
The ligation reactions were prepared by mixing purified restriction fragments (up to 7µl 
volume), 1µl of T4 DNA ligase (Invitrogen) and 2µl of enzyme reaction buffer (5X). The mixture 
was incubated at 16OC for 12-16 hours and transformed in chemicompetent cells TOP10.   
2.5.5 Miniprep plasmid purification 
A small-scale isolation of plasmid DNA from bacterial culture was performed with the use of 
Wizard Plus SV Minipreps DNA Purification System (Promega Madison, WI) based on alkaline 
protease lysis procedure. This step is performed to inactivate endonucleases and 
nonspecifically degrade proteins, thus reducing the overall level of protein contaminants. The 
liquid culture (2-3ml) was grown in selective medium (LB supplemented with 100g/ml 
ampicillin) during 14-16h at 37OC with shaking. Cells were harvested by centrifugation for 5min 
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at 10,000 x g and thoroughly resuspended in 250l of Cell Resuspension Solution (CRA). Next, 
250l of Cell Lysis Solution (CLA) was added, mixed by inverting the tube and incubated until 
the cell suspension cleared (1-5min). Following 10l of Alkaline Protease Solution was added, 
mixed and incubated for 5min. The mixture was then neutralized by addition of 350l of 
Neutralization Solution (NSB) and bacterial lysate was centrifuged at maximum speed in 
microcentrifuge for 10min at room temperature. The cleared lysate was transferred to the 
prepared Spin Column and centrifuged at the maximum speed for 1min. The Spin Column was 
then washed with 750l of Column Wash Solution (CWA) (previously diluted with 95% 
ethanol). Finally, the plasmid DNA was eluted with 100l of Nuclease-Free Water. 
 
Composition of Buffers and Solutions 
LB medium: casein peptone 10g, yeast extract 5g, NaCl 5g, agar (for plates only) 15g. Dissolved 
in 1L of distilled water, autoclaved and cooled to 55ºC before adding antibiotic. 
Cell Resuspension Solution (CRA): 50mM Tris-HCL pH 7.5, 10mM EDTA pH 8.0, RNase A 
100g/ml. 
Cell Lysis Solution (CLA): NaOH 0.2M, SDS 1%. 
Neutralization Solution (NSB): 4.09M guanidine hydrochloride pH 4.8, potassium acetate 
0.759M, glacial acetic acid 2.12M. Final pH of approximately 4.2. 
Column Wash Solution (CWA): potassium acetate 162.8mM, 22.6mM Tris-HCl pH 7.5, 0.109mM 
EDTA pH 8.0. 35ml of 95% ethanol was added before use.  
2.5.6 Maxiprep plasmid purification 
A bigger-scale isolation of plasmid DNA from E.coli culture volume of 100-200ml of LB broth 
was performed using PureYieldTM Plasmid Maxiprep System (Promega Madison, WI) following 
the manufacturer’s instructions. Mainly, 100-200ml of transformed E.coli bacterial cell culture 
in selective medium (LB supplemented with 100g/ml ampicillin) was grown overnight (16-21 
hours) at 37OC with shaking. The cells were pelleted by centrifugation at 5,000 x g for 10min 
and resuspended in 12ml of Cell Resuspension Solution (composition of all buffers and 
solutions can be found in the section 2.5.5). All steps of centrifugation were performed in 
Avanti J-25 centrifuge (Beckman) at 4OC. Following, 12ml of Cell Lysis Solution was added, 
mixed gently and incubated for 3min at room temperature. The mixture was neutralized with 
12ml of Neutralization Solution and mixed thoroughly to ensure complete precipitation of 
cellular debris. The lysate was centrifuged at 14,000 x g for 20min at room temperature in a 
fixed-angle rotor. Vacuum DNA purification has been performed by passing the supernatant 
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through PureYieldTM Clearing Column assembled on the top of PureYieldTM Maxi Binding 
Column to which membrane DNA binds. When all lysate has passed through both columns the 
PureYieldTM Maxi Binding Column was washed with 5ml Endotoxin Removal Wash (prepared by 
adding 5.5ml (for 2 preps system) of isopropanol to the Endotoxin Removal Wash). Then the 
column was washed with 20ml of Column Wash and dried through applying vacuum for 5min. 
For DNA elution, the PureYieldTM Maxi Binding Column was placed into a new 50ml disposable 
plastic centrifuge tube, 1.5ml of Nuclease-Free Water was added to the DNA binding 
membrane and the column was centrifuged in a swinging bucket rotor at 2,000 x g for 5min. 
The eluate was collected from the 50ml tube. Both the washing as well as elution steps were 
performed at room temperature. 
 
2.6 Protein based techniques 
2.6.1 Antibodies 
The antibodies utilized in the present work together with its origin, type, clone, application, 
dilution and manufacturer are shown in Table 11. 
 
Table 11. Characteristics of the antibodies used. 
Antibody Species Type Clone Dilution Manufacturer 
BCL2 mouse monoclonal 124 1:50 (IHC) DakoCytomation 
A20 mouse monoclonal 59A426 1:50 (IHC) Active Motif 
CTSL2 mouse monoclonal ---- 1:50 (IHC) Alexis Biochemicals 
TRAF1 mouse monoclonal H-3 1:50 (IHC) Santa Cruz Biotechn. 
JUNB mouse monoclonal C-11 1:50 (IHC) Santa Cruz Biotechn. 
STAT1 mouse monoclonal C-136 1:50 (IHC) Santa Cruz Biotechn. 
STAT3 mouse monoclonal F-2 1:50 (IHC) Santa Cruz Biotechn. 
STAT4 rabbit polyclonal C-20 1:50 (IHC) Santa Cruz Biotechn. 
ZAP70 goat polyclonal M-20 1:50 (IHC) Santa Cruz Biotechn. 
Ac-H2A rabbit polyclonal ---- 1:2000 (WB) Upstate 
H2A rabbit polyclonal ---- 1:2000 (WB) Upstate 
Ac-H2B rabbit polyclonal ---- 1:400 (WB) Abcam 
H2B rabbit polyclonal ---- 1:2000 (WB) Upstate 
Ac-H3 rabbit polyclonal ---- 1:20000 (WB) Upstate 
H3 rabbit polyclonal ---- 1:2000 (WB) Abcam 
Ac-H4 rabbit polyclonal ---- 1:2000 (WB) Upstate 
H4 rabbit polyclonal ---- 1:2000 (WB) Upstate 
p-ZAP70(Tyr493) rabbit polyclonal ---- 1:1000 (WB) Cell Signaling 
p-ZAP70(Tyr319)/ 
SYK (Tyr352) 
rabbit polyclonal ---- 1:1000 (WB) Cell Signaling 
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ZAP70 goat polyclonal M-20 1:500 (WB) Santa Cruz Biotechn. 
p-AKT (Ser473) rabbit monoclonal D9E 1:1000 (WB) Cell Signaling 
AKT rabbit polyclonal ---- 1:1000 (WB) Cell Signaling 
p-ERK (p44/p42, 
Tyr204) 
mouse monoclonal E-4 1:500 (WB) Santa Cruz Biotechn. 
ERK2 mouse monoclonal 4C11C11C4 1:500 (WB) Santa Cruz Biotechn. 
BTLA mouse monoclonal 185B/E9 1:50 (IHC) CNIO 
PD-1 mouse monoclonal NAT105 1:50 (IHC) CNIO 
CD30 mouse monoclonal CON6D/B9 1:50 (IHC) CNIO 
CD10 mouse monoclonal 56C6 1:50 (IHC) DakoCytomation 
ALK mouse monoclonal ALK1 1:50 (IHC) DakoCytomation 
CXCL13 goat polyclonal BCA-1 1:50 (IHC) R & D Systems 
CD3 rabbit polyclonal ---- 1:50 (IHC) DakoCytomation 
CD56 mouse monoclonal 123C3 1:50 (IHC) DakoCytomation 
FOXP3 mouse monoclonal 206D/G7 1:50 (IHC) CNIO 
EBER mouse monoclonal CS.1-4 1:50 (IHC) DakoCytomation 
 
2.6.2 Protein extraction 
2.6.1.1 Histones extraction 
Histones were obtained from cell lines treated with vorinostat and from respective DMSO 
controls. Histones were isolated by acidic extraction in 0.25M HCl and precipitation with 
acetone as previously described (Turner and Fellows, 1989). Briefly, 107 cells were harvested, 
washed with PBS and incubated overnight in 200μl of 0.25M HCl at 4OC with shaking. For 
histone precipitation eight volumes of acetone were added to the supernatant, and histones 
were pelleted by centrifugation and washed with acetone. Histones were air-dried and 
resuspended in 0.25M HCl for subsequent immunoblot analysis. 
 
2.6.2.2 Total protein extraction 
Total protein extracts were prepared by lysing cells in RIPA lysis buffer (Sigma-Aldrich) 
containing protease inhibitor cocktail set III (Calbiochem, San Diego, CA) plus protease 
inhibitor cocktail set VIII (Calbiochem) for 20min on ice. Cell debris was removed by 
centrifugation (10,000 x g, 10min, 4OC). The supernatant (protein extract) concentration was 
measured using Protein assays reagents A, B, and S (BioRad, Hercules, CA) following the 
manufacturer’s instructions using bovine serum albumin (BSA) as a standard. Briefly, 1ml of 
Agent A was mixed with 20µl of Agent S. First, the adequate amount of either standard (BSA) 
or sample was applied to each well of 96-well plate, following 25µl of previously prepared 
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mixture was added. Finally, 200µl of Agent B was added and the whole preparation was 
incubated for 15min at RT and measured at a wavelength of 750nm. 
 
Composition of RIPA buffer: : 150mM NaCl, 1.0% IGEPAL® CA-630, 0.5% sodium deoxycholate, 
0.1% SDS, and 50mM Tris, pH 8.0. Just before use the protease inhibitor cocktail was added: 
0.1mM sodium vanadate, 5g/ml leupeptine, 5g/ml aprotinine, 1mM phenylmethylsulphonyl 
fluoride (PMSF). 
2.6.3 Western blotting 
Histone acetylation was determined by Western Blot against acetyl forms of histones H2B 
(Abcam, Cambridge, UK), H2A, H3 and H4 (Upstate, Lake Placid, NY). Total histones H3 
(Abcam), H2A, H2B and H4 (Upstate) were used as controls.  
For phosphorylation studies the following primary antibodies has been used: p-ZAP70(Tyr493), 
p-ZAP70 (Tyr319)/SYK (Tyr352), p-AKT (Ser473), AKT (Cell Signaling Technology, Beverly, MA) 
and ZAP70 (Santa Cruz Biotechnology, Santa Cruz, CA). Antibody to -tubulin was from Sigma 
Chemicals Co. (St. Louis, MO). Complete list of antibodies and dilutions used is presented in 
Table 11. 
Western Blotting was performed according to standard protocols. First, the protein extracts 
were subjected to electrophoresis on sodium dodecyl sulfate polyacrylamide (SDS-PAGE) gels 
using the acrylamide concentration adequate for the size of the detected proteins (15% - 
histones and 10% - phosphoproteins) using Mini-Protean 3 system (BioRad). 
 
Electrophoresis buffer 5X composition: TrisHCl 0.13M, glycine 0.95M, SDS 0.5%. 
Sample buffer (Laemmli buffer) 4X composition: 62.5mM TrisHCl pH 6.8, glycerol 20%, SDS 2%, 
2-mercaptoethanol 5%, bromophenol blue 0.025%. 
 
Following electrophoresis, the proteins were wet-transferred onto nitrocellulose membranes 
(Whatman, Dassel, DE) using Mini Trans-Blot Cell equipment (BioRad). Transference was 
performed at 40mA during 12-20h at room temperature or 400mA during 1.5h at 4OC. 
 
Transference buffer 10X composition: TrisHCl 0.025M, glycine 0.2M, 20% of methanol 
 
Membranes were blocked in PBS-T (phosphate-buffered saline with 0.1% Tween-20) during 1h 
with shaking and sequentially immunoprobed with primary antibodies at adequate dilution. 
Anti-histone antibodies were diluted in 5% milk PBS-T while anti-phospho antibodies were 
diluted in 5% BSA PBS-T. Antibody detection was performed using fluorescent-labeled 
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secondary antibodies (Alexa 680m and Alexa 800m, Rockland, Gilbertsville, PA, USA) and 
scanned with Odyssey Infrared System Scanner (LI-COR Biosciences, Lincoln, NE, USA). Band 
intensities were quantified using the ImageJ 1.34S software (National Institute of Health, 
Bethesda, MD, USA). 
2.6.4 Immunohistochemistry 
Immunohistochemical techniques were performed on paraffin-embedded tissue sections 
taken from 35 pre-treatment samples of patients included in the randomised clinical trial of 
PUVA vs. PUVA/IFNα treatment and 10 inflammatory dermatoses (ID) cases. All 
immunostaining was performed using the TechMate 500 (DAKO-Cytomation) automatic 
immunostaining device following LSAB Visualization System protocol (labeled streptavidin-
biotin; DAKO). The slices were first dried at 56OC for 16h through consecutive incubations in 
xylene (2X 10min), ethanol 100% (5min), ethanol 95% (5min), ethanol 70% (5min) and water 
(2min). A Heat-Induced Epitope Retrieval (HIER) step was performed in a 10mM solution of 
sodium citrate buffer pH 6.5 with 0.01M tri-sodium citrate solution, and heated for 2min in a 
conventional pressure cooker. After heating, slides were rinsed in cool running water for 5min. 
They were then quickly washed in Tris-buffered-saline pH 7.4, and incubated with monoclonal 
primary antibodies at appropriate dilutions for approx. 40min. The primary monoclonal 
antibodies used in this study and their dilutions are included in the Table 11. 
Following incubation with the primary antibody, immunodetection was performed with 
biotinylated secondary antibody (25min), followed by peroxidase-labelled streptavidin-biotin 
(DAKO-Cytomation, Glostrup, Denmark) with diaminobenzidine chromogen as substrate and 
contrastained with hematoxilin (1min and washed with distilled water). The preparations were 
dehydrated through consecutive incubations with ethanol 95% (30sec), ethanol 100% (30sec) 
and xylene (1h), and mounted using automatic mounting Tissue-Tek SCA. Incubation omitting 
the specific antibody, including incubation including unrelated antibodies, was used as a 
control of the technique. 
2.6.5 Tissue Microarrays 
Tissue microarrays (TMAs) are used to analyze the expression of genes simultaneously in 
multiple individual tissue samples on one slide. TMAs are composed of small 0.6 - 3.0 mm 
cores of tissue from donor paraffin-embedded tissue blocks which are arrayed at a high 
density on a slide and are prepared as indicated in Figure 7. All tissues were obtained from the 
tissue archives of the CNIO Tumor Bank. Tissue Arrayer device (Beecher Instruments, Sun 
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Prairie, WI) was used to construct tissue microarray (TMA) blocks. All cases were histologically 
reviewed and representative areas were selected. In each case, 2 selected 1-mm-diameter 
cylinders from 2 different areas were included, along with 43 different controls to ensure the 
quality, reproducibility, and homogenous staining of the slides. The biopsies had been taken 
prior to treatment. The histological criteria used for diagnoses of cases were based on 
descriptions of the World Health Organization classification (Swerdlow, 2008). Thus, 7 different 
TMA blocks were constructed, containing a total of 547 cylinders. TMA blocks were sectioned 
and dried for 16 hours at 56OC before being dewaxed in xylene and rehydrated through a 
graded ethanol series and washed with phosphate-buffered saline. Antigen retrieval was 
achieved by heat treatment in a pressure-cooker for 2min in 10mM citrate buffer (pH 6.5). 
Before staining the sections, endogenous peroxidase was blocked. Immunohistochemical 
staining was performed on these sections using antibodies described in Table 11. After 
incubation, immunodetection was performed with the LSAB Visualization System (DAKO, 
Glostrup, Denmark) employing diaminobenzidine chromogen as a substrate. Sections were 
counterstained with hematoxylin. The staining of the TMA sections was evaluated by a panel 
of pathologists using uniform criteria. In order to guarantee the reproducibility of this method, 
the straightforward and clear-cut criteria were employed. Briefly, the pattern of staining for 
each Ab was recorded as positive or negative, and high or low expression. 
 
 
 
Figure 7. Tissue Microarrays preparation procedure.  
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2.7 Statistical Analysis 
In PTCL study, the association between the different markers and disease specific survival 
(DSS) was estimated the log-rank test using the SPSS statistical program.  
In order to identify statistically significant associations between differentially expressed 
microRNAs (FDR < 0.01) and gene expression signatures (FDR < 0.01), the analysis of 
consistency of predicted microRNA-mRNA targeting pairs with the pair components inverse 
regulation, and nonrandom association of the consistent pairs was performed. Briefly, for each 
differentially expressed microRNA a contingency table relating the microRNA and its predicted 
gene targets was produced, taking into consideration whether or not these targets were 
included in a consistent gene expression signature (downregulated targets for upregulated 
microRNAs etc.). Those microRNAs (FDR < 0.01) were subjected to Fisher’s exact test and 
selected on the basis of their non-random association with the gene expression signature of 
interest (FDR < 0.01). Gene target predictions of human microRNAs were obtained from 
miRBase Targets Release v5.0 and TargetScan v5.1. 
 
In the PUVA +/- IFNα study (MF99 trial), statistical differences between response and 
treatment arms were assessed using Pearson or Fisher exact statistics. For survival analysis 
Kaplan-Meier and Cox regression methods were used. 
 
In the HDACi (vorinostat) study, group comparisons of parametric data were made by 
Student’s t-test. Statistical analysis was performed with the SPSS software package, version 
13.0 (SPSS, Chicago, IL). The differences were considered significant when the adjusted p-value 
was smaller than 0.05. 
 
The mean inhibitory concentration 50% (IC50) was calculated using Graph Pad Prism software 
(sigmoidal dose response, variable slope) (GraphPad, San Diego, CA). Isobologram analyses 
using the Chou and Talalay method with Calcusyn (Biosoft, Ferguson, MO) were used to 
determine synergism (Chou and Talalay, 1984). A combination index (CI) value less than 1.0 
indicates synergistic effects. A CI value equal to 1.0 indicates additive interactions. A CI value > 
1 indicates antagonistic interactions.  
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RESULTS I 
Peripheral T-cell lymphoma – molecular heterogeneity revealed 
by integrative genomic analysis 
 
 
 
 
Peripheral T-cell lymphoma (PTCL) has been the subject of a relatively limited number of 
studies to elucidate the molecular pathogenesis. As a result, molecular classification of PTCL is 
still to be developed, targeted drugs are in very early development and clinical outcome is 
dismal. Recently, new technologies in genomic analysis have offered the opportunity to 
improve the knowledge regarding microRNA and gene expression signatures in T-cell 
lymphoma as well as the potential of microRNAs as prognostic markers in this disease.  
Gene expression profiling (GEP) revealed twelve pathways significantly enriched in malignant 
tissue (FDR<0.1), including the ERK, EGF, CDK5, MET and cytokine induced signaling cascades. 
GEP data were analyzed trying to correlate the lymphoma cases with the signatures of 
different T-cell subpopulations including Th1, Th2, T-reg, Th17, TFH and cytotoxic T-cells. The 
analysis of lymphoma samples revealed a group of 20% of cases with a null phenotype lacking 
any resemblance to normal T-cell subpopulations. A signature composed of 102 microRNAs 
was found to be differentially expressed in PTCL compared with reactive lymph node controls 
(LN), including the let-7 family, mir-10, mir-15, mir-16 and miR-101 (p<0.0001). MicroRNA and 
gene expression profiles of the cases with null-phenotype vs. differentiated-phenotype were 
compared and it was found that the former group expressed oncogenic microRNAs, such as 
the miR-17-92 cluster (Oncomir-1) and miR-181 family. In addition, a set of 67 microRNAs was 
lost in the null-phenotype group (FDR<0.0001). These microRNAs target genes of the insulin 
like growth factor 1 (IGF-1) pathway and oncogenic Ras family, signaling cascades that have 
been shown to function as potent proliferation stimuli.  
In conclusion, molecular analysis of PTCL, facilitated by the comparison with normal T-cell 
subpopulations, revealed the existence of a null-phenotype PTCL, characterized by aggressive 
behavior and expressing a microRNA oncogenic signature. This research suggests possible and 
novel roles for microRNAs in the diagnosis and pathogenesis of T-cell lymphoma, and 
identifies promising therapeutic targets  
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3. Peripheral T-cell lymphoma – molecular heterogeneity revealed by 
integrative genomic analysis 
 
3.1 Gene expression profile of peripheral T cell lymphomas 
To explore the genetic alterations in the pathogenesis of PTCL, microarray analysis was 
performed comparing PTCL samples to normal lymph node (LN) tissue. The gene set 
enrichment analysis (GSEA) showed no significant pathways enriched in LN samples. However, 
the gene expression profile of PTCL series revealed several pathways significantly related to 
malignancy, 28 pathways with FDR lower than 0.25 among which 13 gene sets with FDR < 0.1 
were enriched in PTCL. These included pathways known to be involved in cancer pathogenesis, 
such as extracellular signal-regulated kinases (MAPK/ERK), epidermal growth factor (EGF), 
erythropoietin (EPO), mesenchymal-epithelial transition factor (MET), BCL2 and inflammatory 
cytokine induced signaling cascades. Additionally, several cell cycle related pathways have 
been identified, such as cell cycle, cyclin-dependent kinase-5 (CDK5), GS, G1, G2 pathways. The 
complete list of the significant pathways enriched in PTCL is presented in Table 12. 
 
Table 12. Pathways enriched in peripheral T-cell lymphoma identified by gene set enrichment 
analysis (GSEA). 
 
NAME SIZE NOM p-val FDR q-val 
ERK PATHWAY 30 0 0.013 
EGF PATHWAY 26 0 0.030 
EPO PATHWAY 19 0 0.021 
IL3 PATHWAY 15 0.004 0.019 
RACCYCD PATHWAY 21 0 0.018 
CDK5 PATHWAY 13 0.002 0.021 
BCL2 FAMILY 21 0.002 0.050 
IL2 PATHWAY 40 0.002 0.046 
MET PATHWAY 35 0.004 0.045 
IL6 PATHWAY 21 0.007 0.048 
STAT3 PATHWAY 8 0.006 0.045 
ERK5 PATHWAY 17 0.022 0.075 
PROTEASOME PATHWAY 27 0.013 0.096 
CXCR4 PATHWAY 23 0.024 0.103 
IGF1 PATHWAY 20 0.033 0.112 
MAPK PATHWAY 83 0.010 0.135 
GS PATHWAY 5 0.043 0.127 
MTOR PATHWAY 22 0.026 0.121 
CREB PATHWAY 26 0.037 0.124 
PLC PATHWAY 8 0.056 0.126 
G2 PATHWAY 23 0.046 0.123 
CELL CYCLE PATHWAY 22 0.048 0.134 
G1 PATHWAY 26 0.060 0.178 
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VEGF PATHWAY 26 0.065 0.172 
IL22BP PATHWAY 11 0.116 0.182 
UBIQUITINS METAGENE 5 0.124 0.207 
CDC25 PATHWAY 9 0.148 0.228 
WNT PATHWAY 24 0.122 0.236 
 
3.2 MicroRNA profile of peripheral T cell lymphomas 
To date every type of tumor analyzed by microRNA profiling has shown significantly different 
microRNA profiles compared with normal cells from the same tissue. Emerging evidence 
suggests that altered microRNA expression contributes to tumorigenesis. In T-cell lymphoma 
little information is available regarding microRNA expression levels or the potential of 
microRNAs as prognostic markers in this disease. Therefore, a systematic miRNA expression 
profiling analysis of 711 mammalian microRNAs was performed on 20 peripheral T-cell 
lymphoma (PTCL) samples, including 11 PTCLU and 9 AITL, along with 7 reactive lymph nodes 
(LN) as a control samples. To identify microRNAs differentially expressed in PTCL compared 
with the LN, commercial human oligonucleotide microRNA platform from Agilent was used. 
microRNAs differentially expressed between PTCL and LN samples were identified  using 
unpaired t-test implemented in significance analysis of microarrays (SAM) (Tusher et al., 2001) 
and permutation tests (10,000 permutations). A signature composed of 102 microRNAs was 
found to be differentially expressed in PTCL compared with LN, including the let-7 family, mir-
10, mir-15, mir-16 and miR-101 (FDR<0.01). All of them were lost in PTCL samples (Figure 8). 
The complete list of significant microRNAs (FDR<0.01) with its corresponding fold change and 
FDR values are presented in the Supplementary Table 1. To investigate whether microRNA 
profiles were informative with regard to clinicopathological parameters, including patient’s 
overall survival (OS), binary linear regression analysis was performed. This analysis identified 4 
microRNAs significantly (p-value < 0.05) associated with survival, including miR-128a, miR-375, 
miR-425-3p and miR-608.  
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Figure 8. Heatmap representing differentially expressed microRNAs with FDR<0.0001 (SAM 
analysis) in LN and PTCL samples. 
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3.3 Association between miRNAs and mRNA signatures 
Once the initial observation that microRNAs are differentially expressed within the cohort of 
patients analyzed so far was made, an integrated analysis of the microRNAs and mRNA 
expression profiles was carried out to identify putative microRNA targets. In order to identify 
statistically significant associations between differentially expressed microRNAs and gene 
expression signatures the consistency of predicted microRNA – mRNA (FDR<0.01) targeting 
pairs with the pair component inverse regulation was investigated, excluding the random 
associations. The genes targeted by significant microRNAs were first predicted with miRBase 
and TargetScan databases and Fisher’s exact test was then applied to significant list of 
microRNAs and genes. These two databases jointly identified 18 microRNAs lost in PTCL with 
FDR<0.05 on the basis of a significant results of Fisher’s exact tests (Figure 9A). Following, the 
microRNAs targets were filtered on nodes with at least 7 neighbors (within distance 1) to 
narrow the amount of targets to those genes targeted by higher number of microRNAs using 
Cytoscape software. Downregulated miRNAs with connections to upregulated genes are 
represented in the Figure 9B. Of note, microRNAs with the highest number of target genes 
included miR-607, miR-24 and miR-214 whereas among genes with high degree of connections 
comprised members of cell cycle pathway (E2F6, CDK6, CCND1), AKT (AKT2) , IGFR (IGF1R) and 
MAPK (MAP1A) signaling pathways (Figure 9B). 
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Figure 9. Correlation of significant microRNAs and genes differentially expressed between PTCL 
samples and LN controls. A) Downregulated miRNAs with connections to upregulated genes 
were subjected to Fisher analysis applying TargetScan and Miranda databases. Venn diagram 
represents significant microRNAs (FDR < 0.05) common to both databases. B) Network 
representing significant microRNAs and their correlation to target genes (filtered on 7 
neighbours). miRNAs are indicated by yellow circles, while genes are represented by yellow to 
red circles (rainbow distribution) depending on the degree of connections. The size of circles 
representing genes is proportional to their degree of connectivity. Network visualization was 
performed with the use of Cytoscape software. 
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3.4 T-cell subsets signature differentiating two subtypes among peripheral T-cell 
lymphomas 
The morphology and immunophenotype of the hematopietic tumors recapitulate the different 
normal subpopulations that are the counterpart for each type of tumor.  The differentiation 
decision is governed predominantly by the cytokines in the microenvironment and, to some 
extent, by the strength of the interaction of the T cell antigen receptor with antigen. In normal 
T cells, upon interaction with cognate antigen, CD8+ T cells differentiate into T cytotoxic 
subtype, while CD4+ T cells can differentiate into a variety of effector subsets, including 
classical Th1 cells and Th2 cells, the more recently defined Th17 cells, follicular helper T (TFH) 
cells, and induced regulatory T (iTreg) cells. Taking into consideration that PTCL is a malignancy 
of mature T lymphocytes, the hypothesis was stated whether there are any PTCL subtypes that 
could reflect the heterogeneity of the normal peripheral T-cell subsets and whether using this 
approach specific PTCL subtypes with distinctive molecular and clinical features could be 
identified. For this purpose gene expression profiling (GEP) data from a series of twenty PTCL 
patients was analyzed in attempt to correlate the lymphoma cases with the signatures of 
different T-cell subpopulations including CD4-positive Th1, Th2, iTreg, Th17, TFH and CD8-
positive cytotoxic T-cells. This analysis showed that most of PTCL re-express simultaneously 
genes that belong to different T-cell lineage subsets, but allowed to identify a subgroup of 
patients that essentially do not express markers for the specific T cell subpopulations (Figure 
10). The PTCL subtypes identified were called differentiated or null-phenotype group, 
respectively. Furthermore, both groups were characterized on the clinicopathological, 
microRNA and gene expression level.  
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Figure 10. T-cell subsets (Tcytotoxic, TFH, Th1, Th2, Th17 and Treg) signature in PTCL samples. 
Identification of two subtypes of patients with PTCL, null-phenotype and differentiated group. 
The tree node containing samples from null-phenotype group is highlighted in red and 
differentiated group in green. 
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Interestingly, both null-phenotype as well as differentiated groups were quite heterogeneous 
with respect to the diagnostics of the cases. While in the differentiated group equal 
distribution of PTCLU and AITL cases (8 PTCLU, 8 AITL) was observed, in the null-phenotype 
group PTCLU cases predominated (3 PTCLU, 1 AITL). The group of patients lacking resemblance 
to normal T cell subpopulations was found of particular interest, hence more attention to 
characterization of the mentioned group will be paid in this paragraph. Morphologically, in 
null-phenotype group large and medium-size pleomorphic cells were observed in 3 out of 4 
cases (TCL4, TCL11 and TCL12) and typical for AITL small cells in TCL20 case (Figure 11A). The 
immunohistochemistry analysis revealed that in the group that lacks expression of T cell 
differentiation related genes, all cases expressed CD3, however, they lacked the genes 
regulating CD4 and CD8 cells differentiation suggesting other genes involved or their different 
differentiation level. Some of the cases weakly expressed CD4, despite not being classified as 
lymphoblastic lymphomas. All cases were negative for CD8, did not express CD56 (excluding 
the possibility of being NK lymphomas), TdT (excluding leukemias) and ALK (excluding ALCL). 
Two cases weakly expressed CD30 and all cases were of α/β T cell origin (TCR BF1 positive).  
3.4.1 microRNA characterization of null-phenotype vs. differentiated subsets 
Following, microRNA expression profiles of the cases with null-phenotype vs. differentiated-
phenotype were compared. Of note, half of the patients in the null-phenotype group highly 
expressed oncogenic miR-17-92 cluster and mir-181 family (Figure 11B). The miR-17-92 cluster 
has been described to be functionally implicated in fundamental processes of development 
and cancer by targeting several mRNAs of proteins, regulating proliferation, apoptosis and 
differentiation (He et al., 2005). Similarly, miR-181-family has been previously found to actively 
participate in the process of differentiation (Naguibneva et al., 2006). In addition, all cases in 
this group showed enrichment in several EBV-related microRNAs including ebv-miR-BART4, 
ebv-miR-BART7, ebv-miR-BART13 and others (Figure 11C). However, approximately 50% of the 
samples showed upregulation of viral EBV related microRNAs suggesting that this 
phenomenon is not restricted to null-phenotype group. The tumoral cells in samples belonging 
to null-phenotype group did not express Epstein Barr-encoded RNA (EBER), hence the viral 
microRNA expression was ascribed to B cell blast (EBER+). 
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Figure 11. Characterization of null-phenotype vs. differentiated group of PTCL patients. A) 
Morphological assessment of patients constituting null-phenotype group (TCL4, TCL11, TCL12, 
TCL20) by hematoxylin-eosin stain. B) Heatmap representing high oncogenic microRNAs 
overexpression in two cases belonging to null-phenotype group: miR-17-92 cluster and miR-
181 family (highlighted n red). C) Enrichment of Epstein Barr virus-related microRNAs in null-
phenotype group. 
 
In T cells, microRNAs have been shown to be key regulators of the lineage induction pathways, 
and to have strong role in the induction, function and maintenance of the T-cell lineage. In this 
context, the possibility whether the differences in microRNA expression could contribute to 
the distinct phenotypes of those two groups was investigated. Indeed, approximately 120 
microRNAs were found to be differentially expressed (FDR<0.01), of those 67 had FDR-values 
lower than 0.0001. Among significant microRNAs 86 were upregulated and 34 microRNAs were 
downregulated in the differentiatied group. These included miR-223, miR-100, miR-498, miR-
622, miR-610, miR-584, miR-518c and miR-510 which target genes of the insulin like growth 
factor 1 (IGF-1) pathway and oncogenic Ras family, signaling cascades that have been shown to 
function as potent proliferation stimuli (Figure 12).   
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Figure 12. Expression patterns of microRNAs found to be significantly differentially expressed 
between null-phenotype and differentiated group. The heatmap represents only microRNAs 
with FDR-values < 0.0001 with indicated fold changes. 
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3.4.2 Identification of genes and pathways distinguishing two groups of patients 
Consistently, Significance Analysis of Microarray (SAM) allowed identification of a total of 1439 
differentially expressed genes, 1128 downregulated and 311 upregulated genes in null-
phenotype vs. differentiated group. Many genes were targets of microRNAs that have been 
found to distinguish both groups. Significant differentially expressed genes (FDR < 0.01) were 
associated with T cell signaling and differentiation. Furthermore, gene set enrichment analysis 
(GSEA) was applied to identify gene sets correlated with the two groups of patients. Using a 
false discovery rate (FDR) of ≤ 0.25, 36 significant gene sets were found. Many of these gene 
sets were, as expected, related to inflammatory cytokine function and apoptosis. Due to the 
low number of samples in the null-phenotype group, only one pathway was found to be 
significantly enriched in this group of patients. Consistently with the microRNA results as 
outlined above, GSEA analysis demonstrated RACCYCD (Ras and Rho) pathway enrichment in 
the null-phenotype group (FDR = 0.175). This result could partly explain the increased 
proliferation of neoplastic cells in the null-phenotype group. Moreover, some genes of the 
RACCYCD pathway, such as E2F1 are targets of oncogenic microRNAs. In contrast, 
approximately 35 gene sets were significantly enriched in the differentiated group. These 
included cytokine (Inflammatory/Cytokine, IL4, IL5, IL7, IL12, IL10, IL18, IL22BP) and T cell 
subsets (Th1, T cytotoxic, Th2 and CD8-cells) related pathways. Besides, GSEA identified a 
number of pathways that mediated cell survival, proliferation and growth that were enriched 
in  differentiated group, such as NFKB and RELA pathways that has previously been related to 
better prognosis in PTCLU, cell death and apoptosis related BCL2 family, caspase and death 
pathways. Moreover, B cell, dendritic cell (DC) and natural killer cell (NK) signaling, possibly 
contributed by the tumor microenvironment, were also found to be enriched in a group of 
patients with differentiated phenotype. By GSEA, the gene set designated “NOTCH signaling 
pathway” showed the regulation pattern of differentiated group.  The TNFR and IFN response 
(IFNG and IFNA) pathways are involved in the expression of many inflammatory 
cytokines/chemokines. Among highly ranked genes, Toll like receptor 1 and TALL1, another 
upstream activators of NFKB were noticed. The complete list of enriched gene sets is 
presented in Table 13. 
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Table 13. Pathways significantly enriched in null-phenotype and differentiated group identified 
by gene set enrichment analysis (GSEA). 
 
Gene sets enriched in the null-phenotype group 
NAME SIZE NOM p-val FDR q-val 
RACCYC PATHWAY 21 0.008 0.175 
    
Gene sets enriched in the differentiated group 
NAME SIZE NOM p-val FDR q-val 
NKT PATHWAY 25 0 0 
TH1 PATHWAY 14 0 0 
INFLAMMATORY/CYTOKINE 
PATHWAY 
22 0 3.75E-04 
DC PATHWAY 17 0 0.001 
IL12 PATHWAY 20 0 0.002 
T CYTOTOXIC PATHWAY 15 0.002 0.005 
IL10 PATHWAY 12 0.005 0.005 
IL18 PATHWAY 6 0 0.005 
NFKB PATHWAY 36 0 0.005 
IL22BP PATHWAY 11 0 0.005 
CTL PATHWAY 10 0.002 0.009 
IFNG PATHWAY 6 0 0.011 
B LYMPHOCYTE PATHWAY 8 0.003 0.012 
TH2 PATHWAY 7 0.007 0.031 
BCR PATHWAY 33 0.009 0.045 
NOTCH PATHWAY 6 0.014 0.046 
CD8 CELLS 6 0.007 0.050 
IL5 PATHWAY 7 0.015 0.050 
IL7 PATHWAY 16 0.027 0.067 
CASPASE PATHWAY 21 0.043 0.077 
CCR5 PATHWAY 17 0.048 0.081 
TOLL PATHWAY 33 0.026 0.083 
NK CELLS PATHWAY 19 0.024 0.088 
MAPK PATHWAY 82 0.011 0.088 
IL4 PATHWAY 11 0.046 0.089 
TALL1 PATHWAY 15 0.041 0.091 
DEATH PATHWAY 32 0.047 0.092 
TNFR PATHWAY 39 0.048 0.099 
RELA PATHWAY 15 0.101 0.149 
TCR PATHWAY 10 0.089 0.151 
IFNA PATHWAY 8 0.107 0.154 
IL3 PATHWAY 14 0.105 0.155 
BCL2 FAMILY 20 0.136 0.190 
IL17 PATHWAY 11 0.112 0.201 
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3.5 Validation of selected genes by tissue microarrays  
Some of the most significant gene expression data have been validated in Tissue Microarrays 
(TMA) on a extended number of 275 PTCL samples. So far, five markers have been evaluated in 
TMA, which includes three genes upregulated in the differentiated group (BTLA, STAT1, 
NFATC1) and two genes upregulated in the null-phenotype group (TOP2A, GATA3). The genes 
were selected based on its significance (FDR values) in SAM analysis, fold change and the 
biological function. As shown in Figure 13A, all genes were able to clearly distinguish between 
null-phenotype and differentiated group. The initial analysis comparing the percentage of 
cases that expressed or not a specific marker was compared and related to the percentage of 
null-phenotype patients in the hybridized cases. Most of the markers selected (GATA3, BTLA, 
STAT1 and NFATC1), except TOP2A, roughly corresponded with the expected values regarding 
positive or negative expression (Figure 13B). B and T lymphocyte associated gene (BTLA) was 
used as a surrogate marker differentiating two subgroups of patients and from all the markers 
selected gave the closest match of TMA results and gene expression data (Figure 13B-D). BTLA, 
a gene induced during T cell activation with a gradual inhibitory effect on TCR signaling, was 
found to be 44 times upregulated in a differentiated group. Based on TMA analysis lack of 
BTLA expression in 29% of samples was observed. This number approximately corresponds to 
the percentage of null-phenotype patients, which is 20%. Signal transducer and activator of 
transcription 1 (STAT1), a member of JAK/STAT pathway, was found to be lost in 32% of 
patients. Furthermore, loss of nuclear factor of activated T-cells, cytoplasmic, calcineurin-
dependent 1 (NFATC1) was detected in 14% of patients. In addition, loss of expression of GATA 
binding protein 3 (GATA3), an important regulator of T-cell development, was observed in 
majority of cases (92%). Topoisomerase (DNA) II alpha (TOP2A) has been previously found to 
be a member of proliferation signature and related to shorter survival of PTCL patients 
(Cuadros et al., 2007) and is the only gene which did not correspond with the microarray data. 
However, higher percentage of patients with no or less than 25% expression (36.4%) trend has 
been observed for this gene.  
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Figure 13. Validation of gene expression profiling by Tissue Micoarrays. A) Heatmap and table 
representing fold change and significance of the genes selected for validation. B) Chart 
showing the percentage of cases expressing or not the selected markers overexpressed in null-
phenotype group (TOP2A, GATA3) and differentiated group (BTLA, STAT1, NFATC1). The 
analysis was performed on the total of 275 PTCL cases included in the Tissue Microarray. C) Pie 
chart representing BTLA expression in PTCL patients. D) Immunohistochemistry images 
presenting examples of BTLA staining considered positive (left panel) or negative (right panel).
  
 
 
 
RESULTS II 
PUVA ± IFN treatment resistance in MF: the role of tumor 
microenvironment, NF-B and TCR pathways 
 
 
 
 
 
Interferon alpha (IFN) is widely used in the treatment of Mycosis Fungoides (MF) and when 
used in combination with photo-chemotherapy (PUVA), both improved response and duration 
of complete remission have been reported. However, in spite of encouraging results of the 
initial studies, currently there are no specific prognostic factors enabling prediction of 
patients’ resistance to treatment. In order to identify factors responsible for resistance to 
PUVA +/- IFN treatment in MF patients, the gene expression profiling of pre-treatment 
samples from 29 MF patients enrolled in a randomized clinical trial was analyzed using cDNA 
microarrays. A Cox model (SAM) and Gene Set Enrichment Analysis (GSEA) were used for 
identification of genes and biologically significant pathways related to resistance to 
treatment. Genes involved in NF-B signaling, T-cell receptor (TCR) signaling, cytokine 
signaling and proliferation were differentially expressed between responders and non-
responders. Interestingly, expression of markers representative of those pathways was found 
not only in the tumoral cells, but also in specific subpopulations of macrophages, dendritic 
cells and other non-neoplastic cell types constituting the tumor microenvironment, likely 
involved in the promotion of survival and proliferation of cutaneous T-cell lymphoma. Some 
pro-inflammatory factors such as NF-B, inflammatory cytokines and their receptors in 
addition to TCR associated molecules could be promising, targets for MF treatment. 
Furthermore, the resistance-associated signature was connected to the drug-associated 
profiles using Connectivity Maps (cMaps) in order to identify molecules that could potentially 
reverse a drug resistance signature. This screen indicated that Hsp90 inhibitors (17-AAG, 
geldanamycin) and HDAC inhibitors match the PUVA +/- IFN sensitivity profile. 
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4. PUVA ± IFN treatment resistance in MF: the role of tumor 
microenvironment, NF-B and TCR pathways 
 
4.1 Patient characteristics 
The MF99 randomized study of early-stage MF patients testing the efficacy of PUVA vs. PUVA + 
IFNα showed similar response rates of both regimens. Twenty nine pre-treatment samples 
(PUVA: 18 patients; PUVA + IFN: 11 patients) from patients enrolled in MF99 randomized 
clinical trial were profiled in order to assess the genes related and pathways involved in good 
or poor response to the treatment. The clinical trial protocol allowed 24 weeks of treatment, 
which was a rational cut-off used to distinguish between good and poor responders. Complete 
remission (CR) was defined as disappearance of all clinically detectable disease manifestations. 
After 24 weeks, 22/29 patients achieved CR, 4/29 did not respond to therapy and 3/29 
progressed. The patients treated with PUVA alone showed similar response rates to the 
patients treated with the combination of PUVA and IFN. Of 12 patients subjected to PUVA + 
IFN therapy, 9 obtained CR, 2 did not and 1 progressed (Table 14). Of 22 patients that 
obtained CR, 20 patients experienced a relapse (median duration of CR: 66 weeks). Previous 
treatments had no statistical relationship with therapy response. Since both treatment arms 
showed similar response rates, the 29 pre-treatment samples (PUVA: 18 patients; PUVA + 
IFN: 11 patients) from both arms were combined in one analysis, in order to assess the genes 
related to and pathways involved in sensitivity or resistance to treatment.  Clinical and 
pathologic characteristics of patients enrolled are summarized in Table 14. 
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Table 14. Clinical and Pathologic Characteristics of Patients 
 
Patient characteristics 
All Patients  
(N=29) 
Responders 
(N=22) 
Non-Responders 
(N=7) P-value 
No. of patients (%) No. of patients (%) No. of patients (%)  
Gender Male 12 (41) 7 (32) 5 (71) 
0.080  Female 17 (59) 15 (68) 2 (29) 
Age Median (years) 52 52 45   
 Range (years) 18-78 21-78 18-62  
 
 
0.445 
 <40 8 (28) 5 (23) 3 (43) 
 40-59 12 (41) 9 (41) 3 (43) 
 >59 9 (31) 8 (36) 1 (14) 
Stage IA 14 (48) 10 (45) 4 (57) 
0.074 
 IB 6 (21) 3 (14) 3 (43) 
 IIA 9 (31) 9 (41) 0 (0) 
Skin Phototype II 3 (10) 3 (14) 0 (0) 
0.421  III 26 (90) 19 (86) 7 (100) 
2-microglobulin* Median 0.05 0.05 0.05 
  
0.579 
 Range 0.03-0.42 0.03-0.26 0.05-0.42 
 0.05 13 (45) 11 (50) 2 (29) 
 >0.05 4 (14) 3 (14) 1 (14) 
Soluble IL-2R* Median 1118 871 1252 
  
0.041 
 Range 0-3260 0-3260 1148-2001 
 1118 9 (31) 9 (41) 0 (0) 
 >1118 9 (31) 5 (23) 4 (57) 
Extension Median (%BS) 10 10 8.5 
  
0.542 
 Range (%BS) 1.5-44 2-33 1.5-44 
 10% 14 (48) 11 (50) 3 (43) 
 >10% 15 (52) 11 (50) 4 (57) 
Accum. PUVA*
#
 Median 60.81 48.69 122.65 
  
0.049 
 Range 19.32-570 22.38-570 19.32-250.65 
 60 14 (48) 13 (59) 1 (14) 
 >60 15 (52) 9 (41) 6 (86) 
Previous 
Treatments None 13 (45) 10 (45) 3 (43) 
0.626  Yes 16 (55) 12 (55) 4 (57) 
Previous 
Treatments 
No PUVA and/or 
IFN 19 (66) 14 (64) 5 (71) 
0.541   
PUVA and/or 
IFN 10 (34) 8 (36) 2 (29) 
Treatment 
distribution PUVA 17 (59) 13 (59) 4 (57) 
0.631  PUVA+IFN 12 (41) 9 (41) 3 (43) 
 
Results 
CR at 24 weeks Yes 22 (76) 22 (100) 0 (0)   
   No 7 (24) 0 (0) 7 (100) 
Time to CR Median (weeks) 16 13 ---   
Duration of CR Median (weeks) 93 66 ---   
 
Abbreviations:* There is no data available for some patients; # J/CM2 of received PUVA dose; CR: Complete Remission; BS: Body Surface.  
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4.2 Identification of genes correlated with response to PUVA +/- IFNα treatment 
To identify a gene expression profile correlated with the prediction of response to PUVA +/- 
IFNα treatment, the SAM bioinformatics tool based on the Cox model was used. This method 
identified a total of 52 probes corresponding to 42 unique genes significantly associated with 
therapy response, 4 of which were associated with good response to treatment and 38 of 
which were related to poor response or resistance (Table 15) (q-value  0.25). The genes 
significantly overexpressed in the responders group included: CTSL2 (cathepsin L2), ENTPD6 
(ectonucleoside triphosphate diphosphohydrolase 6), PSMD2 (proteasome 26S subunit) and 
LHFPL2 (lipoma HMGIC fusion partner-like 2). 
 
The genes that were associated with the non-responder group are related to a wide range of 
processes favoring growth, differentiation, migration, proliferation and survival of malignant 
cells and tumor accompanying cells, such as ENG, TNC, WNT4, CD69, NFKB2, FYN and ELF4. 
Most of these genes have previously been described as being upregulated in several tumors 
and many of them are involved in regulation of transcription (ASH1L, LRRFIP1, UBTF, IRF2BP, 
and CRI1) and signal transduction. Several genes, such as CH25H, HSXIAPAF1, NFKB2, SOCS1, 
FYN, MAF, PFN1, and STOM show mutual interactions. These genes either regulate each other 
or are regulated by the factors involved in pathways known to be involved in the pathogenesis 
of MF, such as the NF-B pathway and associated cytokine genes (IL2, IL4, IL6, IL7, IL8, IL10 and 
IL13). In addition, T-cell receptor signaling, TNF and the JAK/STAT pathway were also 
implicated (www.ingenuity.com).  
 
4.3 Identification of signaling pathways associated with resistance to PUVA +/- IFNα 
treatment in MF clinical samples 
To examine the possibility that the response or resistance to treatment might be associated 
with the alterations in biological pathway signaling or co-regulated gene sets rather than with 
individual genes, gene set enrichment analysis (GSEA) was performed. Genes were rank-
ordered from highest to lowest by degree of differential expression (using t-test) between the 
R and NR groups. A heat map of the 50 best scoring genes in each group is shown in Figure 14. 
GSEA identified 79 gene sets meeting the gene set size criteria (min=1, max=500 genes) that 
were used in the analysis.  
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Figure 14. The gene expression heat map of the 29 
MF patient samples including 22 responders and 7 
non-responders to treatment. The heat map shows 
an expression data set sorted by correlation with 
response (t-test) of the 50 genes with the best 
enrichment score in each group. 
 
Twenty-two pathways potentially associated with good response to treatment were identified 
in this analysis, including apoptosis and cell-cycle regulation. The apoptosis pathway genes 
included TRAF6, CASP9, survivin (BIRC5) and NME2 involved in the caspase cascade and 
intrinsic apoptosis pathways. The main cell-cycle genes included cyclins, cyclin-dependent 
kinase inhibitors (CDKNs) and transcription factors controlling cell-cycle. The top-score genes 
included CDC25A, CDKN2B, E2F1, CDC25C, CHEK1 and the CDK5 pathway enriched in NGFR, 
CDK5 and MAPK3 (Table 15).  
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Table 15. Genes and pathways associated with good response 
GENES 
(SAM) FUNCTION GSEA PATHWAYS GENES GSEA 
CTSL2 Cathepsin, lysosomal cysteine proteinase Apoptosis (8) BIRC5, CASP9, NME2, TRAF6 
    ACE2 Signalling  (4) AGT, COL4A6 
    B-Lymphocyte Signalling (2) CR2, ICAM1 
    Caspase Signalling (10) BIRC4, CASP9 
    CDC25 Signalling  (6) CDC25A, CDC25C, CHEK1, WEE1 
    CDK5 Signalling  (8) CDK5, MAPK3, NGFR 
    CK1 Signalling  (8) CDK5, PPP1R1B, PRKAR1A, PRKAR2B 
    EGF Signalling (17) EGF, MAPK3, RASA1, PIK3R1 
    EGFR/SMRTE Signalling  (6)  EGF, RARA 
    G1 Cell Cycle Pathway (21) 
CDC25A, CDKN2B, DHFR, E2F1, 
HDAC1, TGFB2   
    G2 Cell Cycle Pathway (14) 
BRCA1,CHEK1, CDC34, CDC25A, 
CDC25C, MDM2, WEE1 
    IGF1 Signalling (12) IGF1, MAPK3, PIK3R1, RASA1 
    IL10 Signalling (9) BLVRB 
    Lymphocyte Signalling (6) ICAM1, ITGA4, SELP 
ENTPD6 Purine and pyrimidine metabolism 
PSMD2 Proteasome regulatory subunit, Ubiquitination, TNF signalling 
LHFPL2 Lipoma HMGIC fusion partner 
a
Correlation between all analyses used in the study showing genes significantly associated with treatment response 
(SAM), gene functions and where applicable, GSEA pathways enriched in good or bad response signatures, including 
gene set size (in parentheses) and genes enriching particular GSEA pathways. 
 
Among the pathways associated with poor response to treatment, gene sets related to 
cytokine inflammatory responses and T helper 2 (Th2) cell response promotions were 
identified, including T-cell activating pathways through IL2R, inflammatory IL6 signaling 
involved in STAT3 activation and IL3 and IL7 signaling pathways implicated in the cell survival 
and proliferation signals necessary for T-cell development. IL2 signaling (enriched by IL2RB, 
IL2RG, SOCS1, CFLAR, JAK3, JUN, PIK3CA, HRAS, PTPN6, SOS1, SYK, SOCS3, BCL2, NMI) can not 
only activate T-cells and stimulate their proliferation but could also block T-cell apoptosis 
through several pathways including activation of anti-apoptotic BCL-xL. This activation of T-cell 
signaling could lead to upregulation of the NF-B pathway associated gene set (NOM p=0.053), 
including genes such as NIK (MAP3K14), A20 (TNFAIP3), IKBA (NFKBIA), NEMO (IKBKG) and 
TGF1 (MAP3K7) and NF-B target genes (NFKB2, TNFAIP3, TRAF1, ID2, CXCL9 and BIRC3).  
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Table 16. Genes and pathways associated with poor response 
GENES 
(SAM) FUNCTION GSEA PATHWAYS GENES GSEA  
NFKB2 NFKB subunit 
NFKB Signalling (23) 
BIRC3, TRAF1, MAP3K7, NFKBIA, 
CXCL9, TNFAIP3, ID2, NFKB2, IKBKG, 
MAP3K14 CH25H# Cholesterol/ lipid metabolism  
SOCS1* Negative regulation of JAK/STAT signalling 
IL4 Signalling (4) IL2RG, JAK3 
MAF* Transcription regulation, Oncogene 
STOM# Stomatin, cation conductance IL6 Signalling (14) HRAS, IL6R, JAK3, JUN, SOS1, STAT3 
RGL1# Rho GTPase  TNFR Signalling (24) 
CASP8, IKBKG, JUN, MAP3K7, 
MAP3K14, NFKB1A, PRKDC, TANK, 
TNFAIP3, TRAF1, TRAF3 
    CCR5 Signalling (6) CCL2, CCR5, CXCL12, JUN, MAPK14, PRKCA 
    Cytokines (2) CCL2, CXCL9 
    FAS Signalling (12) CASP8, CFLAR, DAXX, FAF, JUN, MAP3K7, PRKDC 
    IL2 Signalling (27) 
BCL2, CFLAR, HRAS, IL2RB, IL2RG, 
JAK3, JUN, LCK, NMI, PIK3CA, PTPN6, 
SOCS1, SOCS3, SOS1, SYK 
    IL3 Signalling (9) CSF2RB, HRAS, SOS1, PTPN6 
    IL7 Signalling (13) BCL2, CREBBP, FYN, IL2RG, JAK3, LCK, NMI, PIK3CA 
    MTOR Signalling (12) EIF3S10, EIF4A1, EIF4A2, MKNK1, PIK3CA, RPS6 
    NOTCH Signalling (2) ADAM17, FURIN 
    Plasma Cell Differentiation (1) XBP1 
    Regulatory T-cell Signalling (7) CD4, IL2RB, PDCD1 
AI429215 Unknown 
ANTXR1 Anthrax toxin receptor, Tumor endothelial marker 
ARHE Rho family GTPase, Cell adhesion, Actin cytoskeleton organization and biogenesis  
ARL2BP ADP-ribosylation factor binding protein 
ASH1L Histone methyltransferase, Transcription regulation 
CCNL1 Transcriptional regulation, splicing, candidate proto-oncogene, cell cycle control  
CD69 Lymphocyte proliferation, Signal transduction 
CRI1 Negative regulation of transcription 
DSP Cytoskelton organization 
ELF4 ETS family transcription factor, development and function of NK and NK T-cells 
ELMO1 Engulfment and cell motility 1 
ENG Angiogenesis, Cell adhesion 
EVI2A Ecotropic viral integration site,  Transmembrane receptor activity  
FBXO9 Ubiquitin-protein ligase activity  
FYN oncogene related to SRC, FGR, YES, T-cell signaling regulation, control of cell growth 
HSXIAPAF1# BIRC4/XIAF binding protein 
IPO8 Nuclear protein import, Ran GTPase binding, Signal transduction 
IRF2BP2 Ubiquitin cycle, Interferon regulatory factor 2-binding protein 
LRRFIP1 Transcriptional repressor,  Regulation of TNF, EGFR and PDGFA expression 
MBNL1 Development, mRNA splice site selection 
MYO1B Cell migration, vesicular transport 
PAPD5 DNA polymerase, DNA repair, Cell cycle control 
PCDHB10 Protocadherin beta 10 precursor, Cell adhesion 
PFN1 Profilin, Actin binding, transcription regulation, cytoskeleton organization and biogenesis 
RBM17 Splicing 
SAT Enzyme which catalyzes the acetylation of polyamines, regulation of polyamine transport, transferase activity  
TNC Cell adhesion, signal transduction, cell communication 
TNKS2 Vesicle trafficking and sub-cellular distribution, Regulation of telomere length, Transferase activity, Regulation of body size  
UBTF Transcription activation 
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USP12 Ubiquitin specific protease 
WNT4 Development, Signal transduction, Cell-Cell signalling, Extracellular matrix structural constituent  
ZNF521 Zinc finger protein 
a
Correlation between all analyses used in the study showing genes significantly associated with treatment response 
(SAM), gene functions and where applicable, GSEA pathways enriched in good or bad response signatures, including 
gene set size (in parentheses) and genes enriching particular GSEA pathways. 
b
Genes regulated by each other. 
c
Core 
genes with the highest enrichment score (ES) in the GSEA pathway. 
 
GSEA also highlighted gene sets in poor responders correlated with chemokine receptors that 
are differentially expressed by different T-cell subsets and play a role in T-cell migration and 
homing, including CCL2, CXCL12 and CCR5. CCR5 is associated with homing to inflamed tissues 
and together with CCR3 is abundantly expressed on T-helper cells (Table 16). Finally, the 
immunosuppressive T-regulatory cell pathway, Notch, mTOR and FAS pathways have been 
found to be enriched in the group of patients with poor treatment outcome.  
 
4.4 Involvement of NF-B activation, TNF signaling and Th2 inflammatory cytokine 
signaling in poor response of MF patients to treatment 
Two different systems for analysis of the expression profiles of patients undergoing treatment 
in the PUVA +/- IFN randomized clinical trial were used. These systems apply different 
approaches such as: expression of particular genes in relation to time to CR (Cox model: SAM) 
and enrichment of pathways with genes overexpressed in good or bad responders (t-test: 
GSEA). Both bioinformatic methods used to identify genes and gene sets significantly 
associated with response to treatment have pinpointed several common pathways. 
Upregulation of NF-B pathway genes and inflammatory cytokines related to T-cell signaling 
(mainly Th2) seemed to play a central role in the poor response to treatment. There appear to 
be important mutual interactions between pathways indicated by both bioinformatics tools. 
The upregulation of IL2, IL3, IL4, IL6 and IL7 signaling pathways could lead to activation and 
proliferation of T lymphocytes and the activation and enrichment of the TNF receptor pathway 
could jointly cause the activation of NF-B leading to growth, proliferation and survival of 
malignant cells. The remaining pathways identified by only one of the approaches such as 
mTOR or CCR5 pathways could enhance the effect triggered by NF-B, TNF signaling or 
cytokine signaling and contribute to proliferation and migration of the neoplastic cells. 
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4.5 Immunohistochemical evaluation of the expression of representative genes 
related to response to therapy 
The results obtained from the gene expression analysis were further validated at the protein 
level by immunohistochemistry (IHC) on MF samples and ID controls, for markers 
representative of the pathways identified by GSEA as follows: (1) NF-B pathway: A20 
(TNFAIP3) and TRAF1 and apoptosis-related targets of NF-B pathway (BCL2); (2) JAK/STAT and 
TCR signalling: STAT1, STAT3, STAT4, ZAP70; (3) immune response: CTSL2 and (4) oncogenes: 
JUNB. 
 
Interestingly, the genes selected were expressed not only by the tumoral cells, but also by 
specific subpopulations of macrophages, dendritic cells and other non-neoplastic 
accompanying cell types present in MF. Three of the markers — antiapoptotic BCL2, TCR-signal 
transducer ZAP70 and NF-B target A20 — were expressed mainly by tumoral cells, and their 
expression could drive tumor proliferation and apoptosis escape. The remaining markers were 
expressed not only by neoplastic cells but also in the cytoplasm of macrophages (TRAF1, 
STAT4) and nucleus of epithelial cells (JUNB). The expression of markers implicated in the 
JAK⁄STAT pathway (STAT3, STAT1) and immune response (CTSL2) was absent in the malignant 
cells of MF cases but present in macrophages and dendritic cells (Figure 15A). Cytoplasmic and 
nuclear expression of STAT3 were observed, the latter suggesting the presence of the 
constitutive active form of the protein in accompanying cells. 
 
In inflammatory dermatitis (ID) control cases (psoriasis, psoriasiform dermatitis and spongiotic 
dermatitis), STAT1, STAT3, TRAF1, STAT4 and CTSL2 were observed only in nonlymphoid cells 
such as dendritic cells, histiocytes, macrophages and epithelial cells, while JUNB was found in 
both stroma and lymphocytes. Furthermore, expression of those markers found only in the 
surrounding cells in ID cases was usually less intense (Figure 15B) compared with MF, with the 
exception of chronic inflammatory diseases such as lichen planus, which showed comparable 
expression. 
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 (A) 
 
(B) 
A B C
D E F
 
 
Figure 15. Immunohistochemistry on selected markers in mycosis fungoides cases and 
control inflammatory dermatitis samples. (A) Immunohistochemical staining for markers 
expressed in tumor cells: BCL2 (A), ZAP70 (B) and A20 (C); tumour and stroma cells: JUNB (D), 
STAT4 (E) and TRAF-1 (F); and only by stroma cells: STAT3 (G), STAT-1 (H), (A, B, C) CTSL2 (I). (B) 
Immunohistochemical staining for JUNB (A, D), TRAF1 (B, E) and CTSL2 (C, F) in benign control 
samples. Upper panel of (B), psoriasis (A, B, C); bottom panel of (B), psoriasiform dermatitis (D, 
E, F). Immersion oil; original magnification x 40 (main images) and x 100 insert images. 
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4.6 Identification of compounds that could reverse the PUVA +/- IFN therapy 
resistance signature  
Having identified a signature of to PUVA +/- IFN treatment by SAM and GSEA analyses, a 
clinical application of this information was sought. The knowledge of resistance signature was 
applied to identify molecules that could reverse the drug resistance signature. For this purpose 
Connectivity Maps (cMaps) was used. This bioinformatics tool allowed rapid in silico 
assessment of molecules contained in the database with regards to their ability to reverse 
signatures related to specific drug resistance or disease state profiles. This screen indicated 
several hits (Table 17), such as protein kinase C inhibitor H-7 (p-value < 0.0001), HSP90 
inhibitors: geldanamycin (p-value < 0.0001), tanespimycin (17-allylamino-geldanamycin 17-
AAG; p-value < 0.0001), HDAC inhibitors: vorinostat (SAHA; p-value = 0.0002), scriptaid (p-
value = 0.00673), CDK2 inhibitor – GW-8510 (p-value = 0.00084), cyclosporins and anti-
bacterial and anti-protozoal agents.  
 
Table 17. Connectivity Map (cMap, version 2) hits - potential molecules able to reverse PUVA 
+/- IFN resistance signature. 
 
cMap 
Molecules 
Dose 
[M] 
Cell lines #  
instances 
Enrichment 
score 
p-value 
 
H-7 
 
100 PC3, MCF7 4 -0.96 0 
 
Geldanamycin 
 
1 
HL60, PC3, 
MCF7 
15 -0.586 0 
 
Tanespimycin (17-AAG) 
 
0.1-1 
HL60, PC3, 
MCF7 
62 -0.373 0 
 
Vorinostat (SAHA, Zolinza
TM
) 
 
10 
HL60, PC3, 
MCF7 
12 -0.591 0.0002 
 
GW-8510 
 
10 MCF7, PC3 4 -0.854 0.00084 
 
Ciclosporin 
 
1-3 PC3, MCF7 6 -0.708 0.00153 
 
Alsterpaullone 
 
10 MCF7,PC3 3 -0.863 0.00527 
 
Dantrolene 
 
12 
HL60, PC3, 
MCF7 
6 -0.647 0.00534 
 
Scriptaid 
10 MCF7, PC3 3 -0.849 0.00673 
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Cefotetan 
 
7 
HL60, PC3, 
MCF7 
3 -0.84 0.00815 
 
Diloxanide 
 
12 
HL60, PC3, 
MCF7 
4 -0.744 0.00849 
 
The highest scoring molecules included histone deacetylase inhibitors (HDACi): vorinostat 
(SAHA, ZolinzaTM) and Scriptaid (Takai et al., 2006) as well as known anticancer antibiotics that 
bind heat shock protein 90 (Hsp90) which antitumor activity has been shown in both leukemias 
(Meyer et al., 2008) and solid cancers (Zsebik et al., 2006), such as Tanespimycin (17-AAG) and 
geldanamycin. Furthermore, H-7 – protein kinase C (PKC) inhibitor – has been found to inhibit 
tumor cell invasion and metastasis in melanoma cells via suppression of phosphorylated 
extracellular signal-regulated kinase 1/2 (ERK1/2) (Tsubaki et al., 2007). Additionally, two 
selective  cyclin-dependent kinase (CDK) inhibitors: GW-8510 (CDK2 inhibitor) (Sielecki et al., 
2000) and Alsterpaullone (GSK-3, CDK5/p25 and CDK1/cyclin B inhibitor) (Schultz et al., 1999) 
have been selected by cMap. Other molecules identified include Cyclosporin which possess a 
potent inhibitory action on T lymphocytes and interleukin release leading to reduced function 
of effector T-cells (Berth-Jones, 2005) and Dantrolene (acting trough decreasing intracellular 
calcium concentration) (Krause et al., 2004). It seems that many of the molecules identified by 
cMap either directly or indirectly negatively regulate T lymphocytes proliferation and signaling 
which could explain their antitumor activity in CTCL. 
 
4.7 Validation of the best cMap hit with clinical application (17-AAG) in a model of 
advanced disease (CTCL cell lines) 
The cMap analysis revealed 17-AAG and vorinostat (SAHA) as one of the most significant hits 
negatively connected with the resistance versus sensitive signature and suggested the 
hypothesis that this small molecules could induce the PUVA +/- IFN sensitivity (reverse 
resistance to PUVA +/- IFN) in resistant patients. As representation of resistance SS and MF 
cell lines were selected that could serve as a model of advanced CTCL. In order to further 
assess the activity and ability of the candidate molecules to downregulate the resistance 
signature, the viability, apoptosis, cell cycle and gene expression studies were performed on 
17-AAG and vorinostat (Results III).  
 
To determine the antilymphoma activity of Hsp90 inhibitor – 17-AAG – a panel of CTCL cell 
lines was exposed to increasing concentrations of 17-AAG (0.01, 0.05, 0.15, 0.5, 1.25, 4, 10, 35, 
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100M) for 72 hours. The inhibitory effect of 17-AAG on the CTCL cells viability was assessed 
using CellTiter-Glo proliferation assay. All CTCL cell lines were sensitive to investigated Hsp90 
inhibitor. 17-AAG suppressed the growth of CTCL cells at nanomolar concentrations with the 
IC50 values in a range 146nM (Myla cells) – 803nM (HH cells) (Figure 16A). Similarly, 17-AAG 
killed CTCL cells in a dose- and time-dependent manner, preferentially through induction of 
apoptosis, as shown by Annexin V and PI staining. Higher apoptosis levels were observed in 
Myla, SeAx and MJ cells (approximately 60-70%) following 72h treatment with the drug (Figure 
16B). The effect of 17-AAG on cell cycle arrest was further explored. Surprisingly, the effect of 
17-AAG on cell cycle in CTCL cells seemed to be rather cytotoxic as in all cell lines a significant 
increase in sub-G0 was observed following treatment with 1M concentration of Hsp90 
inhibitor both for 24 and 48 hours. Only modest G0/G1 cell cycle arrest was recorded for Myla 
and HuT78 cells as shown in Figure 16C. 
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Figure 16. Effect of 17-AAG on viability, apoptosis and cell cycle in cutaneous T cell 
lymphoma (CTCL) cell lines. HH, HuT78, MJ, Myla, and SeAx cell lines were treated with or 
without 17-AAG (1M).  
A) Sensitivity to 17-AAG for a panel of CTCL cell lines was established by the 
proliferation/viability assay (CellTiter-Glo Viability Assay) following 72 hours of treatment. The 
IC50 values were calculated using GraphPad Prism software.  
B) Apoptosis: Each point represented the percentage of annexin V+PI-, annexin V+PI+ and 
annexin V-PI+ cells. The cell death of control DMSO was subtracted from each value (error bar 
represents mean SD of n=3 determinations). 
C) Cell-cycle distributions were determined by DNA content analysis with propidium iodide (PI) 
staining and flow cytometry. 
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To further characterize the actions of 17-AAG in CTCL, cells were treated with 1M 17-AAG 
over 4, 8, 12, 24 hour time course and gene expression profiling was performed. In total, 
approximately 3400 genes were downregulated and 2450 were upregulated by exposure to 
17-AAG in all the cell lines following Short Time Series Expression Miner (STEM) analysis. The 
least number of genes was altered in the HH cell line (283) which in proliferation assays has 
shown the highest IC50 value. Consistently, in HuT78, Myla and SeAx cells the higher number 
of genes was changed following 17-AAG treatment leading to the conclusion that the amount 
of genes modulated by the Hsp90 inhibitor used was clearly related to their sensitivity levels. 
The numbers of genes enriched in downregulated and upregulated profiles in CTCL cells upon 
exposure to 17-AAG is presented in Figure 17. 
 
 
 
Figure 17. Gene expression profiles of 17-AAG-regulated genes in CTCL cells. The figure 
represents selected up- and down- regulated profiles obtained from the Short Time Series 
Expression Miner (STEM) analysis. The significant genes within selected profiles are visualized 
for each cell line. Genes selected as differentially expressed were clustered using CLUSTER and 
visualized by TreeView.  
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The list of downregulated genes was enriched for those involved in cytokine-cytokine receptor 
interactions, MAPK signaling pathway, antigen processing, NK-mediated cytotoxicity, 
apoptosis, WNT signaling and TCR signaling pathways. The downregulation of the latter 
pathway could partially confirm the ability of 17-AAG to reverse PUVA +/- IFNα resistance 
signature as TCR – associated genes were found to be upregulated in poor responders. 
Furthermore, the upregulated genes were enriched for metabolism, focal adhesion, cytokine-
cytokine receptor interactions, MAPK signaling, JAK/STAT signaling. The complete list of 
pathways modulated by 17-AAG and enriched genes is presented in Table 18.   
 
Table 18. Pathways and genes altered following 17-AAG (1M) treatment. Functional analysis 
of the significant genes was performed using FatiGO Search. 
 
Genes downregulated by 17-AAG 
Pathway Genes Enriched 
Cytokine-cytokine receptor 
interaction (hsa04060) 
IL28RA, CCL3, FAS, TNFRSF10A, IL1A, LTB, TNFSF11, LTA, IL13RA1, 
CCL21, TNFRSF1B, IL3RA, TNFRSF8, TNFSF10, IL6 
MAPK signaling pathway 
(hsa04010) 
PPP3R2, RAP1A, PPP3CB, JUND, A_24_P204414, ATF4, CRK, 
DDIT3, CACNA1S, RASGRP3, FAS, IL1A, RAP1B 
Antigen processing and 
presentation (hsa04612) 
PSME2, HLA-DQB2, HLA-DPB1, IFI30, TAP1, HLA-DQA2, LTA, 
CD74, HLA-DOA, CREB1, HLA-B, CALR 
Natural killer cell mediated 
cytotoxicity (hsa04650) 
PLCG1, PPP3R2, PPP3CB, TNFSF10, HLA-B, PIK3R3, FAS, 
TNFRSF10A, ICAM2, ULBP2 
Apoptosis (hsa04210) TNFRSF10A, IL1A, PPP3R2, IL3RA, PPP3CB, TNFSF10, PIK3R3, FAS 
Calcium signaling pathway 
(hsa04020) 
PPP3R2, PPP3CB, SLC25A6, PHKG1, CACNA1S, PLCD3, PLCG1, 
GNAQ 
Purine metabolism (hsa00230) 
A_24_P400815, POLR2F, ADSS, ATIC, FHIT, NME1, ENTPD8, 
PDE7A 
Wnt signaling pathway (hsa04310) TCF7, NKD2, WNT7A, PPP3R2, PPP3CB, APC2, LRP5 
Cell adhesion molecules (CAMs) 
(hsa04514) 
ICAM2, HLA-DQB2, HLA-DPB1, HLA-DQA2, HLA-DOA, HLA-B 
Regulation of actin cytoskeleton 
(hsa04810) 
APC2, PIK3R3, NCKAP1L, CRK, A_24_P689479, PFN1 
T cell receptor signaling pathway 
(hsa04660) 
CDK4, PLCG1, PPP3R2, PPP3CB, PIK3R3 
  
Genes upregulated by 17-AAG 
Pathway Genes Enriched 
Purine metabolism (hsa00230) 
PDE9A, AMPD3, ENPP3, ENST00000371207, ADK, PDE3B, 
ENST00000327299, POLD4, ENTPD1 
Focal adhesion (hsa04510) SHC1, BAD, ITGB1, PDGFB, LAMC3, MYLC2PL, MRCL3 
Regulation of actin cytoskeleton 
(hsa04810) 
CD14, MYLC2PL, MRCL3, A_24_P689479, ITGB1, MRAS, PDGFB 
Cytokine-cytokine receptor 
interaction (hsa04060) 
PRL, IL2RA, PDGFB, IL13, IL12A, CCR5 
MAPK signaling pathway 
(hsa04010) 
MRAS, CACNA2D1, PDGFB, CD14, ATF2, CACNA1E, RASGRP2 
Toll-like receptor signaling CD14, TICAM2, TLR1, TLR3, IL12A 
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pathway (hsa04620) 
Calcium signaling pathway 
(hsa04020) 
GRIN1, CACNA1E, SLC25A6, TNNC2, CYSLTR2 
Insulin signaling pathway 
(hsa04910) 
SHC1, BAD, PDE3B, TSC1 
Jak-STAT signaling pathway 
(hsa04630) 
PRL, IL2RA, IL13, IL12A 
 
 
  
 
  
 
 
 
 
RESULTS III 
Vorinostat interferes with the signaling transduction pathway 
of TCR and synergizes with PI3K inhibitors in CTCL 
 
 
 
 
 
Vorinostat (SAHA), an orally administered inhibitor of class I and II histone deacetylases, has 
been approved by FDA for the treatment of cutaneous T-cell lymphoma (CTCL). In spite of 
emerging information on vorinostat effect on many cancer types, there is still little knowledge 
on mechanism and the kinetics of gene expression, essential for its effective use in 
combination therapy. In this chapter the alterations in gene expression profile (GEP) in CTCL 
cells treated with vorinostat over time were investigated. Subsequently, the evaluation of 
PI3K, PIM and HSP90 inhibitors as potential combination agents with HDAC inhibitors – HDACi 
(vorinostat and panobinostat) was performed. The functional analysis of gene expression data 
suggested that vorinostat modifies signaling of T cell receptor (TCR). The phosphorylation 
studies of ZAP70 (Tyr319, Tyr493) and its downstream target AKT (Ser473) revealed that this 
HDACi inhibits phosphorylation of these kinases. Based on the expression analysis, vorinostat 
was combined with PI3K, PIM and HSP90 inhibitors. The combination with PI3K inhibitors 
resulted in synergy while cytotoxic antagonism was observed when combining vorinostat with 
HSP90 inhibitor in CTCL. These results demonstrate the potential targets of vorinostat which 
shares many biological pathways with other HDACi studied – panobinostat and underline the 
importance of TCR signaling inhibition following vorinostat treatment. Furthermore, these 
findings show that concomitant administration of vorinostat/panobinostat and PI3K inhibitors 
(LY249002 and new ETP-45658) results in synergism and can potentially be efficacious for the 
treatment of CTCL. In addition, vorinostat and PIM inhibitors showed an additive effect while 
the use of vorinostat and HSP90 inhibitor (17-AAG) produces antagonistic reaction.    
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5. Vorinostat interferes with the signaling transduction pathway of TCR 
and synergizes with PI3K inhibitors in CTCL 
 
5.1 Vorinostat induces cell death and cell cycle arrest in cutaneous T-cell lymphoma 
(CTCL) cells  
In a previous chapter cMap analysis identified vorinostat as one of the molecules able to revert 
a signature of resistance to PUVA +/- IFN treatment. Taking into consideration the high 
significance in cMap screen (Figure 18) and the demonstrated clinical benefit for CTCL patients 
(Duvic et al., 2007), the mechanisms of vorinostat action in CTCL cells were explored in depth. 
 
 
Figure 18. Result of cMap screen for vorinostat. Screen shot from web browser represents the 
dose, cell line used and enrichment score.  
 
The inhibitory effect of vorinostat on the viability of CTCL cell lines was examined through a 
CellTiter-Glo Assay using various concentrations of vorinostat (0.01, 0.05, 0.15, 0.5, 1.25, 4, 10, 
35, 100M) for 72 hours. All CTCL cell lines were sensitive to investigated HDAC inhibitor. The 
inhibitory effect of vorinostat was reflected as a dose-dependent reduction in cell 
proliferation/viability. Vorinostat suppressed the growth of CTCL cells in a dose-dependent 
manner. The IC50 of proliferation was determined at 0.146 M in HH cells, at 2.062 M in 
HuT78 cells, at 2.697 M in MJ cells, at 1.375 M in MYLA and at 1.510 M in SeAx cells, 
respectively (Table 19). 
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Table 19. Sensitivity to Vorinostat for a panel of CTCL cell lines from the proliferation/viability 
assays (CellTiter-Glo Viability Assay). Proliferation/viability was analyzed following 72 hours of 
treatment. 
 
Cell lines 
Name Source IC50 [M] 
HH Peripheral blood of patient with aggressive CTCL 0.146 
HuT78 Peripheral blood of patient with Sézary syndrome 2.062 
MJ Peripheral blood of patient with Mycosis fungoides 2.697 
MYLA Peripheral blood of patient with Mycosis fungoides 1.375 
SeAx Peripheral blood of patient with Sézary syndrome 1.510 
 
In addition, the relation between the observed sensitization effect to the increase in apoptosis 
was investigated. To study this aspect of vorinostat treatment, HH, Hut78, MJ, Myla and SeAx 
cells were treated with various doses of vorinostat. Apoptosis was detected after 24-48h 
through Annexin V and propidum iodide (PI) staining. In all cells a time- and dose-dependent 
increase in the population of apoptotic cells was observed (Figure 19A). HH cells were most 
responsive to vorinostat and showed 18  3.9 percent of apoptosis after only 24 hours and 44 
 1.6 after 48 hours. HuT78 cells were less sensitive to vorinostat with 3.4  1.3 and 17  3.9 
percent of death at 24 and 48 hours, respectively. MJ, Myla and SeAx cell lines showed 
approximately 26% cell death after 48 hours.  
 
Furthermore, the effect of vorinostat on the cell cycle progression in CTCL cell lines was 
investigated. Cell cycle analysis of CTCL cell lines treated with vorinostat or vehicle alone 
(DMSO) was performed for 24 and 48 hours and analyzed for cell cycle distribution by flow 
cytometry. The S phase decreased in MJ and SeAx cells compared with control. G2/M cell cycle 
arrest was induced in HuT78, while a G0/G1 phase arrest was detected in Myla, MJ and SeAx 
cells (Figure 19B). 
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Figure 19. Effect of vorinostat (SAHA) on apoptosis and cell cycle in cutaneous T cell 
lymphoma (CTCL) cell lines. HH, HuT78, MJ, Myla, and SeAx cell lines were treated with or 
without vorinostat (5M) for 24 and 48 h.  
A) Apoptosis: Each point represented the percentage of annexin V+PI-, annexin V+PI+ and 
annexin V-PI+cells. The cell death of control DMSO was subtracted from each value (error bar 
represents mean SD of n=3-8 determinations). * p<0.05, ** p<0.001. 
B) Cell-cycle distributions were determined by DNA content analysis with propidium iodide (PI) 
staining and flow cytometry. 
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5.2 Vorinostat treatment leads to accumulation of acetylated histones in CTCL cell 
lines 
The effect of vorinostat on histone acetylation status in human CTCL cell lines was determined 
by Western blot analysis. CTCL cells were exposed to 5M SAHA for 0, 0.5, 1, 2, 4, 8, 12 and 
24h. As shown in Figure 3, all four core nucleosomal histones (H2A, H2B, H3, and H4) become 
hyperacetylated following culture in the presence of vorinostat when compared to DMSO 
control. These effects were visible after 0.5h exposure (Myla) and showed a time dependent 
increase (Figure 20).  
 
 
Figure 20. Effect of vorinostat on acetylation of histones. CTCL cell lines: HuT78 (A), Myla (B) 
and SeAx (C) were exposed to vorinostat (SAHA) (5M) for 0.5, 1, 2, 4, 8, 12, 24 hours. 
Histones were extracted and analysed by Western Blot. The acetylation of histones H3, H4, 
H2B and H2A was determined. Nonacetylated histone H3, H4, H2A and H2B were used as a 
loading control. 
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5.3 Transcriptional profile of vorinostat treatment 
Based on flow cytometry data, the CTCL cells were cultured in the presence of vorinostat over 
a 24-hours time course. Gene expression data were obtained from two independent 
microarray hybridizations for each time point. Data were then analyzed using STEM and genes 
with a significant up- or down-regulated profile (FDR<0.05) were used for further analysis. The 
number of genes altered progressively increased following 24-hours treatment (Figure 21A-B). 
Around 20% of genes on the array were significantly activated or repressed in response to 
vorinostat. The number of genes that were modulated in response to treatment, increased 
from 318 (HH), 424 (HuT78), 528 (MJ), 301 (Myla) and 155 (SeAx) at 4 hours to 3512 (HH), 
2379 (HuT78), 3081 (MJ), 2022 (Myla) and 3275 (SeAx) at 24 hours. 
 
The functional analysis of up- and down- regulated genes in response to vorinostat treatment 
revealed pathways that have previously been identified as being altered by the drug. They 
include cell proliferation, apoptosis and cell cycle related genes, as well as new pathways that 
have not been reported previously but could crucially contribute to the understanding of the 
mechanism of action of above mentioned drug (Supplementary Table 2).  
 
Consistent with the previous findings of Ruefli et al (Ruefli et al., 2001) vorinostat modulated 
expression of key apoptosis genes, such as IRAK1, FAS, CASP6, BID, BIRC4, cFLAR, CAPN2, 
BCL2L1, TNFRSF1A and TNFRSF10A. Multiple MAPK signaling pathway members were also 
altered by vorinostat. Interestingly, the expression of genes involved in signal transduction and 
response to stress (MAPK12, MAP3K6, MAPK13, MAP4K1) was inhibited, while the genes 
playing a role in induction of apoptosis (MAPK1, MAPK8, MAPK9, MAPK10, MAPK14 MAP2K6, 
MAP3K7, MAP3K10, MAP4K2, MAP2K2) were upregulated. 
 
HDAC inhibition of CTCL cells modulates the expression of genes involved in cell cycle 
(Mitsiades et al., 2004; Zhang et al., 2005). Thus, vorinostat downregulated genes required for 
G1/S transition (often aberrantly expressed in tumor cells), including E2F1, E2F4, E2F5, SKP2 
(Latres et al., 2001), CDC25A, CDK4, CDK6, CDC6, CDC25B and several cyclins (cyclins A2, D2, 
D3, E2), as well as G2/M phase regulators (CDC23, CDC25B, CHEK1). Furthermore, vorinostat 
treatment induced expression of genes with an antiproliferative or arrest functions (CDKN2A, 
CDKN2B, CDKN2C, CDKN2D, CDKN1A, CDKN1C) (Supplementary Figure S1).  
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Additionally, significant changes after vorinostat treatment were observed in members of 
JAK/STAT pathway, cytokine-cytokine receptor interactions and expression of the members of 
tumor necrosis factor (TNF) receptor superfamily. Vorinostat also showed significant 
alterations in the network of interleukins (ILs) and their receptors; inhibits expression of IL4, 
IL5, IL10, IL11, IL13, IL15A, IL19, IL21, IL29, IL2RB, IL4R, IL6R, IL10RA, IL15RA; and enhances 
expression of IL1A, IL6, IL9, IL12A, IL15, IL22, IL23A, IL24, IL1RAP, IL3RA. Interestingly, many of 
the repressed interleukins are known to enhance cell growth, proliferation and promote Th2 
responses, which is a hallmark of CTCL pathogenesis. Furthermore, we found that upon 
vorinostat treatment a set of chemokines and their receptors also experienced a shift in 
expression profile. Among the downregulated set we encountered genes related to T-cell 
migration and chemotaxis, such as: CCL1, CCL22, CCL26, CCL28, CXCL10, CXCL13, CXCL16, CCRA, 
CCR4, CCR6, CXCR3 and CXCR4; the genes induced by vorinostat include: CCL19, CCL20, CCL27, 
CXCL9, CXCL11, CX3CL1, CCR2 and CCR6. Besides, we observed alterations in expression of the 
remaining members of JAK/STAT pathway, among them suppression of STAT6, STAT5A, SOCS2, 
SOCS6 and SOS accompanied by enhanced expression of STAT1, STAT2, STAT3, STAT5B, SOCS3, 
IFNAR2, INFG, IFNGR1 and JAK1.  
 
Finally, the repressive influence of vorinostat on the TCR pathway signaling was shared by all 
the CTCL cell lines. Thus, vorinostat repressed a remarkably large set of genes directly 
associated with the TCR, together with molecules acting downstream, including ZAP70, LAT, 
VAV2, CD247, CD3D, CD3E, CD3G, CD4, IL4, IL5, IL10, IL13, IL4R, IL6R, PTPN6, PAK2, PAK6, 
ICAM1, NMI, FOXP3, while upregulated genes included: FYN, IFNG, IFNGR1, IL12A and others 
(Figure 21C). TCR signaling has also being found as associated with resistance to PUVA +/- IFN 
(Wozniak et al., 2009), which could partly explain why vorinostat sensitizes PUVA +/- IFN 
resistant patients.  
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Figure 21. Gene expression profiles of vorinostat-regulated genes.  
A) Numbers of genes up- and down-regulated at each time point after treatment with 
vorinostat. Number of genes with significant profile that were differentialy expressed by at 
least 2-fold from time 0 h to at least one later time point in response to vorinostat are shown. 
B) Short time series expression miner (STEM) analysis flowchart. The figure represents 
selected up- and down- regulated profiles and significant genes within selected profiles are 
visualized for each cell line. Genes selected as differentially expressed were clustered using 
CLUSTER and visualized by TreeView. Genes were hierarchically clustered based on standard 
correlation coefficients. 
C) Functional clustering of vorinostat-regulated T-cell receptor associated genes. The red 
asterisks indicate genes chosen for qRT-PCR validation. 
 
5.4 Analysis of early and late response genes after vorinostat treatment  
During the first two hours of treatment with vorinostat no significant change in gene 
expression profile was observed. At four hours of exposure to vorinostat between 155 (SeAx) 
and 528 (MJ) genes were altered. Genes that were demonstrated to be downregulated 
included TNF receptor associated factor 2 (TRAF2), telomerase reverse transcriptase (TERT), 
histone methyltransferase (SUV39H1), BCL6 co-repressor BCOR, interferon regulatory factor 2 
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binding protein (IRF2BP2) and metabolism related lipoyltransferase 1 (LIPT1). In the group of 
genes that were upregulated by vorinostat after 4 hours of treatment we identified genes 
associated with JAK-STAT signaling (IFNGR1, TSLP), calcium signaling (ADRB2), metabolic 
processes (PFKFB4, IDH1, CYB5R1) and MAPK pathway (MAP3K). 
 
After 8 hours a dramatic change in gene expression was observed in all cell lines. During this 
time vorinostat altered from 912 (Myla) to 1389 (MJ) genes. At 8h, SAHA induced 
downregulation of cell adhesion molecules (ICAMs) including: ICAM2, CD58, CD2, cytokine 
receptors (IL4R, IL15RA), Notch signaling (CTBP1, GCN5L2), TCR (LCP2) and Wnt pathway 
(CTBP1). Moreover, HDACi further upregulated JAK-STAT pathway (STAT1, STAT3, SOCS3), 
apoptosis (CASP7, BCL2L12), cell cycle (CDKN2D, CCND3, PTTG1, CDC6) and oxidative 
phosphorylation (ATP6V1G2). 
 
Furthermore, after 12 hours vorinostat changed the expression of over 2000 genes in each of 
the cell lines: 2069 (Myla) – 2704 (HuT78). At this time point vorinostat continued its 
repressive effect on TCR signaling (ZAP70, LAT, CARD11, CD3G, PTPN7), cytokine interactions 
(CCL28, FAS, CCR4, CXCR3, IL6R), apoptosis (IRAK1, FAS, BIRC4, CFLAR, LMNB2,CAD), purine and 
pyrimidine metabolism (ATIC,ADSS,AMPD3/ DTYMK,TYMS). Vorinostat also further increased 
the expression of MAPK pathway members (MAP3K9, MAP3K7), cell cycle (CDKN1A, CDK7, 
CDKN2D, CDKN1C) and JAK-STAT signaling (JAK2, IL15, SPRY1). 
 
5.5 Validation of Expression Profiles of Selected Genes by Quantitative Real-Time 
PCR 
To verify changes in gene expression detected by our microarray analysis, quantitative real-
time PCR analysis on 8 genes belonging to the T-cell receptor pathway, where expression 
profiles were altered by vorinostat in at least two cell lines was performed. These genes 
included: Zap70, STAT3, FYN, IFNGR1, CD3G, LAT, IL4R and CD3E. As shown in Figure 22A-5H 
there was a high correlation between the microarray and real-time PCR data for all 8 genes.  
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Figure 22. Validation of microarray data by TaqMan quantitative real time PCR.  
The influence of vorinostat on mRNA expression of ZAP70 (A), STAT3 (B), FYN (C), IFNGR1(D), 
CD3G (E), LAT (F), IL4R (G) and CD3E (H) for all cell lines before and after 8 and 12 hours of 
treatment. Values for each gene were normalized to expression levels of HGUSB endogenous 
control. Data were performed in triplicates. 
 
Furthermore, the changes in expression of ZAP70 and FYN in peripheral blood tumoral 
lymphocytes samples from a leukemic MF patient treated with vorinostat were analyzed. The 
samples were taken before and after 1, 3, 6, 24, 48, 120 and 360 hours of treatment. The 
expression profiles of ZAP70 and FYN in the leukemic cells after vorinostat treatment closely 
matched those obtained in the cell lines, with a slight delay in the beginning of the action 
attributed to the pharmacokinetics of vorinostat in vivo; thus after the first 6 hours a 
contradictory effect (upregulation of ZAP70 and downregulation of FYN) occurred, followed by 
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downregulation of ZAP70 and upregulation of FYN, both more profound after 15 days of 
treatment (Supplementary Figure S2).  
 
5.6 Vorinostat decreases the TCR activation through inhibition of kinase 
phosphorylation 
Considering the critical role of ZAP70 in transmitting signals from the TCR signaling complex, 
the ability of vorinostat to inhibit the tyrosine phosphorylation in two of the CTCL cell lines was 
examined. Two representative cell lines: HuT78 (SS) and Myla (MF) cells were treated with 
vorinostat for 0.5, 1, 6 and 24 hours at the concentration of 5 and 25M. Phosphorylation of 
Tyr319 and Tyr493 within the activation loop results in enzymatic activation of ZAP70 (Watts et 
al., 1994; Williams et al., 1999). Decrease in phosphorylation of ZAP70 on Tyr493 after 
vorinostat treatment was observed after 0.5h (25M) and 1h (5M) in HuT78 and after 1h in 
Myla for both concentrations. Phosphorylation of Tyr319 was diminished after 1 h (25M) and 
6 h (5M) in HuT78 and 1h in Myla (25M) (Figure 23A). In both cases the inhibition of 
tyrosine phosphorylation was time and concentration dependent. Meanwhile, vorinostat 
modestly decreased total ZAP70 cellular level. 
 
Tyrosine phosphorylation of ZAP70 correlates well with its increased kinase activity and 
downstream signaling events. To extend the understanding of the potential impact of 
vorinostat on the T-cell signaling the downstream effector molecules were evaluated. PI3K/AKT 
pathway has been shown to be implicated in signal transmission leading to activation, 
differentiation as well as cellular survival of T-lymphocytes (Bauer and Baier, 2002). The 
activating phosphorylation of AKT within the carboxy terminus at Ser473 was decreased 
already after 0.5h at 25M concentration and was further reduced at 1, 6 and 24h in HuT78. In 
the Myla cell line slight reduction in AKT (Ser473) phosphorylation was observed after 1h 
followed by significant reduction after 24h. Vorinostat also decreased the total AKT levels in a 
dose-dependent manner (Figure 23B).  
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Figure 23. Effect of vorinostat on TCR related genes. 
A, B, C) HuT78 and Myla cells were incubated with 5M (+) or 25M (++) of vorinostat for 0.5, 
1, 6 and 24 hours. Whole cell lysates were examined by Western Blotting for phospho-ZAP70 
(Tyr319 and Tyr493) (A) and phosphor-AKT (Ser473) (B). Total ZAP-70 and AKT were used as 
controls, respectively. Tubulin was used as a loading control of total proteins.  
 
5.7 Overexression of ZAP70 does not increase vorinostat resistance 
To test the hypothesis that the increased expression of ZAP70 could correlate with vorinostat 
resistance or decreased sensitivity in CTCL cells, ZAP70 was successfully overexpressed in 
MYLA cells. Due to relatively high initial expression of ZAP70 in CTCL cells, approximately 16-
30% increase in ZAP70 levels was achieved. The effect of ZAP70 overexpression was assessed 
by cell viability/proliferation assays; however, increase of 16-30% in ZAP70 kinase expression 
(and overexpression of ZAP70 alone) was not sufficient and did not correlate with vorinostat 
sensitivity (Figure 24).  
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Figure 24. Overexpression of ZAP70 after microporation with pcDNA3 vector in Myla cells. 
(A) Myla cells were microporated with 2 pulses of 1300V with pcDNA3 (empty vector) or with 
pcDNA3-ZAP70 (containing ZAP70 insert). After 24 hours, cells were incubated with 800g/ml 
of G418 (Geneticin) antibiotic for selection of transfected cells. Following, cell lysates were 
prepared for western blot (WB) analysis. ZAP70 was detected with anti-ZAP70 antibody and -
tubulin was used as a loading control. Right panel represents quantification of WB analysis 
using the ImageJ 1.34S software; the ratio of ZAP70 vs. Tubulin is represented. (B) 
Viability/Proliferation assays of Myla cells with empty vector or ZAP70-containing vector 
following vorinostat treatment. The results are represented as the percentage of DMSO 
vehicle control. IC50 values were calculated using Graph Pad Prism software. 
 
5.8 Combination of Vorinostat with PI3K, PIM and HSP90 inhibitors 
Vorinostat, being a multi-HDAC inhibitor, could be suitable for use in a combination therapy 
with other anti-neoplastic agents. As candidates for combination therapy PI3K inhibitors 
(LY294002, ETP-45658), PIM kinase family inhibitor (ETP-39010) and HSP90 inhibitor (17-AAG) 
were selected. This selection was done following the analysis of the genes targeted by 
vorinostat (PI3Ki, PIMi) or cMAP data. Thus, GSK-3 (PI3K substrate) and PIM1/PIM2 were 
upregulated after vorinostat treatment (Figure 25A). HSP90 (target of 17-AAG) was 
downregulated, but was included in this analysis since it has the best score in the cMap 
analysis (Table 17). 
 
The sensitivity of CTCL cells to each of the compounds after 72 hours of exposure individually 
or in combination was determined by Luminescent Cell Viability Assay. The IC50 values for 
LY294002 ranged between 1.797M (HH) and 34.669M (SeAx). Additionally, a more potent 
and selective PI3K inhibitor – ETP-45658 was used, with the IC50s of a magnitude from 
0.442M (HH) to 1.5M (SeAx), being 4-28 times lower than those of LY294002. The inhibitor 
of PIM kinases family – ETP-39010 was also tested which resulted to have the IC50 values 
varying from 1.286M (MJ) to 5.042M (HH) after 72-hour exposure and from 3.083M (MJ) 
to 17.051M (HH) after 48-hour treatment. The IC50 values for the HSP90 inhibitor – 17-AAG 
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(17-allylamino-geldanamycin) were in the nanomolar range for all the cell lines, with MYLA 
being the most sensitive (146nM) and HH having the highest value of 803nM (Table 20).  
 
Table 20. Sensitivity of CTCL cells to ETP-45628, LY294002, ETP-39010, 17-AAG. 
Proliferation/viability was analyzed using CellTiter-Glo Viability Assay after 3 days of treatment 
unless stated otherwise. 
Cell lines IC50 [M] 
Name ETP-45628 LY294002 ETP-39010* ETP-39010 17-AAG 
HH 0.442 1.797 17.051 5.042 0.803 
HuT78 1.444 10.853 5.977 2.695 0.235 
MJ 0.603 10.158 3.083 1.286 0.644 
MYLA 1.033 28.776 4.639 2.708 0.146 
SeAx 1.500 34.669 4.194 3.190 0.258 
 
* Proliferation/viability was analyzed after 48 hours. 
 
To study the possible synergy between vorinostat and the combination drugs, approximately 
equipotent concentration of each drug were used. Combination Index (CI) values were 
calculated using CalcuSyn software with a formula initially proposed by Chou and Talay (Chou 
and Talalay, 1984). The drugs were used in constant ratios to determine the effectiveness of 
combinations. When at least 80% of CI values for combination in all cell lines were less than 1, 
the drug combination was considered to be synergistic. Similarly, if more than 80% of CI was 
higher than 1 the drug was considered antagonistic. Otherwise, the drug was asserted to be 
additive with a synergistic/antagonistic tendency.   
Combined treatment of vorinostat with LY294002 demonstrated moderate to strong synergy, 
usually with the best CI values for IC50 concentrations and above for all CTCL cell lines, with 
the SeAx cell line showing the strongest synergy. Coadministration of vorinostat with more 
potent and selective PI3K inhibitor ETP-45658 also showed clearly synergistic relation at the 
concentration of 0.5 times IC50 and above (Figure 25B). Concomitant as well as sequential 
addition (addition of the drug after 24 hour pretreatment with vorinostat) of PIM inhibitor 
(ETP-39010) resulted in additive to synergistic effect in HuT78 and SeAx  - SS cell lines, additive 
to antagonistic effect was observed in MYLA and varying results were obtained for HH and MJ 
cell lines (Figure 25C). Clear antagonism was observed when concomitantly administering 
vorinostat with the inhibitor of HSP90 – 17-AAG (Figure 25D). The combination results seemed 
to be conversely related to the expression changes of the targets of inhibitors used following 
treatment with vorinostat. In summary, synergistic/additive combination effect was 
demonstrated for the compounds targeting genes whose expression was upregulated by 
vorinostat. 
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Figure 25. Combination studies of vorinostat with PI3K, PIM and HSP90 inhibitors in 
cutaneous T-cell lymphoma (CTCL) cells. (A) Effect of vorinostat on the targets of the 
inhibitors used for combination studies: PI3K inhibitors (GSK-3 - left panel), PIM inhibitor 
(PIM1 and PIM2 – middle panel) and HSP90 inhibitor HSP90 – right panel) in five CTCL cell 
lines. The HH, HuT78, MJ, MYLA, SeAx cells were treated with 5M of vorinostat over 24h time 
course. The gene expression values were normalized with respect to time 0 hours. The 
selected genes were visualized using CLUSTER and TreeView. (B) Synergistic interactions 
between vorinostat and PI3K inhibitors (LY294002 and ETP-45658). (C) Additive interactions for 
concomitant and sequential coadministration of vorinostat with PIM inhibitor (ETP-39010). (D) 
Antagonistic interactions between vorinostat and HSP90 inhibitor (17-AAG). 
B, C, D) Synergistic, additive, or antagonistic effects of the drug combinations were determined 
by calculating the combination index value (CI) by isobologram analysis with CalcuSyn 
software. A CI < 1 indicates synergism, CI  1 indicates additivity and CI > 1 indicates 
antagonism. 
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5.9. Validation of vorinostat (SAHA) mechanism of action using a different histone 
deacetylase inhibitor - panobinostat (LBH589)  
Multiple HDACi have been developed to date and several are in clinical investigation. The 
hydroxamic acid based HDACi, vorinostat and panobinostat are pan-inhibitors of class I and II 
HDACs that have demonstrated potent cytotoxicity in vitro against a variety of solid tumor cell 
lines. While vorinostat is FDA-approved treatment for CTCL, panobinostat is under extensive 
clinical investigation in CTCL and several solid tumors. Is the mechanism of action and synergy 
with PI3K inhibitors identified in the previous paragraphs common for pan-HDACi or specific 
for vorinostat? In this section the similarities in the effects of these two clinically relevant 
HDACi were analyzed.  
5.9.1 Panobinostat similarly to vorinostat inhibits the growth and induces cell cycle 
arrest and apoptosis of CTCL cells 
The CTCL cell lines were analyzed to determine the effects on cellular proliferation using 
CellTiter-Glo Assay. Cells were exposed to increasing concentrations of each drug for 72 hours 
and subsequently analyzed for the luminescent signal. The IC50 values for all cell lines 
following panobinostat treatment were 2-30 times smaller than that for vorinostat and were in 
the nanomolar range (Figure 26A). 
Subsequently, flow cytometry was utilized to examine the effects of panobinostat on apoptosis 
and cell cycle distribution in CTCL cells and its comparison to vorinostat. HH, Hut78, MJ, Myla 
and SeAx cells were treated with 50nM concentration of panobinostat and followed by 
apoptosis examination at 24, 48 and 72 hours. Similarly to vorinostat, all cell lines showed 
sensitivity to panobinostat with 10% (SeAx) to 45% (MJ) cell death following 48-hour treatment 
(Figure 26B). This result together with IC50 values demonstrates higher potency of 
panobinostat over vorinostat in CTCL. 
Analysis of the cell cycle distribution of CTCL cells after treatment with panobinostat showed 
that this drug similarly to vorinostat caused an increase in G0-G1 in Myla and SeAx cells, 
decrease in S phase in HuT78, MJ, Myla and SeAx and decrease in G2/M in HH, Myla and SeAx 
(Figure 26C).  
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Figure 26. In vitro characterization of panobinostat (LBH589) in CTCL cells. Proliferation (A), 
apoptosis (B) and cell cycle (C) analysis was measured in HH, HuT78, MJ, MYLA and SeAx cells 
following treatment with panobinostat. (B, C) Cells were treated with a concentration of 50nM 
panobinostat. DMSO was used as a vehicle control. Error bar represents mean SD of all 
determinations). 
5.9.2 Microarray profiling in HDACi treated CTCL cells 
To compare the molecular events which occur in response to HDAC inhibition, CTCL cells were 
treated with the clinically relevant concentration of 50nM panobinostat and analyzed using 
microarray platform as outlined in the methods section. Genes with a FDR-adjusted p-value of 
< 0.05 following STEM analysis were considered differentially expressed genes relative to 
vehicle treated controls over time.  
5.9.3 Differentially expressed genes in response to HDACi treatment 
To check for the similarities of the effects exerted by both HDACi, Venn analysis was 
performed. Based on flow cytometry data, the CTCL cells were cultured in the presence of 
panobinostat over a 24-hours time course. Similarly to vorinostat, the number of genes altered 
by panobinostat increased continuously following 24-hours treatment. Panobinostat 
modulated approximately 2000 genes in each of the cell lines. The number of genes modified 
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in response to treatment included the decrease in expression of 1283 (HH), 861 (HuT78), 1079 
(MJ), 1029 (Myla) and 973 (SeAx) genes and increase in the level of 941 (HH), 1293 (HuT78), 
1182 (MJ), 965 (Myla) and 938 (SeAx) genes. Up to 50% of the genes altered by panobinostat 
were common with those modulated by vorinostat (Figure 27) suggesting a substantial overlap 
in the mechanism exerted by both HDACi. The classification of the common genes according to 
functional categories indicated that the downregulated genes were involved in purine and 
pyrimidine metabolism, apoptosis, cytokine-cytokine receptor interaction, TCR and MAPK 
signaling. In addition, the genes upregulated following treatment with both HDACi were 
related to metabolism, apoptosis, regulation of actin cytoskeleton and tight junction, axon 
guidance and MAPK signaling. The down- and up- regulated genes common for both inhibitors 
are presented in the Supplementary Table 3.  
 
 
Figure 27. Venn analysis of differentially expressed genes in panobinostat (LBH589) and 
vorionstat (SAHA) – treated CTCL cells. HH, HuT78, MJ, MYLA and SeAx cells were treated with 
either 50nM panobinostat or 5M vorinostat over 24-hour time course. Significant genes were 
subjected to Venn analysis.   
5.9.4 Panobinostat similarly to vorinostat synergize with PI3K inhibitors.  
To investigate whether panobinostat likewise vorinostat potentiate the activity of other 
agents, such as PI3K inhibitors, CTCL were treated with serial dilutions of panobinostat and 
PI3K inhibitor (LY294002) individually or with both drugs simultaneously at a fixed ratio of 
doses 0.25, 0.5, 1, 2, 4 times the individual IC50 (ED50) values (Figure 26A, Table 20, 
respectively). Similarly to vorinostat, coadministration of panobinostat with PI3K inhibitor 
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demonstrated a strong synergy (the lowest CI values) for the concentrations of 1- and 2- times 
IC50 in all CTCL cell lines (Figure 28). These results confirm our hypothesis that HDACi in 
combination with PI3K inhibitors could be of significant benefit to PTCL patients. 
 
Figure 28. Synergistic effect of panobinostat and PI3K inhibitor in cutaneous T-cell lymphoma 
(CTCL) cells. Cells were treated with each drug both individually and in combination. After 72h 
of exposure, the luminescence was measured using CellTiter-Glo Assay. Combination effects of 
the drug combinations were determined by calculating the combination index value (CI) using 
CalcuSyn software (CI < 1 indicates synergistic effect). 
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7. Discussion 
 
Cancer is the end result of the accumulation of genetic mutations that function cooperatively 
to promote neoplastic transformation. These lesions provide many advantages to transformed 
cells, including an increased ability to grow and proliferate and insensitivity to programmed 
cell death or apoptosis. Two major categories of mutated genes are oncogenes and tumor 
suppressor genes. Mutational and regulatory changes in specific oncogenes may have 
important implications for diagnosis, therapy, and prognosis, which have fueled multiple 
research studies on the molecular biology of lymphomas during the past two decades. The 
development of new cytogenetic and molecular techniques have led to a wealth of 
information on lymphomagenesis and its impact on the diagnosis, prognosis, and management 
of lymphoma, which will continue into the next decade. However, in contrast to B-cell 
lymphomas, peripheral T-cell lymphomas (PTCL) have been the subject of only a limited 
number of studies to elucidate their pathobiology and identify novel pharmacological 
approaches. Understanding of the biology and optimal treatment of PTCL has been limited due 
to only recent recognition of PTCL in addition to disease rarity and histologic subtype 
heterogeneity. With the development of new technologies in genomic analysis new 
opportunities arose to improve the current knowledge as far as microRNA and gene expression 
signatures are concerned.  
 
In the present manuscript, different approaches were undertaken to investigate alterations in 
gene and microRNA expression of a series of PTCL samples. Furthermore, the mechanisms of 
action and resistance of CTCL treatments were studied and possible new therapies were 
suggested. 
 
7.1 Identification of microRNAs, genes and biological pathways implicated in 
pathogenesis of peripheral T cell lymphoma 
Peripheral T-cell lymphoma represents an orphan pathology. This can be explained by their 
relatively low prevalence, diagnostic difficulties and dismal prognosis. One of the drawbacks of 
the functional studies is because of the lack of suitable cell lines in most of the aggressive 
PTCL, such as PTCLU or AITL, indicating the difficulty to establish cell lines from these tumors, 
and probably, a relevant role played by the infiltrating reactive cells in these PTCLs. Thus, most 
studies have been performed on cutaneous T-cell lymphoma (CTCL), ALCL and lymphoblastic T-
cell lymphoma. However, an improved understanding of the biology of the PTCL should allow 
development of better treatments for these disorders.  
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Aberrant microRNA expression patterns have been described in various hematological and 
solid cancers, and alterations in microRNA expression correlate highly with progression and 
prognosis of human malignant diseases. However, profiles of microRNAs differ and need to be 
investigated in every type of tumor. In the first study, substantial associations between 
differential expression of specific microRNAs and course of disease and prognosis of peripheral 
T-cell lymphoma were recorded. The global microRNA expression comparing a series of PTCL 
samples with LN tissue revealed loss of 102 microRNAs. The most remarkably down-regulated 
microRNAs belonged to the families of let-7, miR-10, miR-101, miR-29, miR-215, miR-150, miR-
139, miR-126 and miR-195 which regulate stemness, stress response, apoptosis, proliferation, 
angiogenesis, and expression of genes. The significant decrease in most members of let-7 was 
observed (FDR < 0.0001) which correlates with the enrichment of RACCYCD (Ras and Rho) 
pathway (FDR = 0.018) in PTCL patients. The Ras family of oncogenes has been previously 
described to be regulated by the let-7 family in solid tumors (lung cancer) (Esquela-Kerscher et 
al., 2008; Kumar et al., 2008). Additionally, in tumor-initiating cells of breast cancer (which 
have stem cell like properties), let-7 regulates self-renewal (by silencing HRAS) and 
differentiation (by silencing HMGA2). Furthermore, miR-101, significantly repressed microRNA 
with the highest score in SAM analysis was shown to be downregulated in hepatocellular 
carcinoma and colon cancer (Strillacci et al., 2009). Interestingly, decrease in miR-101 
expression was found during cancer progression. In addition, it was suggested that miR-101 
could exert its proapoptotic function via targeting MCL1, an important prognostic factor in NHL 
(Kuramoto et al., 2002; Su et al., 2009; Varambally et al., 2008). Moreover, miR-101 turned out 
to be significant (FDR < 0.05) in the Fisher analysis correlating microRNA and mRNA expression 
in the presented series of PTCL. Taken together, this data suggest an important role of miR-101 
in the molecular etiology of cancer (including PTCL) and implicate the potential application of 
miR-101 in cancer therapy. Importantly, the loss of miR-15 and miR-16, known to act as tumor 
suppressors was observed which is consistent with previous reports of downregulation of the 
mentioned microRNAs in chronic lymphocytic leukemia (CLL), pituitary adenomas, and 
prostate carcinoma. Expression of these miRNAs inhibits cell proliferation, promotes apoptosis 
of cancer cells, and suppresses tumorigenicity both in vitro and in vivo, possibly through 
targeting multiple oncogenes, including BCL2, MCL1, CCND1, and WNT3A (Aqeilan et al.; 
Cimmino et al., 2005). Of note is the fact that miR-15a has also been found to be significant in 
Fisher analysis which makes it an attractive candidate for further studies in PTCL. Other 
significant microRNAs, including miR-215, miR-10 and miR-126, were previously described to 
be downregulated in lung and colon cancers (Georges et al., 2008; Guo et al., 2008; Izzotti et 
Discussion 
 
 
125 
 
al., 2009; Sun et al.). Moreover, tumor suppressor function of miR-215 could be related to 
their suppression of cancerogenesis through CDKN1A/p21 accumulation and cell cycle arrest 
(Braun et al., 2008). As the protein encoded by CDKN1A binds to and inhibits the activity of 
cyclin-CDK2 or -CDK4 complexes, and thus regulates cell cycle progression at G1, these data 
reflect the alterations of G1 and cell cycle pathways identified by gene expression data (FDR 
equal to 0.178 and 0.134, respectively). Furthermore, miR-126, in addition to controlling cell 
proliferation, negatively regulates the angiogenesis through targeting vascular endothelial 
growth factor (VEGF) (Guo et al., 2008). Besides, miR-10a, miR-150 and miR-29, likewise in the 
presented PTCL series, were found to be downregulated in other hematological malignancies, 
such as chronic myeloid leukemia (miR-10a, miR-150) as well as mantle cell lymphoma (miR-
29, miR-150) (Agirre et al., 2008; Zhao et al.). Down-regulation of miR-10a was related to the 
increase in levels of USF2 and hence contribution to the increase in cell proliferation of chronic 
myeloid leukemia cells (Agirre et al., 2008). On the other hand, ectopic expression of miR-150 
in breast cancer and leukemic cells was associated with  repressed endogenous c-Myb at both 
messenger RNA (mRNA) and protein levels (Lin et al., 2008). Notably, changes in the 
expression levels of miR-29 family were previously reported to be associated with disease 
prognosis (mantle cell lymphoma). The patients with significant downregulated miR-29 had 
shorter survival as compared to those who express relative high level of miR-29. In addition, a 
mechanism through which miR-29 exerts its function was suggested to be through 
overexpression of cyclin D1 and activation of CDK4/6 (Zhao et al.). Similar mechanism was 
implied for miR-195 which downregulation was described in various types of cancers, including 
hepatocellular carcinoma and bladder cancer (Ichimi et al., 2009; Xu et al., 2009). Xu et al 
showed that miR-195 may block the G1/S transition by repressing Rb-E2F signaling through 
targeting multiple molecules, including cyclin D1, CDK6, and E2F3 (Xu et al., 2009).  
 
In summary, this review of the microRNAs most significantly repressed in PTCL samples  (Fold 
change < 0.2) suggests, as expected, alterations in such important pathways as apoptosis 
(through BCL2 signaling), cell cycle (CDK, G2, G1 pathways), proliferation (WNT, RACCYCD 
pathway) and angiogenesis (VEGF pathway). This confirms the gene sets identified by gene set 
enrichment analysis, in addition to ERK and EGF pathways with high level of significance (FDR: 
0.013 and 0.030, respectively).  
 
Taking into consideration the heterogeneity of PTCL tumors and limited data on microRNA and 
gene expression patterns, we sought to identify also genes and microRNA related to various 
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subsets of PTCL. In the attempt to verify the immune profile of a series of PTCL cases, two 
groups were identified with distinct T-cell subsets signature. Interestingly, the null-phenotype 
group lacked expression of genes characterizing normal T-cell subtypes (both CD4+ and CD8+). 
In contrast, higher plasticity of T cell lineages than previously appreciated was observed in the 
differentiated group. Even though the division into null-phenotype and differentiated group 
did not show a reflection in the cases diagnostics, the microRNA as well as gene expression 
characterization of both groups brought along interesting findings. 
 
Interestingly, half of the patients in the null-phenotype group highly expressed oncogenic miR-
17-92 cluster (oncomir-1) and miR-181 family. miR-17-92 cluster expression is described to 
concomitantly reduce E2F1 protein expression, regulating proliferation and/or apoptosis E2F1 
protein levels, thereby enhancing survival of leukemic T-cells (Mu et al., 2009; Nagel et al., 
2009). Moreover, He et al showed that enforced expression of the miR-17-92 cluster 
accelerated MYC-induced lymphomagenesis, suggesting the oncogenic potential of the 
overexpressed microRNAs (He et al., 2005). miR-17-92 cluster and miR-181 were also 
delineated to have a 'permissive' function in the maturation, proliferation and differentiation 
of myeloid and lymphoid cells. Importantly, these actions of miRNAs often involve interactions 
with transcription factors (Tsitsiou and Lindsay, 2009). Among the most significant microRNAs, 
able to distinguish between the null-phenotype and differentiated group, many have not been 
previously described in any cancer types. However, overexpression of oncogenic miR-372 in 
the null-phenotype group was observed, which could be related to the increased proliferation 
of neoplastic cells in this group as this microRNA plays a role in controlling cell growth, cell 
cycle, and apoptosis through down-regulation of a tumor suppressor gene, LATS2 (Cho et al., 
2009). In contrast, the increase of tumor suppressor microRNAs was observed in the 
differentiated group, including miR-205 and miR200a. The fact that downregulation of these 
microRNAs might be an important step in tumor progression could give a rationale for the 
worst outcome of patients with the null-phenotype. miR-205 inhibits tumor cell migration 
through down-regulating the expression of the LDL receptor-related protein 1 (Song and Bu, 
2009) and possibly through its direct targets ErbB3 and vascular endothelial growth factor A 
(VEGF-A) (Wu et al., 2009). Similarly, miR-200a was reported to affect the metastatic potential 
of cervical cancer cells by coordinate suppression of multiple genes controlling cell motility (Hu 
et al.) and inhibit ovarian cancer cell migration. Moreover, low-level expression of miR-200 is 
thought to predict poor survival (Hu et al., 2009). Furthermore, upregulation of miR-601, miR-
331 and miR-146b in differentiated group could have an impact on regulation of actin 
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cytoskeleton and Fas-induced apoptosis (mir-601) (Ohdaira et al., 2009), cell proliferation and 
survival (through miR-331 putative target - SOCS1) (Zanette et al., 2007), and inhibition of 
invasion and migration (miR-146b)  (Hurst et al., 2009). Increased expression of miR-15a and 
miR-223 could also be indicative of better course and disease outcome in the differentiated 
group of patients as miR-15a is known to induce apoptosis in other hematological malignancies 
(Cimmino et al., 2005) and enhanced levels of miR-223 are described to restore cell 
differentiation (Fazi et al., 2007). Several pathways identified as significantly differentially 
expressed between null-phenotype and differentiated group have the representation in 
targets of significant microRNAs, including BCL2 family, caspase and death pathways enriched 
in differentiated group or RACCYCD pathway in null-phenotype group. 
 
Prognostic biomarkers are urgently needed to identify patients at high risk for peripheral T-cell 
lymphoma. microRNA expression profiles have been linked to the clinical features of several 
cancers; this suggests that some microRNAs have potential as diagnostic and prognostic 
markers. In the present study, microRNA expression profiles were assessed in PTCL and several 
attractive targets for more in depth investigation were found. However, further studies are 
needed to establish whether the microRNAs identified in the presented study have full 
potential as either biomarkers or therapeutic targets in PTCL as the number of samples used 
was quite limited and lacking clinical information did not allow final validation. The association 
between aberrant expression of microRNAs and malignancy is now so compelling that research 
is rapidly focusing on the therapeutic use of these molecules. Perhaps one of the biggest 
problems/limitations facing the use of microRNAs and/or associated agents as therapeutics is 
their pleiotropic mode of action. As a single microRNA can target several hundred genes their 
perturbation may be expected to give rise to a complex phenotype that may not be readily 
predictable. It is therefore imperative that such therapeutics is precisely delivered in order to 
mitigate effects on non-targeted cells.  
 
7.2 Identification of new pathways associated with resistance to PUVA +/- IFNα 
therapy 
There are several treatment options, such as skin directed therapies (topical corticosteroids, 
carmustine, bexarotene gel, total skin electron bean therapy or PUVA), systemic therapies 
(retinoids, rexinoids, HDAC inhibitors, denileukin diftitox, IFN, monoclonal antibodies) and 
other treatment modalities available for treatment of CTCL (Kim et al., 2005; Wollina and 
Dummer, 2006). IFN therapy is frequently used and found to be effective in the treatment of 
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early stages of MF, especially in combination with PUVA (Chiarion-Sileni et al., 2002; Roenigk 
et al., 1990). Some authors report very promising results of 80% CR rate when using the 
combination of IFN and PUVA showing higher response rate and longer duration that PUVA 
or IFN monotherapies (Kuzel et al., 1990; Kuzel et al., 1995; Mostow et al., 1993; Roenigk et 
al., 1990). However, it is not clear why some patients respond better to the therapy than the 
others and what could be the underlying molecular mechanisms contributing to treatment 
resistance. 
 
In this study, gene expression profiling and response data from early stage MF patients 
enrolled in a randomised clinical trial of PUVA alone or in combination with IFN was used in 
order to identify markers associated with lack of remission and resistance to treatment. The 
randomized clinical trial of PUVA +/- IFN performed here showed no significant difference 
between the treatment arms. The patients treated with PUVA alone showed similar response 
rates to the patients treated with PUVA and IFN, nevertheless, lower UVA doses can be used 
during the combined treatment.  However, the information and clinical samples obtained 
allowed identification patients resistant to treatment and to describe that the molecular 
signature of resistance in these early stage MF patients is composed by a combination of 
signals derived from  NF-B activation, known to be important in the MF lymphomagenesis 
(Tracey et al., 2003), T-cell receptor signaling, inflammatory cytokine signaling and JAK/STAT 
signaling.  
 
The poor response-associated group of genes, interesting for the identification of markers 
associated with therapy resistance, highlighted characteristics of CTCL cells as well as non-
malignant cells present in the tumor tissue. Many of the genes and pathways identified in this 
study confer a survival advantage on tumoral T-cells, including genes important for T-
lymphocyte activation and proliferation (CD69, FYN, TNC, MAF), migration (ENG, TNC, MYO1B, 
FYN) and survival (WNT4, NFKB2). Additionally, IFN signaling pathway genes such as SOCS1 and 
IRF2BP2 were associated with treatment outcome. SOCS1 negatively regulates IFN activity and 
therefore it is not surprising that its expression was associated with poor response. Moreover, its 
expression has previously been associated with poor response to IFN in chronic myeloid 
leukaemia (Roman-Gomez et al., 2004). IRF2BP2 is a co-repressor of IRF2, which is induced by 
IFN treatment. This induction is correlated with the clinical response of IFN treatment in 
carcinoid tumours (Zhou et al., 2000), shedding some light on the association of IRF2BP2 with 
poor response to treatment in MF patients. Although the molecular mechanisms by which PUVA 
Discussion 
 
 
129 
 
acts are not well understood, it has been described that the exposure may lead to expression of 
inflammatory cytokines (IL10, IL8, IL6) that could influence IFN and TNF (Kim-Han et al., 2001; 
Wolf et al., 2006). The in vivo elevation of SOCS and IRFBP2 gene expression found may be part 
of the host/tumour response, as has been suggested in other tumors (Raccurt et al., 2003). 
Treatment resistance is a complex and dynamic process involving interactions between many 
pathways. Using GSEA we identified several pathways related to unfavorable response to 
treatment, which could interact with each other and cause a series of subsequent events 
leading to activation and/or up regulation of the other pathways contributing to treatment 
outcome. The pathways highlighted by GSEA analysis showed similar results to Ingenuity 
Pathway Analysis. In addition, signaling by the CCR5 chemokine, FAS, MAPK, T-regulatory cells, 
Notch and mTOR were found to be of importance. Finally, separate analysis of only PUVA-
treated patients and PUVA/IFN-treated patients also revealed the importance of the same 
pathways. In summary, gene expression profiling showed that the cytokine inflammatory 
response, TCR and NF-B pathway activation, as well as expression of certain chemokine 
receptors promoting migration and homing of T-cells to skin and inflamed tissues are an 
important determinant of treatment outcome. Full understanding of the interaction between 
the mentioned pathways could be predictive of survival and the patient response to the 
therapy at the time of diagnosis.  
 
Tumor microenvironment is an important factor in conferring drug resistance, and one of the 
major causes underlying treatment failure and relapse in cancer (Herreros et al., 2007). The 
epithelial cells, squamous cells, fibroblasts, macrophages and dendritic cells are the important 
cells constituting the tumor microenvironment. Emerging information highlights the 
importance of tumour-accompanying non-neoplastic cells in cancer progression. Those cells 
could promote production of immunosuppressive factors and inhibit anti-tumor immune 
responses promoting growth, survival and proliferation of tumor cells. The interaction 
between the cytokines, chemokines, growth factors and matrix degrading enzymes produced 
in the tumor microenvironment have complex functions and account for various cell 
interactions and regulation of differentiation, activation, proliferation and survival of different 
cell types (Galmarini and Galmarini, 2003; Li and Dalton, 2006).  For example, stromal dendritic 
cells can protect from apoptosis, stimulate proliferation, and induce tumoral T-cell homing to 
the skin through expression and secretion of specific chemokines and cytokines (Shurin et al., 
2006).  
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Other cells such as macrophages, dendritic cells, epithelial cells and non-malignant 
lymphocytes also interact directly with neoplastic cells. A high density of tumor-associated 
macrophages is associated with chronic inflammation, resulting in suppression of the anti-
tumor immune response (Balkwill et al., 2005) and NF-B activation, a key player in the 
tumorigenesis of MF (Tracey et al., 2003).  This interplay between the neoplastic cells and the 
tumor microenvironment could promote cell-cycle progression and survival, thereby 
conferring increased drug resistance to malignant cells. Many of the markers identified in this 
study, are expressed not only by tumoral cells but also by the tumor microenvironment, 
underlining the important role of the stroma in conferring therapy resistance in MF.  
 
In MF, it appears that activation of the NF-B pathway and T-cell signaling in both tumor cells 
as well as in the microenvironment plays a central role in treatment resistance. The activation 
of the JAK/STAT pathway in MF reported here suggests that this pathway may play a role in 
the pathogenesis of cutaneous T-cell lymphomas, as has been previously described in other T-
cell lymphomas (Zhang et al., 1996). Notch signaling, recently described to play a role in T-cell 
leukemogenesis (Gothert et al., 2007), was also associated with poor response and may play a 
role in treatment outcome as has been shown in other hematological malignancies (Nefedova 
et al., 2004). Furthermore, Notch signaling is known to induce secretion of IL6 (Li and Dalton, 
2006), which leads to constitutive activation of STAT3, an oncogene expressed in tumor stage 
MF cases and thought to be a characteristic feature of MF neoplastic transformation. In earlier 
stage cases, as studied here, STAT3 expression is more clearly observed in the tumor 
microenvironment, with constitutively active STAT3 expression observed in NK cells, 
neutrophils and macrophages of the tumor stroma (Sommer et al., 2004). STAT3 can alter the 
cell-cycle, prevent apoptosis, and mediate the proliferation and survival of tumor cells and it is 
known to have a negative influence on Th1-type inflammation (Brender et al., 2001; Takeda et 
al., 1999) attenuating the inflammatory properties of type 1 cytokines. Meanwhile the 
expansion of Th2 phenotype is recognized as one of the hallmarks of MF 
progression(Whittaker, 2006). Constitutive activation of NF-B and STAT3 play an important 
role in resistance to chemotherapy in other tumor types (Bhardwaj et al., 2007), and have 
previously been linked with resistance to IFN and other treatments in MF (Sors et al., 2006; 
Tracey et al., 2004; Yang et al., 1998).  Taken together, these data point towards the 
importance of mutual interactions and overlap of signaling pathways in the resistance to PUVA 
+/- IFN therapy. Many of these markers, as shown by immunohistochemistry, are expressed 
not only by the tumor but also in the tumor microenvironment, suggesting the important role 
Discussion 
 
 
131 
 
that the stroma may play in conferring therapy resistance. In many other haematological 
malignancies, the tumor microenvironment is thought to provide nutrition and survival factors 
to the tumor contributing to disease progression. Among the factors related to survival and 
growth in haematological malignancies are vascular endothelial growth factor (VEGF), IL6, IL3, 
TNF super family members and many others (Li and Dalton, 2006). Many of those factors are 
also angiogenic factors that indirectly promote tumor progression through angiogenesis and 
metastasis (Yu et al., 2007). Those factors utilize several signaling pathways such as JAK/STAT, 
MAPK, NF-B and the others. Seemingly, activation of the NF-B pathway in both tumor cells 
as well as in the microenvironment plays a central role in treatment resistance. The up-
regulation of T-cell signalling (Th2 cytokine profile, T-regulatory cells) and TNF signaling leading 
to NF-B pathway activation seem to play an essential role in the phenomenon of resistance. 
 
Furthermore, the use of Connectivity Maps has identified the potential molecules that could 
be used in combination for treatment of PUVA +/- IFN resistant patients. As described in 
Results section the potential molecules for use in a combination therapy included histone 
deacetylase inhibitors (HDACi): Vorinostat (SAHA, ZolinzaTM) and Scriptaid, known anticancer 
antibiotics binding to heat shock protein 90 (Hsp90): Tanespimycin (17-AAG) and 
geldanamycin. Moreover, 17-AAG, tested in vitro in CTCL cells, has shown potent cytotoxic 
activity. Toyooka et al showed that the HDACi, remarkably enhanced the cell killing effect of 
psoralen plus UVA (PUVA) in several cancer cell lines including skin melanoma. Moreover, 
HDACi (sodium butyrate)-induced augmentation of the cell killing effect was more dramatic in 
combination with PUVA than with anticancer drugs. The immediate potential application of 
HDACi-PUVA treatment could be in therapy of CTCL as both PUVA and HDACi (suberoylanilide 
hydroxamic acid – vorinostat), are presently used as monotherapy for CTCL. Additionally, 
HDACi-PUVA treatment killed the CTCL cells more effectively than PUVA treatment alone 
(Toyooka and Ibuki, 2009).  
 
The results gleaned from these studies illustrate that not only are gene expression changes in 
the tumor important for drug resistance, but also changes in the tumor microenvironment are 
an important determinant of treatment outcome. Treatment resistance can be conferred by 
both direct and indirect interaction between the tumor cells and the tumor microenvironment. 
These bi-directional interactions provide survival and proliferation signals by pathways 
involved in up-regulation of anti-apoptotic molecules and promotion of cell growth and 
proliferation, and identify potential therapeutic targets expressed by inflammatory cells. 
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Therefore, the tumor microenvironment plays a crucial role in response to treatment and 
survival of the malignant cells. Some pro-inflammatory factors such as NF-B, TFN and 
interleukins such as IL6 and their respective receptors in addition to STAT3 could be promising 
targets for MF treatment, and their inhibitors could help to overcome treatment resistance in 
combination with other drugs, such as Hsp90 or HDAC inhibitors. 
 
7.3 Identification of mechanism of action and synergistic agents for HDACi  
Recent reports have highlighted the pre-clinical activity of HDAC inhibitors in human leukemia 
and lymphoma cells (Marks and Breslow, 2007; Ungerstedt et al., 2005), as well as the 
promising results in a substantial proportion of patients with advanced CTCL (response rate of 
around 30%) (Duvic et al., 2007), leading to its approval by FDA. Presently, the therapeutic use 
of vorinostat focuses on application in combination therapies which is reflected in undergoing 
numerous clinical trials.  However, the mechanism of action, essential for efficient use and 
combination, has not been fully identified. A likely model for the anti-tumor action of 
vorinostat is that the inhibition of HDAC activity, and subsequent accumulation of acetylated 
nucleosomal histones, leads to the alteration of genes involved in regulation of differentiation, 
apoptosis and tumor growth (Marks et al., 2001). The study presented in chapter 5 shows that 
vorinostat at the concentration of 5M induces CTCL cell apoptosis via several different but 
nonexclusive mechanisms.  Cellular kinetics of particular tumors is an important consideration 
in the design of antineoplastic drug regimens and may influence the dosing schedules and 
timing intervals of treatment. 
 
In CTCL the balance between cell proliferation and cell death is altered, which contribute to a 
clonal expansion of cancer cells. Zhang et al (Zhang et al., 2003) .investigated the expression of 
apoptosis regulators in CTCL cells reporting shift of the equilibrium between inducers and 
inhibitors to the side of inhibitors. The expression of BCL2L1 (BCL-xL), MCL1, BAD and BAX, but 
not BCL-x was found to be expressed in CTCL and could be sufficient for survival of malignant 
CTCL cells. Similarly to Rosato et al.(Rosato et al., 2003) we observe decrease in expression of 
BCL2L1, MCL1, BCL2, BID which indicate enhanced apoptosis upon treatment with vorinostat 
Moreover, our data reveal alterations in both intrinsic (CASP9, CASP7, APAF1) as well as 
extrinsic (FAS, BID, cFLAR) apoptosis pathways following vorinostat treatment. Similarly to 
previous observations in leukemic cells (Mitsiades et al., 2004; Peart et al., 2005; Ruefli et al., 
2001) we noted activation of intrinsic apoptotic pathway through upregulation of CASP9 and a 
key downstream effector of the pathway - APAF1. Furthermore, we identified decrease in 
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expression of important members of extrinsic apoptosis pathway upon treatment with 
vorinostat, such as FAS BID, cFLAR (CASP8). The extrinsic apoptotic pathway, either alone or 
together with intrinsic pathway, has been previously described to be altered upon treatment 
with HDACi in other cancer types, including leukemias (Rosato et al., 2003), breast (Mitchell et 
al., 2007), lung (Kim et al., 2006a) and head and neck (Gillenwater et al., 2007) malignancies. 
As vorinostat promotes upregulation and activation of multiple proapoptotic factors we reckon 
that downregulation of FAS, BID and cFLAR could be a compensating mechanism of CTCL cells 
in response to treatment. Additionally, vorinostat inhibited members of TNF receptor 
superfamily and their downstream signaling cascades, expressed in activated T cells,  which are 
responsible for transduction of survival and proliferation signals while upregulated genes 
mediating signals for apoptosis (Tracey et al., 2003). Consistent with the previous findings of 
Duvic et al (Duvic et al., 2007) and Fantin et al (Fantin et al., 2008) modulation of JAK/STAT 
pathway was observed, including suppression of STAT6, STAT5A, SOCS2, SOCS6 and SOS 
accompanied by enhanced expression of STAT1, STAT2, STAT3, STAT5B, SOCS3, IFNAR2, INFG, 
IFNGR1 and JAK1. 
 
Finally, vorinostat repressed several members of TCR as well as factors acting downstream. 
vorinostat treatment caused downregulation of ZAP70, LAT, VAV2, CD247, CD3D, CD3E, CD3G, 
CD4, IL4, IL5, IL10, IL13, IL4R, IL6R, PTPN6, PAK2, PAK6, ICAM1, NMI, FOXP3 but upregulated 
genes included: FYN, IFNG, IFNGR1, IL12A suggesting a shift in the balance of T helper cells 
from Th2 (phenotype of malignant T cells) to Th1. In chapter 4 relation between TCR pathway 
and PUVA +/- IFN treatment resistance was established. To my knowledge, this is the first 
report that identifies TCR signaling pathway as a target for vorinostat. 
 
T-lymphocytes play a crucial role in the immune response, both as direct effector cells and as 
regulatory cells that modulate functions of other cell types. Among the earliest recognizable 
events after T-cell receptor (TCR) stimulation are the activation of LCK (p56lck) and FYN 
(p59fyn), which result in phosphorylation of tyrosine residues(Zamoyska et al., 2003). 
Subsequently, ZAP70 (-associated protein 70) tyrosine kinase is recruited to the TCR where it 
is activated by LCK through tyrosine phosphorylation (Iwashima et al., 1994).  ZAP70 is a key 
signaling molecule in T cells, where it couples the antigen-activated T-cell receptor (TCR) to 
downstream signaling pathways (Chu et al., 1998). Once ZAP70 is activated, LCK and ZAP70 
presumably act synergistically to phosphorylate specific downstream substrates, which in turn 
orchestrate the cytoplasmic signaling cascades leading to T-cell activation. These central roles 
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of LCK and ZAP70 in TCR signaling have been amply documented. ZAP70 causes 
phosphorylation of LAT (linker for activation of T-cells), which in turn activates important 
downstream signaling pathways, including protein kinase C (PKC), protein kinase B (PKB), and 
mitogen-activated protein kinases (MAPKs), such as extracellular signal-regulated kinase (ERK), 
p38 MAPK, c-JUN N-terminal kinase (JNK) (Janeway and Bottomly, 1994). The PI3K/AKT 
pathway is also necessary for the survival of T-lymphocytes through both increased expression 
of BCL-XL and as a consequence of the role AKT plays in supporting metabolism in proliferating 
lymphocytes (Juntilla and Koretzky, 2008). Activation of ERKs in response to TCR stimulation is 
largely, but not entirely, dependent on ZAP70 (Griffith et al., 1998).  We examined the 
activation of TCR through evaluation of phosphorylation of ZAP70 and its downstream factors 
such as ERK and AKT. Consequently, we observed a reduction in activating phosphorylation of 
all members including ZAP70, ERK and AKT which confirms that vorinostat inhibits TCR 
signaling by both downregulation of the expression of several members of the pathway as well 
as phosphorylation of key tyrosine kinases. 
Due to the broad activity of vorinostat, the inhibition of other kinases affecting T-cell function 
cannot be excluded. The increase of the SRC family tyrosine kinase FYN, which is also 
participating in activation of TCR, also observed by Peart et al (Peart et al., 2005), seems to be 
a compensating mechanism in response to stress caused by vorinostat to tumoral cells, and 
likely indicating that fine tuning of TCR signaling is essential for vorinostat action in CTCL cells. 
 
Clinical trials of vorinostat, both alone or in combination therapy, are on-going and show 
promising anti-cancer activities in both hematologic as well as solid tumors. The molecular 
events underlying the synergistic effect using vorinostat in combination remain to be fully 
elucidated; the mechanisms will plausibly be dependent on the tumor cell type, specific 
molecular events and the precise added agent. So far a limited amount of reports have focused 
on describing the interactions of HDACi (including vorinostat) and inhibitors targeting 
phosphoinositide 3-kinase (PI3K) and all of these efforts have centred on LY294002 (Rahmani 
et al., 2003b). Our current work indicates that a more potent and selective, hence less toxic, 
inhibitor of PI3K - ETP-45658, demonstrates comparable to LY294002 synergy with vorinostat. 
Several properties that are critical for therapeutic agents differentiate ETP-45658 from 
previously tested PI3K inhibitors, including wortmannin and LY294002 (Bain et al., 2007; 
Hennessy et al., 2005; Nagata et al., 2004), mainly ETP-45658 is highly selective for class IA 
PI3K (Link et al., 2009). These make ETP-45658 an attractive candidate for further clinical 
studies in combination with vorinostat and other HDACi. For combination of vorinostat and 17-
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AAG, we observed the opposite effect to the one described in human leukemia cells (Rahmani 
et al., 2005; Rahmani et al., 2003a) and mantle cell lymphoma (Rao et al., 2009). Our data 
show that coadministration of vorinostat and 17-AAG results in antagonistic interaction, which 
could be related to the fact that vorinostat by itself already inhibits expression of HSP90 
(Fiskus et al., 2007). This result suggests that coadministration of vorinostat and 17-AAG 
should be avoided in CTCL. Moreover, we observed a correlation between the expression 
levels of targets of the inhibitors used following vorinostat treatment and the effect of the 
combination. Whenever the molecule targeted by the inhibitor was upregulated (GSK-3, 
PIM), the combination therapy resulted in synergistic or additive interaction. Furthermore, 
downregulation of HSP90 (target of 17-AAG) upon vorinostat treatment showed an 
antagonistic effect of coadministration of 17-AAG with vorinostat. This suggests that inhibitors 
of the genes whose levels significantly increase following vorinostat treatment could be the 
potential candidates for successful combination therapy. 
 
The presented data provide substantial new information improving our knowledge and 
understanding of vorinostat action, and suggest that clinical trials of vorinostat, either alone or 
in combination, performed in CTCL should evaluate its in vivo effect on the signal transduction 
of TCR and correlate the results with the treatment response. In addition, several clinical 
implications can be drawn from our studies. First, PI3K inhibitors, such as ETP-45658 could be 
used in combination with vorinostat-based therapies, and, based on our current study, it is 
anticipated that the combination could be highly effective. Therefore, combining vorinostat 
with PI3K inhibitors is a rational approach to increase the cytotoxic effects in CTCL. These 
results provide proof-of- principle that a comprehensive understanding of the mechanisms of 
vorinostat action is central to designing rational combination approaches using HDACi. 
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1. Peripheral T-cell lymphomas (PTCL) showed a characteristic microRNA signature  
including downregulation of microRNAs let-7 family, miR-10, miR-15, miR-16, miR-101, 
miR-29, miR-215, miR-150, miR-139, miR-126 and miR-195 regulating stemness, stress 
response, apoptosis, proliferation, angiogenesis, and cell cycle pathways. 
 
 
2. Neoplastic T cells in most cases of peripheral T-cell lymphoma (PTCL) were endowed 
with functional plasticity, expressing simultaneously genes that identify different 
normal peripheral T-cell subpopulations.  
 
3. A group of peripheral T-cell lymphoma (PTCL) with a null-phenotype (lacking normal T-
cell subpopulations’ markers) has been identified, expressing oncogenic microRNA 
signature. This group showed an increased proliferation with enrichment of Ras and 
Rho associated pathways.  
 
4. The gene signature associated with activation of NF-κB survival pathway, inflammatory 
cytokine and T cell signaling pathway were found to be of importance in prognosis of 
response to PUVA and IFNα treatment in mycosis fungoides (MF) patients. 
 
5. Many of the markers identified as related to PUVA and IFNα resistance, were 
expressed not only by tumoral cells but also by the tumor microenvironment, 
underlining the important role of the stroma in conferring therapy resistance in 
mycosis fungoides (MF) 
 
 
6. The Connectivity Map analysis revealed molecules that could potentially reverse the 
PUVA and IFNα resistance signature, including 17-AAG and vorinostat. 
 
 
7. HDACi inhibited proliferation, increased acetylation of histones, induced cell death and 
cell cycle arrest in cutaneous T-cell lymphoma (CTCL) cells 
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8. HDACi decreased T-cell receptor (TCR) signaling through inhibition of kinase 
phosphorylation (ZAP70, AKT) in cutaneous T-cell lymphoma (CTCL) cells.  
 
 
9. The combination of HDACi with phosphatidylinositol 3-kinase (PI3K) inhibitors resulted 
in synergy while cytotoxic antagonism was observed when combining vorinostat with 
heat shock protein 90 (HSP90) inhibitor in cutaneous T-cell lymphoma (CTCL) 
suggesting that combination therapies involving histone deacetylase (HDAC) and PI3K 
inhibitors can potentially be efficacious for the treatment of CTCL. 
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1. Los linfomas periféricos de célula T (LPCT) presentan un perfil de microARNs 
característico, incluyendo una disminución en la expresión de los microARNs de la 
familia de let-7, miR-10, miR-15, miR-16, miR-101, miR-29, miR-215, miR-150, miR-139, 
miR-126 y miR-195 que regulan las rutas responsables de las propiedades de células 
troncales, respuesta al estrés, apoptosis, proliferación, angiogénesis y ciclo celular. 
 
 
2. En la mayoría de los casos estudiados, las células T tumorales estaban dotadas de 
plasticidad funcional y expresaban genes que identificaban a las diferentes 
subpoblaciones de células T periféricas normales. 
 
3. Se identificó un grupo de linfomas periféricos de célula T (LPCT) con un fenotipo nulo 
(carecen de los marcadores de subpoblaciones normales de células T) que expresaba 
un conjunto de microARNs oncogénicos. Este grupo mostraba una mayor proliferación 
y una mayor activación de las rutas asociadas a Ras y Rho. 
 
 
4. Se descubrió que el perfil genético asociado a la activación de las rutas de 
supervivencia de NF-κB, citoquinas inflamatorias y señalización de células T son 
importantes en el pronóstico y la respuesta al tratamiento con PUVA e IFNα en 
pacientes con micosis fungoides (MF). 
 
5. Muchos de los marcadores identificados como relacionados con la resistenacia a PUVA 
e IFNα se expresaban no sólo en la población de células tumorales sino también en el 
microambiente del tumor, subrayando la importancia del estroma en otorgar 
resistencia a la terapia en micosis fungoides. 
 
 
6. El análisis in silico realizado con el  “Connectivity Map” reveló algunas moléculas como 
17-AAG y vorinostat que podrían, potencialmente, revertir el perfil de expresión 
asociado a la resistencia a PUVA e IFNα. 
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7. Los HDACi inhiben la proliferación, incrementan los niveles de acetilación de histonas e 
inducen muerte celular y parada del ciclo celular en células de linfoma cutáneo de 
célula T (LCCT). 
 
 
8. Los HDACi disminuyen la señalización del receptor de célula T mediante la inhibición 
de la fosforilación de quinasas (ZAP70, AKT) en células de linfoma cutáneo de célula T 
(LCCT). 
 
 
9. La combinación de HDACi con inhibidores de la fosfatidilinositol 3-quinasa (PI3K) 
resultó en un efecto sinérgico. Sin embargo, se observó antagonismo citotóxico 
cuando se combinó el vorinostat con el inhibidor de HSP90 (Heat shock protein 90) en 
linfoma cutáneo de célula T (LCCT) lo cual sugiere que las terapias combinadas de 
inhibidores de histona desacetilasas y fosfatidilinositol 3-quinasas pueden, 
potencialmente, ser eficaces en el tratamiento de LCCT. 
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Figure S1. Functional clustering of vorinostat-regulated cell cycle associated genes. 
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Figure S2. Validation of microarray data by TaqMan quantitative real time PCR in CTCL 
patient. Effect on vorinostat on mRNA expression of ZAP-70 and FYN in a treated patient. A 
patient with high load of tumoral cells was treated with vorinostat (24h dose schedule) and the 
samples were taken before and after 1, 3, 6, 24, 48, 120 and 360 hours from the 
commencement of the treatment. The figure represents RT-qPCR results for ZAP70 and FYN. 
The expression values before treatment were set to 1 and the percent of alteration was 
calculated. 
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